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Background: Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus 
(MRSA) represent the most worrying Gram-negative and Gram-positive nosocomial 
pathogens of the present age. They are of increasing concern in the clinical environment 
due to their multi-drug resistance and the dwindling therapeutic options available.  A. 
baumannii is the most frequently isolated clinical species of the genus, and is able to 
rapidly acquire resistance. Hypermutators, most frequently deficient in mismatch repair 
(MMR) via defects in the mutS gene, have been associated with antimicrobial resistance 
in several bacterial populations. To date, however, the potential role of MMR-deficient 
mutators in the development of resistance in clinical Acinetobacter spp. has not been 
investigated. Biocides, most notably chlorhexidine (CHX), are increasingly used in the 
hospital environment to prevent bacterial spread. This has led to concerns about the 
development of reduced biocide susceptibility and associated antibiotic resistance in 
hospital bacterial populations, where there is frequent exposure to both of these factors. 
The effect of CHX upon defined clinical MRSA isolates is examined here.  
 
Methods: The mutS gene of clinical Acinetobacter spp. isolates with varying 
sensitivities was sequenced and compared to establish whether any variations were 
present. Mutation studies were performed on isolates by challenging them with 
ciprofloxacin to determine whether different mutS types correlated with any variation in 
their ability to develop significant fluoroquinolone resistance. The response of clinical 
MRSA isolates to a range of CHX concentrations was examined with susceptibility 
 iii 
testing methods, and effects were compared with standard strains. Determination of 
post-exposure minimum inhibitory concentrations (MICs) of a range of antibiotics 
enabled evaluation of whether exposure to CHX had an effect on susceptibility to 
antibiotics.  
 
Results: Variation was observed in the mutS gene of clinical Acinetobacter spp. isolates, 
with greater homology observed as resistance increased. A highly conserved and 
previously unreported amino acid sequence was discovered in resistant isolates. Non-
resistant isolates with this ‘R-type’ mutS sequence appeared to have a greater ability to 
develop significant ciprofloxacin resistance. Clinical MRSA isolates had varying 
susceptibility to CHX, and there were differences in the susceptibility of standard strains 
compared to clinical isolates. CHX residues exerted a prolonged minimal inhibitory 
effect, and several increases in antibiotic MICs following CHX exposure were observed.  
 
Conclusions: The correlation of the mutS sequence with mutation ability suggests that 
defects in the mutS gene may have a role to play in the ability of certain Acinetobacter 
spp. to rapidly acquire resistance. This could have implications for the treatment of 
Acinetobacter spp. infections, and may enable quick determination of which clinical 
isolates have the potential to develop clinically significant resistance. Incomplete 
eradication due to the prolonged minimal effect of CHX residues may act as a selective 
pressure in the hospital environment, allowing survival of reduced susceptibility MRSA 
isolates. Increases in antibiotic MICs following CHX exposure is of grave concern for 
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Chapter 1 – Introduction 
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Chapter 1 - Introduction 
1.1 Nosocomial Pathogens and Problems of Resistant Bacteria 
1.1.1 The Antibiotic Era 
The accidental discovery of the antibiotic properties of penicillin in the late 1920s by Sir 
Alexander Fleming (Fleming, 1929), followed by its development and use as a 
chemotherapeutic agent in the 1940s (Chain et al, 1940) began a new age in the war 
between clinicians and infectious diseases: the antibiotic era.  
 
The discovery and development of new antibiotics led to their widespread use, with the 
development of many different classes of antibiotics, seen as safe and effective targeted 
treatment against the specific causes of infection. They were initially regarded as 
‘wonder drugs’ and a cure-all treatment, often used for even minor infections, some non-
bacterial. An increasing number of infectious diseases seemed within the clinician’s 
control and it was hoped that continued antibiotic development could lead to the 
eradication of infectious diseases. 
 
However, the current situation is very far from this ideal picture; since the introduction 
of the first antibiotics, bacteria have in turn evolved resistance mechanisms to counteract 
the attacks of these drugs.  
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Even in the early days of antibiotic use, there was an awareness of developing resistance 
to these agents, particularly in common hospital bacteria of the time; there were 
increasing reports of penicillin-resistant Staphylococcus pyogenes in the mid-1940s, 
compared to very few before 1944 (Barber & Rozwadowska-Dowzenko, 1948). It could 
not have been known then that the development, use, and subsequent overuse of 
antibiotics would escalate to what has been likened to an arms race between bacteria and 
the drugs used against them brought about by the rise in antibiotic resistance in first 
Gram-positive and then Gram-negative bacteria.  
 
1.1.2 The Rise of Antibiotic Resistance 
With increasing resistance apparent, more classes of antibiotics and iterations of existing 
compounds were developed to replace those that were failing; this continued ability to 
treat infections effectively kept the problem of antibiotic resistance at bay, as treatment 
options were not affected. However, the lack of development of new classes of 
antibiotics and reliance, instead, upon iterations of existing classes, has meant that 
treatment is now compromised (Amyes, 2000). It now seems clear that antibiotics will 
not live up to the hopes they once inspired for the eradication of infectious diseases. 
Indeed, there are new and recent emerging infectious diseases such as AIDS (Acquired 
Immuno-Deficiency Syndrome) and SARS (Severe Acute Respiratory Syndrome) to 
contend with, in addition to increasing multi-drug resistance in bacteria leading to the re-
emergence of previously well-controlled infections, such as Mycobacterium tuberculosis 
(Gillespie, 2002).  
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Of particular concern is the prevalence of multi-drug resistant (MDR) strains, not only 
of traditionally important bacteria in the clinical environment such as methicillin-
resistant Staphylococcus aureus (MRSA), but also of bacteria never previously 
associated with infection, such as Acinetobacter baumannii, including isolates resistant 
to all routinely used available antibiotics (Kuo et al, 2004), leaving the clinician with 
few treatment options.  
 
The adaptation of bacteria to their environmental stresses is a Darwinian ‘survival of the 
fittest’ scenario, where those of the population able to survive the pressure are those that 
are able to reproduce and give rise to the subsequent generation. Bacteria are advantaged 
in this evolution not only by their large numbers and fast replication rate in comparison 
to higher organisms, but also in their ability to readily acquire and exchange genetic 
information, thereby introducing variation (Wise, 2004), in which hypermutation may 
play a role (as detailed in Section 1.5). 
 
Briefly, antibiotic resistance will develop in a population where at least one bacterium 
exists which is able to survive the presence of that antibiotic. The initial development of 
resistance involves random production of new combinations of genes and strains, but 
this in itself is not enough to drive resistance development; instead interplay of complex 
factors favours survival and proliferation of a particular combination at that time 
(Livermore, 2007). It is the combination of resistance genes being developed and the 
selective pressure exerted by antibiotics that can lead to proliferation of these survivors 
and the antibiotic resistance problem which is now evident. Continued selective pressure 
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of the antibiotic challenge can lead to resistant phenotypes from an originally 
heterogenous population becoming predominant over the course of several generations. 
As such, antibiotic resistance has only become a problem since the increased use of 
antibiotics. However, even in the absence of the selecting antibiotic, resistant bacteria 
may remain (Levy, 2002a). 
 
The changes that may lead to resistance arising in a bacterial population vary depending 
on the mode of action of the antibiotic, and also upon the target bacteria. There are 
several major classes of antibiotic, with various modes of action. Table 1.1 provides 
examples of the modes of action of some of the major antibiotic classes. For each of 
these classes however, there now exists at least one and often several mechanisms of 
resistance.  
Table 1.1 The modes of action of major antibiotic classes 
Adapted from Levy & Marshall, 2004. 
Mode of Action Antibiotic Families 












Inhibition of DNA synthesis Fluoroquinolones 
Inhibition of RNA synthesis Rifampicin 




Membrane disorganising agents Polymyxins  
(Polymyxin-B, Colistin) 
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Bacterial resistance arises through the development of variation via horizontal transfer or 
mutation. Horizontal transfer includes the acquisition of resistance genes from other 
organisms carried on plasmids, transposons and integrons, mediated by conjugation, 
transduction or transformation; foreign DNA may also be incorporated into the 
chromosome by recombination. Mutations in chromosomal loci relevant to antibiotic 
resistance development include those leading to changes in genes encoding the antibiotic 
target, alterations in the expression of intrinsic resistance mechanisms and 
overproduction of antibiotic inactivating enzymes (some examples are detailed in 
Section 1.5.2) (Spratt, 1994; Mazel & Davies, 1999; de la Cruz & Davies, 2000). The 
importance of mutation in resistance development is discussed in Section 1.5, and 
fluoroquinolone resistance is detailed in Section 1.4. 
 
Whilst the factors influencing the development of resistance, and the complexities of 
resistance development itself, are often uncertain, it is clear that the selective pressure 
exerted by antibiotic use is a major factor driving this development (Barbosa & Levy, 
2000). 
 
1.1.3 Multi-drug Resistance 
Multi-drug resistant (MDR) bacteria are a serious problem, particularly in the hospital 
environment where the increased use and presence of antibiotics compared to the 
community can create a greater selective pressure. Reports of ‘pan-drug’ resistant strains 
of bacteria, resistant to all commonly used agents including last-resort treatment options, 
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has serious implications for the continued ability to treat infections caused by these 
bacteria and has led to the re-use of and reliance upon toxic agents such as polymyxin as 
therapy (Falagas and Bliziotis, 2007; Meyer, 2005).  
 
1.1.4 Impacts of MDR Bacteria in the Hospital Environment 
Patients and healthcare workers within the hospital may be colonised by bacteria which 
may also be subjected to these selective pressures and develop into MDR bacteria. As 
such, colonised patients can act as a reservoir of MDR bacteria and immuno-
compromised patients, as found in the Intensive Care Unit (ICU), are particularly 
vulnerable to subsequent infection (Walsh & Amyes, 2004). This has led to 
opportunistic pathogens such as Acinetobacter spp becoming an increasing problem. 
Additionally, several bacteria have been found to persist in the hospital environment. 
For example, Acinetobacter spp have been found on many surfaces, from intravascular 
catheters to curtains (Das et al, 2002) and are able to survive for long periods (Jawad et 
al, 1998), and MRSA is a prevalent coloniser of the skin (Gordon & Lowy, 2008), 
stressing the importance of the colonised hospital environment and patients as a 
reservoir within the hospital allowing the opportunistic pathogens their opportunity. 
Also, cross-transmission from patient to patient, directly via lapses in infection control, 
or via contaminated instruments such as catheters (Dijkshoorn et al, 1987), is a 
fundamental problem in nosocomial infections.  
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In effect, the hospital environment can act as a training ground for bacterial populations. 
Bacteria are able to colonise the environment and patients, infecting those more 
susceptible, and during this colonisation they are likely to come into contact with many 
different kinds of antibiotic and other antibacterial agents. Only the strongest will 
survive; this leads to an increasingly resistant population being present in the hospital 
environment.  
 
Antimicrobial resistance is a global problem, which has been likened to an independent 
disease entity. Of particular current concern, as highlighted by The 2005 Global 
Advisory on Antibiotic Resistance Data (GAARD) Report issued by the Alliance for the 
Prudent Use of Antibiotics (APUA) (APUA, 2005), is the rise of Gram-negative MDR 
bacteria, some of which are becoming untreatable, alongside exacerbation of the much-
publicised MRSA problem with the increasing prevalence of community-associated 
MRSA (Section 1.2). Increasing travel and globalisation may be a factor in the 
worldwide spread of MDR strains, and there is the possibility that the global events of 
war and natural disasters may help the spread of resistant bacteria via global transfer of 
infected patients (McGowan Jr, 2006).  
 
Initially Gram-positive bacteria were the major problem in the hospital environment, 
with clinicians struggling to control staphylococcal infections. The introduction and 
widespread use of antibiotics brought these infections under some control. This, 
however, appeared to allow Gram-negative bacteria to fill the vacant niche and they 
have become an increasing threat, typified by opportunistic infections in vulnerable 
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hospital patients and rapid development of resistance to many antimicrobials, probably 
helped by their prevalence in the environment, limiting the therapeutic options available 
(McGowan Jr, 2006). Currently, both Gram-positive and Gram-negative bacteria are 
causes for concern in the hospital environment, and examples of multi-drug resistance 
exist in both. Predominant amongst these are methicillin-resistant Staphylococcus 
aureus (Gram-positive) and Acinetobacter baumannii (Gram-negative). These two 
organisms are described in more detail in Sections 1.2 and 1.3. 
 
Nosocomial (hospital-acquired) infections have been increasingly publicised in recent 
years following several outbreaks and celebrity ‘endorsements’ (TimesOnline, 2004). 
The use of sensational names such as ‘superbug’, commonly used to describe 
methicillin-resistant Staphylococcus aureus (MRSA) (Foster, 2004), has also helped to 
bring the problem of rising antibiotic resistance to the public’s attention. Additionally, 
various initiatives and surveillance groups are now evident, such as the Surveillance and 
Control of Pathogens of Epidemiologic Importance (SCOPE) project, the National 
Nosocomial Infections Surveillance (NNIS) system in the US, the Antibiotics Resistance 
Prevention and Control (ARPAC) project and the aforementioned APUA and the 
GAARD project.  
There is also greater acknowledgement of the problem in government as evidenced by 
initiatives such as the Scottish Executive Health Department Antimicrobial Resistance 
Strategy and Scottish Action Plan, introduced in 2002, which integrated the government 
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commitment to a UK Antimicrobial Resistance Strategy with an Action Plan for 
Scotland (Scottish Government website, 2002) and reports urging government action to 
tackle the problem such as those of the Infectious Diseases Society of American (IDSA) 
which led to the STAAR (Strategies to Address Antimicrobial Resistance) Act being 
presented to the US government in 2007 (IDSA website, 2007).  
 
The outbreaks and prolonged patient colonisation that are associated with MDR bacterial 
infections not only draw negative publicity and increase the concern of individuals at the 
prospect of hospital stays but also have an economic cost. This includes costs connected 
with the specialised infection control practices needed to control an outbreak, such as 
barrier nursing, and disinfection of both wards and patients. A recent review of the direct 
health care cost of MRSA in Canada, for example, calculated an average cost of $12,216 
per infected patient, with hospitalisation the main contributor to cost followed by barrier 
precautions, antimicrobial therapy and laboratory investigations (Goetghebeur et al, 
2007). Likewise a study into the cost of hospital-acquired infections in a UK hospital 
estimated on average a cost for infected patients almost three times higher than that of 
uninfected patients, alongside a 2.5 times longer hospital stay, the largest contribution to 
additional costs being nursing care (Plowman et al, 2001). 
 
Infection with MDR bacteria in the hospital can also be associated with increased 
morbidity and mortality as it can delay the administration of appropriate therapy and 
limit available therapeutic options. Whilst there can be debate about the attribution of 
mortality directly to MDR bacteria as they often infect those that already have a poor 
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prognosis, recent reviews have concluded that both A. baumannii and MRSA infections 
are associated with increased mortality (Falagas & Rafailidis, 2007; Falagas et al, 2006; 
Cosgrove et al, 2003; Whitby et al, 2001).  
 
1.1.5 Dwindling Therapeutic Options 
The situation of using toxic agents as a last resort treatment highlights a fundamental 
problem associated with the rise in antibiotic resistance; clinicians are rapidly running 
out of options to treat infections by MDR bacteria that have become resistant to all 
normal treatments. Dwindling therapeutic options are in part due to a lack of investment 
into the discovery and development of new antibiotic agents; the last decade has seen a 
steady decrease in the number of new antibiotics being approved. There has been much 
attention in recent years on the subject of why the big pharmaceutical companies have 
been investing less in this sector; it seems that the situation involves many factors such 
as a greater return on drugs for chronic conditions such as cardio-vascular disease, 
diabetes, arthritis, and from anti-HIV drugs, the need to prioritise in the light of the 
emergence of new global diseases, and an increase in safety regulations to be adhered to. 
These factors combine to give antibiotics a low placing on the list of priorities for 
companies (Spellberg et al, 2004; Projan, 2003). Rising costs of manufacture, pricing 
pressures and a higher safety profile requirement by the FDA means that many drugs in 
development do not reach the latter stages of the process (Spellberg et al, 2004). Indeed, 
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current commonly used agents which are highly active chemical compounds (such as 
ciprofloxacin) may not have been passed for use if subject to current regulations.  
 
The tendency to derive new antibiotics from different iterations of older ones has also 
contributed to the current situation; great hope was placed upon new technologies to 
provide ways forward in drug discovery but so far these have not led to the multitude of 
new agents that was hoped for despite some progress in this area (Projan & Shlaes, 
2004). Ironically, the very steps taken to slow the emergence of MDR bacteria may also 
have contributed to the current lack of new antibiotics in development; restricting the 
use of antibiotics is a fundamental measure in controlling the rise of resistance but of 
course, from the company’s perspective, it leads to a reduction in market size and 
subsequently becomes a less attractive investment prospect (Projan & Shlaes, 2004). 
 
1.1.6 Future Directions 
It seems clear that the promise of the antibiotic era has ended. It is no longer hoped, at 
least not within the scientific community, that miracle cures can be found to rid the 
world of infectious diseases. Bacteria have a much longer history than humans and, 
rather than trying to defeat them, focus is needed on preserving the usefulness of current 
treatments and attempting to slow the trend of rising antibiotic resistance; calling a truce 
instead of aiming to win a war. Reversal of the resistance process, whilst it may be 
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possible through replacement with susceptible strains (Levy & Marshall, 2004), seems 
an increasingly naïve proposition (Livermore, 2007).   
 
Initial steps towards halting the rise of resistance must include improved surveillance 
with faster and more reliable typing methods to further delineate which strains are 
important in the epidemiology of hospital infections (Levy & Marshall, 2004; APUA, 
2005). As mentioned there are several groups that are involved in monitoring the global 
spread of resistant bacteria, including SCOPE, NNIS and ARPAC, and government 
supported initiatives and strategies to tackle the problem. It is important that surveillance 
measures attempt to examine a spectrum of isolates to get a true picture of the 
epidemiological aspects, rather than purely reactive surveillance in response to outbreaks 
(Dijkshoorn et al, 2007), though of course there is value in specifically studying 
outbreak strains.  
 
Infection control measures are vital to help prevent transmission and persistence of 
bacteria in general and MDR bacteria specifically within the hospital environment and 
larger community. The plethora of active antibiotics led to leniency in infection control 
procedures in the past; however it now seems that healthcare professionals are once 
again very aware of how important infection control measures such as reduced patient 
contact and hand-washing can be, and there is evidence for such measures successfully 
controlling outbreaks.  
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A recent study demonstrated successful control of an outbreak of carbapenem-resistant 
A. baumannii in the neurosciences critical care unit of a UK hospital by early 
management and patient segregation, screening of patients and the environment (which 
was found to be heavily contaminated), and subsequent increased environmental 
cleaning and hand hygiene (Enoch et al, 2008). Equally, increased infection control and 
hand hygiene have been shown to have successfully reduced the occurrence of MRSA 
infections (Grayson et al, 2008). However, with the efficacy of infection control comes 
the increased used of disinfectants and antiseptics, which are becoming prevalent not 
only in the clinical environment, but also in the community at large, even being found in 
make-up and toothpaste (Levy, 2001). Biocides and their possible implications for 
antimicrobial resistance in MRSA are discussed in more detail in Section 1.2. 
 
A more rational and controlled use of antibiotics is required to reduce the selective 
pressure that they provide. However clinicians are often under pressure, sometimes from 
the patients themselves, to prescribe antibiotics, and sometimes the information provided 
to clinicians to guide their prescribing is confusing (Fleming, 2007). This situation has 
improved somewhat with campaigns to highlight the problems of antibiotic resistance 
and improved public awareness. The media in this respect has been immensely helpful 
in bringing the issue of MDR nosocomial pathogens into the public eye. However their 
coverage often borders on the hysterical and could lead to misinformation. Continual 
non-sensational education is important to maintain and increase public awareness of the 
issues, and encourage both patients and clinicians against the misuse of antibiotics.  
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Improved cooperation between industry, academia and government, maybe even with 
incentives being offered to encourage research into new antibiotic possibilities, may be 
needed to encourage the initiation of more antibiotic discovery and development 
programmes. Different approaches rather than modification of old compounds would 
also be useful in finding new agents to combat infections; any new products may have 
limited usefulness as it seems likely that bacteria will continue to adapt to their 
environment and develop resistance to whatever new compounds are used against them, 
but those which are entirely novel would have the advantage, even in the short term, 
over new iterations of old formats. However, given the lack of either iterations or novel 
antibiotics in development, immediate priorities must focus on other means of slowing 
the development of resistance (Projan & Shlaes, 2004; Spellberg et al, 2004). 
 
The best way to gain some control over nosocomial infections is to increase our 
understanding of bacterial resistance development; not only is this essential to pinpoint 
new targets for antibiotic agents, it is also vital to enable the implementation of effective 
methods to slow the seemingly relentless rise of resistance, and to forewarn against 
potential new aspects of resistance development.  
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1.2 MRSA and the Increased Use of Biocides  
1.2.1 Gram-positive Bacteria  
Gram positive bacteria have historically been important pathogens in the hospital 
environment and they continue to present clinicians with major treatment and infection 
control problems. For example, analysis of data collected for the Surveillance and 
Control of Pathogens of Epidemiologic Importance (SCOPE) project reported that 65% 
of the nosocomial bloodstream infection cases reported from 49 US hospitals over 7 
years were due to Gram-positive organisms, and of these 20% were Staphylococcus 
aureus (Wisplinghoff et al, 2004).  
 
Staphylococci are common skin commensals and have long been problematic in 
hospitals, causing urinary and respiratory tract infections and bacteraemia. They are also 
common infective agents during surgery due to their commensal nature; numerous sites 
on the body can be colonised and this provides a reservoir and important routes of 
infection when the host defences are breached (Gordon & Lowy, 2008). Staphylococcal 
infections were tackled at first with penicillin, at the advent of the antibiotic era, but 
developed resistance first to penicillin and then to further antibiotics developed against 
them, including methicillin. 
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1.2.2 MRSA 
Methicillin-resistant Staphylococcus aureus (MRSA) has received the greatest publicity 
of the nosocomial MDR bacteria, as evidenced by its frequent appearance in the media, 
often termed ‘superbug’ (Foster, 2004). Methicillin was introduced in 1959 in Europe to 
treat infections by penicillin-resistant S. aureus, as the rates of resistance to penicillin 
were already high. It was initially successful but resistant strains developed, following a 
pattern similar to earlier penicillin resistance development. The first MRSA strain was 
reported in the UK in 1961, and others were subsequently reported worldwide. Several 
outbreaks of MRSA followed in the 1970s, usually associated with high methicillin use 
in ICUs and, during the 1980s, MRSA became a significant problem globally (Rice, 
2006; Boucher & Corey, 2008),  
 
Resistance to methicillin is via the expression of the mecA gene, encoding the low-
affinity penicillin binding protein (PBP) 2a which also confers resistance to other β-
lactams. mecA is carried on a mobile genetic element called the staphylococcal 
chromosomal cassette (SCC)mec, of which there are several types; Types I, II and III are 
normally associated with HA-MRSA and Types IV and V with community-associated 
(CA)-MRSA (Hiramatsu et al, 2001; Otter & French, 2006; Stryjewski & Chambers, 
2008). 
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1.2.3 Impact of MRSA 
The term MRSA is a useful label but in fact hospital-acquired (HA) MRSA is generally 
multi-drug resistant and demonstrates a clonal pattern of spread (Amyes, 2000). For 
example the two epidemic MRSA (EMRSA) clones EMRSA-15 and EMRSA-16 are 
predominant in the UK, and are highly resistant to most antibiotics (Amyes 2005). 
MRSA can colonise the skin and particularly the anterior nares of a patient, transiently 
or persistently. MRSA has also been found to persist in the hospital environment on 
inanimate objects and in the area surrounding patients. Transmission is thought to be 
mainly via infection control lapses by healthcare practitioners, with patients and the 
hospital environment as a reservoir. In addition, patient-to-patient and visitor-to-patient 
contact may be important transmission routes of bacteria within the hospital setting 
(Gordon & Lowy, 2008; Gould, 2005). 
 
As mentioned, MRSA is highly associated with nosocomial bloodstream infections 
(Wisplinghoff et al, 2004) and can also be implicated in surgical-site infections, 
pneumonia, endocarditis, osteomyelitis and invasive skin infections (Gordon & Lowy, 
2008). The percentage of MRSA bloodstream infections in the US was found to be 
significantly higher in the ICU where the most vulnerable patients are found, and the 
percentage of S. aureus bloodstream infections that were MRSA had risen from 22% to 
57% from 1995 to 2001 (Wisplinghoff et al, 2004). There is evidence that MRSA 
bloodstream infections may be levelling off in certain areas; for example, Health 
Protection Agency (HPA) figures show a decline in cases reported in England from 
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April 2006 to September 2007 (HPA website, 2008a). However this may be partially due 
to changes in the surveillance system, and rates are currently still high compared to other 
European countries (Gould, 2005).  
 
Although, as with Acinetobacter spp (Section 1.3.3), attributable mortality directly due 
to MRSA can be unclear due to the association with patients with adverse prognosis, 
several meta-analyses comparing MRSA to methicillin-susceptible S. aureus (MSSA) 
have indicated MRSA infection is associated with greater mortality, morbidity and 
treatment costs (Cosgrove et al, 2003; Whitby et al, 2001). Whilst their conclusions 
regarding MRSA versus MSSA can be questionable due to broad inclusion criteria and 
possible lack of accounting for all factors, they do indicate an association between 
MRSA infection and increased mortality. Additionally, it is apparent that difficulties in 
the treatment of MRSA will also contribute to increased mortality. MRSA outbreaks are 
also associated with high economic costs; this includes antimicrobial therapy, care of 
MRSA-infected patients, infection control procedures and surveillance (Gould, 2005). 
As mentioned, a recent review of the direct health care cost of MRSA in Canada 
calculated an average cost of $12,216 per infected patient, with hospitalisation the main 
contributor to cost, followed by barrier precautions, antimicrobial therapy and laboratory 
investigations (Goetghebeur et al, 2007). 
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1.2.4 Community-associated MRSA 
Initially MRSA was solely a hospital problem, but it is now apparent that it can also be 
community associated or acquired (CA-MRSA), causing infections in patients with no 
previous history of healthcare contact. This is highlighted by the recent publication of 
guidelines by a Working Party on behalf of the British Society for Antimicrobial 
Chemotherapy (BSAC) for the diagnosis and management of MRSA infections 
presenting in the community (Nathwani et al, 2008), which aim to increase awareness of 
the problem of CA-MRSA in the hopes of preventing and controlling recurrence and 
exacerbation of the problems seen with HA-MRSA.  
 
CA-MRSA commonly causes skin and soft tissue infections, though it may also cause 
more serious infections such as necrotising pneumonia. There are several differences 
between CA-MRSA and HA-MRSA; CA-MRSA is capable of rapid spread and causes a 
higher rate of infection than HA-MRSA, but tends not to be multi-drug resistant and is 
polyclonal (Stryjewski & Chambers, 2008; Nathwani et al, 2008). Additionally the 
presence of the smaller SCCmec Types IV and V in CA-MRSA as opposed to Types I, II 
and III in HA-MRSA is currently a useful molecular distinction (Otter & French, 2006; 
Stryjewski & Chambers, 2008), although ciprofloxacin susceptibility has also been 
reported as a helpful marker for CA-MRSA strains identified in the London area (Otter 
& French, 2008a).  
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This study, reporting the recent emergence of CA-MRSA in a London hospital (Otter & 
French, 2008a), also highlights a growing concern arising from CA-MRSA; its 
increasing movement into hospitals and associated outbreaks. This is a particularly 
disconcerting aspect, as the movement of these strains between hospital and community 
could lead to a greater number at risk of infection in both environments, and the 
development of multi-drug resistance in CA-MRSA due to antibiotic pressure present in 
the hospital environment (Otter & French, 2006).  
 
The recent epidemiological advance of MRSA in the form of CA-MRSA is hence a 
growing area of concern, not only for its impact in the community, but also in the 
clinical environment, furthering the urgency of the need to control MRSA infection and 
spread.  
 
1.2.5 Control of MRSA 
Glycopeptides, including vancomycin, are currently used to treat serious MRSA 
infections. However, there are reports of vancomycin intermediate and vancomycin 
resistant S. aureus (VISA and VRSA respectively) which are of growing concern for 
treatment options (Wang et al, 2006). Daptomycin, a cyclic lipopeptide recently 
approved for use in certain infections, has shown rapid bactericidal activity against S. 
aureus, including against resistant strains (French, 2006).  However, further trials are 
needed to confirm the usefulness of this agent against MRSA in the clinical 
environment. 
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In light of the reduction in treatment options, it is vital in the meantime to employ 
suitable infection control measures to: minimise the spread of MRSA in hospitals, 
reduce the emergence of resistant isolates, and reduce the movement of CA-MRSA into 
and within the hospital environment. Given the aforementioned colonisation and 
transmission of HA-MRSA within hospitals, good infection control procedures would 
seem to be of great importance.  
 
Indeed, samples of worldwide national guidelines stress the importance of early 
detection through surveillance, isolation, decolonisation and hand hygiene, with 
increasingly evidence based approaches for guidelines (Humphreys, 2007). Recently a 
report on the outcome of a multi-site hand hygiene culture-change programme in 
Australian hospitals indicated a significant reduction in both the number of patients with 
MRSA bacteraemia and the number of clinical MRSA isolates, as measured per 100 
patient discharges per month and compared to mean baseline rates (Grayson et al, 2008). 
Whilst one of the products used was developed by the authors, its composition was 
similar to the other product used (0.5% chlorhexidine with 70% ethanol or 70% 
isopropanol respectively) so this is unlikely to have biased the results. There are novel 
methods of cleaning being developed with success, such as the recently reported 
inactivation of bacteria renowned for survival in the hospital environment (MRSA, 
Acinetobacter spp, Clostridium difficile and Klebsiella pneumoniae) with hydrogen 
peroxide vapour (Otter & French, 2008b), but these are not yet regularly used. As such 
infection control methods currently involve the use of biocides.  
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1.2.6 Rise of Biocide Use 
With the re-establishment of the importance of infection control, there has been a 
concurrent rise in the use of biocides. Biocides are used as antiseptics, disinfectants, 
preservatives and some, such as chlorhexidine, are used for all three purposes. They are 
frequently used in the hospital environment for disinfection of inanimate objects, as 
antiseptics or topical antimicrobials on the skin, and as preservatives in products to 
avoid contamination (Russell, 2003), with suggested incorporation into invasive 
equipment such as endotracheal tubes a recent manifestation (Pacheco-Fowler et al, 
2004). Hence, biocides are aimed at prevention and control, whereas antibiotics are for 
the treatment of infections. But whilst they are of increasing importance and usefulness 
in the hospital environment, there has also been a rise in biocides incorporated into a 
wide range of products within healthy households; for example in toothbrushes, soaps, 
cleansers, food storage containers and even chopsticks (Levy, 2001).  
 
1.2.7 Chlorhexidine 
Chlorhexidine is an antiseptic solution that has been used since the 1950s for 
applications including hand-washing, treatment of gingivitis and preoperative skin 
preparation. It is a cationic biguanide which, at high concentrations, binds to the 
bacterial cell wall, altering the osmotic equilibrium and causing cell death via 
precipitation of the cytoplasmic contents. At low concentrations it affects membrane 
integrity. There is evidence supporting its safety in a wide variety of clinical uses 
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(Milstone et al, 2008) and it is also a frequent ingredient in mouthwashes and dental 
products in the home.  
 
1.2.8 Reduced Susceptibility to Biocides 
The rise in biocide usage has been accompanied with concerns that their overuse and 
misuse could lead to the emergence of bacteria with reduced susceptibility to biocides, 
and even cross-resistance to antibiotics (Russell et al, 1998; Levy, 2001). Despite the 
increase in biocide products, there has not been a simultaneous increase in our 
understanding of the interaction of biocides with bacteria (Maillard, 2007). 
 
Possible worse-case scenario implications of biocide reduced susceptibility in the 
hospital environment could include failure of preoperative, hand hygiene and 
environmental disinfectants and antiseptics, leading to the possibility of increased auto-, 
cross- and environmental infection rates respectively. This could also have implications 
upon antibiotic usage by increasing the need for them to treat infections (Cookson, 
2005).  
 
There are several problems associated with the subject of biocide reduced susceptibility. 
Compared to antibiotic resistance there is a low profile and little funding into research, 
with no structured surveillance systems. Additionally there are currently no 
internationally agreed efficacy tests or tests for biocide reduced susceptibility (Cookson, 
2005). The European suspension test has been developed but may not adequately 
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address the clinical situation; for example the presence of bacterial biofilms and biocide 
residues in the hospital environment. Thomas and colleagues have developed some 
promising methods to test not only bacteria susceptibility to biocides in suspension, but 
also to biocide residues and biocides’ efficacy upon dried surface bacteria (Thomas et al, 
2005). Another issue is the lack of evidence at present to support reduced susceptibility 
to biocides in practice, and difficulties in correlating in vitro experiments with the 
practical clinical situation (Maillard, 2007). 
 
Whilst there are some similarities in specific antibiotic and biocide mechanisms of 
action, there is a fundamental difference; whereas many antibiotics exert their effect by 
growth inhibition via a specific target, biocides usually have multiple targets which are 
concentration-dependent, their desired rapid kill effect apparent at in-use concentrations, 
with subtle effects occurring at low concentrations (Russell, 2003). As such, the 
terminology in relation to biocides is to use ‘reduced susceptibility’ as opposed to 
‘resistance’, and MICs are not generally considered a suitable means of testing biocide 
reduced susceptibility (Bloomfield, 2002).  
 
Biocide efficacy is generally dependant on rapid kill effects, which can be measured by 
the microbiocidal effect (ME): the log reduction in cell number compared to a control 
(Thomas et al, 2005). There is a suggestion that efficacy testing of biocides should use 
an equal to or greater than a 5 log reduction (equivalent to 99.999%) in numbers of 
challenged organisms after contact as the boundary for an acceptable ME (Payne et al, 
1999). 
Chapter 1 – Introduction 
 25 
1.2.9 Mechanisms of Reduced Susceptibility to Biocides 
Biocide reduced susceptibility is not a new occurrence and has been reported in 
laboratory studies (Thomas et al, 2000; Kõljalg et al, 2002; Moken et al, 1997; Kampf et 
al, 1998). However, reports from the clinical environment are rare as it can be difficult 
to correlate biocide reduced susceptibility with the clinical situation, and there is a lack 
of awareness of the potential problem (Maillard, 2007). Suggested resistance 
mechanisms are defined, similarly to antibiotic resistance (Sections 1.1.2 and 1.5.1), as 
both intrinsic and acquired. Mechanisms of resistance to biocides include reduced 
uptake by impermeability (via porins, the outer membrane, cell envelope and biofilm 
formation) or by active efflux, and modification (via target modification or 
overproduction of targets) (Maillard, 2007; Russell, 2003).  
 
There is debate about whether laboratory studies of biocides relate well to the clinical 
situation as the use of biocides in the clinical environment is generally at very high 
concentrations; however, the study of biocide reduced susceptibility at low 
concentrations is increasingly being advocated (Maillard, 2007; Russell, 2003). This is 
partly because of the increasing incorporation of low concentrations of biocides into 
products (surfaces, liquids and textiles) throughout the domestic and more importantly 
clinical environments (Levy, 2001). Also the use of some biocides (such as 
chlorhexidine) as preservatives in solutions, cosmetics and other domestic items 
alongside their simultaneous use for de-contamination leads to the concern that reduced 
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susceptibility could result from these low concentrations and lead to their use for 
disinfection and antisepsis being compromised (Maillard, 2007).  
 
Additionally it is likely that even in clinical use low concentrations of biocide will be 
present at some point via misuse (for example the topping-up of biocide containers or 
failure to remove residue) and excessive use (for example general cleaning and 
disinfection rather than targeted use); indeed, it has been suggested that there is likely to 
be a continuum of biocide concentration in the environments in which they are used, and 
as such sub-lethal concentrations of biocide for their targets could be present, meaning 
that low concentrations of biocide would act more akin to antibiotics and specifically 
affect only certain targets (Bloomfield, 2002).  
 
Exposure to low concentrations of chlorhexidine has been reported to lead to selection of 
reduced susceptibility isolates. Stable reduced susceptibility in P. aeruginosa developed 
following exposure to increasing concentrations of chlorhexidine, and also after repeated 
exposure to a residual concentration of chlorhexidine (Thomas et al, 2000). Additionally 
some tested antibiotic resistant strains were found to have less susceptibility to 
chlorhexidine, suggesting that selective pressure from the biocide could select out 
antibiotic resistant strains (Kõljalg et al, 2002).  
 
Cross-resistance to antibiotics is a particularly disconcerting aspect of this area, and 
there are several additional reports of parallel resistance to antibiotics. For example E. 
coli mutants selected for reduced susceptibility to pine oil also showed resistance to 
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several antibiotics and overexpression of the marA gene, which activates the multidrug 
AcrAB efflux pump, indicating that biocides were acting in the same way as antibiotics 
(Moken et al, 1997; Levy, 2002b). It does seem that a situation where use of low 
concentrations of biocides leading to reduced susceptibility and also to parallel antibiotic 
resistance is not unlikely and warrants further investigation, especially as there is a lack 
of information about clinical isolates (Russell et al, 1998).  
 
Of further concern is that the effectiveness of biocides can vary with different strains, as 
highlighted in a study where MRSA isolates were reported to be significantly less 
susceptible to chlorhexidine than MSSA isolates (Kampf et al, 1998). Also, in an 
evaluation of the standard strains used to test biocide efficacy against clinical isolates it 
was found that with a shorter contact time microbiocidal effects were higher for both P. 
aeruginosa and S. aureus ATCC strains than the tested clinical strain for these 
organisms (Payne et al, 1999). This questions the use of standard strains in biocide 
efficacy testing, and whether they are sufficient to test the effectiveness of biocides 
against current clinical isolates.  
 
As such, it is important to study the effects of biocides at low concentrations, on clinical 
isolates compared to standard strains. Given the renewed importance of infection control 
in combating the spread of MRSA and the increased use of biocides, early warning as to 
reduced susceptibility of these prevalent nosocomial pathogens is vital.  
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1.3 Acinetobacter 
Gram-negative non-fermenters, those unable to ferment glucose as an energy source, 
have become an increasing concern as hospital pathogens in recent years. It is thought 
that Gram-negative bacteria began to predominate in the niche created by a reduction of 
Gram-positive bacteria in the hospital environment during the heyday of antibiotics. 
Gram-negative non-fermenters are opportunistic pathogens, prevalent in the hospital 
environment as colonisers and predominantly causing infections in those who are 
seriously ill or immunocompromised (Falagas & Bliziotis, 2007). 
 
There is much attention focused on the rise of Gram-negative bacteria but the 
fundamental problem is not so much an increase in infections caused as the growing 
prevalence of strains that are multi-drug resistant and in some cases pan-drug resistant 
(Kuo et al, 2004). A recent review of nosocomial Gram-negative infections, using data 
from the National Nosocomial Infections Surveillance (NNIS) System, concluded that 
the percentages of Gram-negative bacteria associated with the top four nosocomial 
infections (pneumonia, surgical site infection, urinary tract infection and bloodstream 
infection) had not significantly changed from 1986 to 2003, with the exception of ICU 
pneumonia episodes associated with Acinetobacter which had increased. However, 
significant increases in resistance levels were observed and it is this aspect which is of 
greatest concern clinically (Gaynes et al, 2005).  
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1.3.1 The Acinetobacter genus 
Acinetobacter spp are a prime example of this group of bacteria. In the last 20 years the 
Acinetobacter genus has emerged as a problem pathogen in hospitals worldwide, 
implicated in nosocomial infections including bacteraemia, secondary meningitis and 
pneumonia, and has generated much attention in the scientific community due to its 
ability to rapidly acquire resistance (Perez, 2007). It is an opportunistic pathogen, 
considered generally harmless to colonised healthy individuals but often leading to 
increased morbidity and mortality when infecting immuno-compromised patients 
(Falagas & Rafailidis, 2007). As well as the ability to rapidly acquire multi-drug 
resistance Acinetobacter spp have the capacity for long-term survival in the hospital 
environment (Jawad et al, 1998; Das et al, 2002). As such hospital ICUs and the patients 
within provide a niche for Acinetobacter, with an environment in which they may be 
exposed to many different antibiotics and have the opportunity to accumulate resistance.  
The more recent growing prevalence of carbapenem-resistant (Evans et al, 2008) and 
pandrug-resistant (Kuo et al, 2004) isolates of Acinetobacter baumannii is of particular 
concern to clinicians, threatening their ability to treat infections. 
 
Acinetobacter spp comprise Gram-negative coccobacilli which are strictly aerobic, 
nonmotile, catalase positive and oxidase negative (Bergogne-Bérézin & Towner, 1996). 
The Acinetobacter genus is genotypically heterogenous and has a complex and 
confusing taxonomic history which has been refined in the last 20 years in tandem with 
the emergence of Acinetobacter spp as nosocomial pathogens (Dijkshoorn et al, 2007). 
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A phenotypic classification system for Acinetobacter speciation was first described in 
1986 (Bouvet & Grimond, 1986) which, together with subsequent systems (Gerner-
Smidt et al, 1991), was useful for identifying most but not all Acinetobacter spp. DNA-
DNA hybridisation has been used to further delineate species (Tjernberg & Ursing, 
1989; Bouvet & Jeanjean, 1989) and there are currently 18 named Acinetobacter spp and 
a further 14 genomic species (gen.sp.), encompassing both clinical and environmental 
strains (see Table 1.2). 
  
The key aspects of this genus are the prevalence of Acinetobacter spp in hospitals, their 
association with nosocomial infections and, most importantly, their ability to rapidly 
develop multi-drug resistance. Acinetobacter baumannii is regarded as the most 
important clinical species of the genus, most frequently involved in nosocomial 
infections (Bouvet & Grimond, 1986; Bergogne-Bérézin & Towner, 1996; Wisplinghoff 
et al, 2000). After A. baumannii, genospecies (gen.sp.) 3 and gen.sp. 13TU are the most 
prevalent species in clinical specimens (Dijkshoorn et al, 2007), and there is evidence 
that these species may also be implicated in nosocomial infections.  
 
Acinetobacter gen.sp.3 has been associated with tracheobronchitis infection (Dijkshoorn 
et al, 1993) and Acinetobacter gen.sp. 13TU is particularly evident in the hospital 
environment; for example, gen.sp.13TU was responsible for hospital outbreaks in the 
Netherlands (van Dessel et al, 2002; van den Broek et al, 2006), has been reported to be 
prevalent in Korean hospitals with a greater resistance rate to imipenem than 
A.baumannii isolates (Lee et al, 2007) and, with A. baumannii, appears to be a prevalent 
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cause of infections in UK hospitals (Spence et al, 2002). The increasing reports of 
gen.sp.13TU may be partly due to an increased awareness of its genetic similarity to A. 
baumannii and the growing ability to discriminate between the two, as mentioned below 
in Section 1.3.2. 
 
Table 1.2 – Species and genomic species of the Acinetobacter genus  
(adapted from Dijkshoorn et al, 2007) 
Species name Source 
 
Acinetobacter calcoaceticus (species 1) Soil and humans (inc. clinical) 
Acinetobacter baumannii (species 2) Humans (inc. clinical), soil, meat, vegetables 
Gen.sp. 3 Humans (inc. clinical), soil, vegetables 
Acinetobacter haemolyticus (species 4) Humans (inc. clinical) 
Acinetobacter junii (species 5) Humans (inc. clinical) 
Gen.sp. 6 Humans (inc. clinical) 
Acinetobacter johnsonii (species 7) Humans (inc. clinical) and animals 
Acinetobacter lwoffii (species 8 & inc. gen. sp. 9) Humans (inc. clinical) and animals 
Gen.sp. 10 Humans (inc. clinical), soil, vegetables 
Gen.sp. 11 Humans (inc. clinical) and animals 
Acinetobacter radioresistens (species 12) Humans (inc. clinical), soil and cotton 
Gen.sp. 13BJ or 14TU Humans (inc. clinical) 
Gen.sp. 14BJ Humans (inc. clinical) 
Gen.sp. 15BJ Humans (inc. clinical) 
Gen.sp. 16 Humans (inc. clinical) and vegetables 
Gen.sp. 17 Humans (inc. clinical) and soil 
Gen.sp. 13TU Humans (inc. clinical) 
Gen.sp. 15TU Humans (inc. clinical) 
Gen.sp. ‘between 1 and 3’ Humans (inc. clinical) 
Gen.sp. ‘close to 13TU’ Humans (inc. clinical) 
Acinetobacter ursingii Humans (inc. clinical) 
Acinetobacter schindleri Humans (inc. clinical) 
Acinetobacter parvus Humans (inc. clinical) 
Acinetobacter baylyi Activated sludge and soil 
Acinetobacter bouvetii Activated sludge 
Acinetobacter towneri Activated sludge 
Acinetobacter tandoii Activated sludge 
Acinetobacter grimontii Activated sludge 
Acinetobacter tjernbergiae Activated sludge 
Acinetobacter gerneri Activated sludge 
Acinetobacter venetianus Sea water 
Letters indicate the initials of the authors of the studies in which the species were designated  
(TU = Tjernberg & Ursing, 1989. BJ = Bouvet & Jeanjean, 1989).  
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1.3.2 Typing and Speciation  
Detailed surveillance of isolates both within and between hospitals, and in the 
worldwide community, is essential for understanding the epidemiology of organisms, 
especially during outbreaks where knowing whether the infecting isolates are clones or 
endemic to the patient may have impacts on both eradication and treatment options.  
 
PFGE with restriction by ApaI is considered a reliable and reproducible method for 
typing of Acinetobacter isolates (Gouby et al, 1992; Seifert et al, 1994). Use of the 
advocated method (Bannerman et al, 1995) with the control strain RUH 2034 for gel 
normalisation, allows comparison of resulting band patterns between laboratories via the 
Antibiotic Resistance Prevention and Control (ARPAC) project’s database (Towner et 
al, 2008). 
 
The species most frequently involved in nosocomial infections, A. baumannii, can not be 
easily separated from A. calcoaceticus (a predominantly environmental species), gen.sp. 
3 or gen.sp. 13TU (also clinically relevant species) by phenotypic means. Commercial 
systems such as the automated Vitek™ system and the API 20NE system from 
bioMériux™, commonly used for identification in diagnostic laboratories, are generally 
considered unsuccessful at delineating different Acinetobacter spp and often classify 
various species as A. baumannii (Bernards et al, 1996; Apisarnthanarak et al, 2007; 
Zbinden et al, 2007).  Even DNA-DNA hybridisation, which remains the ‘gold standard’ 
for determining whether organisms belong to the same species but is outwith the 
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capabilities of most laboratories to perform, does not distinguish well between these 
species, particularly between A. baumannii and gen.sp. 13TU (Tjernberg & Ursing, 
1989). It has been proposed that these 4 species be grouped together into the A. 
calcoaceticus-A. baumannii (Acb) complex (Gerner-Smidt et al, 1991). However, this 
may not be considered wise from a clinical standpoint as it groups the environmental 
strain A. calcoaceticus with the prevalent clinical strains (Dijkshoorn et al, 2007). 
 
The confused taxonomy of the Acinetobacter genus has meant that a quick, reliable and 
reproducible speciation technique which can be employed throughout clinical and 
research laboratories has often been lacking, resulting in confusion and frequent 
misidentification of other species as A. baumannii. As such, several genotypic 
procedures have been developed for the identification of all Acinetobacter spp. including 
tRNA spacer (tDNA) fingerprinting, amplified fragment length polymorphism (AFLP), 
amplified 16S ribosomal DNA restriction analysis (ARDRA) and DNA sequence 
analysis (Ehrenstein et al, 1996; Vaneechoutte et al, 1995; Janssen et al, 1997; Chang et 
al, 2005).  
 
The tDNA fingerprinting method, which amplifies the region between tRNA genes 
(Welsh & McClelland, 1991), is a valuable tool for the rapid identification of most 
Acinetobacter spp (Ehrenstein et al, 1996; Spence et al, 2002; Higgins, 2002), although 
it does not successfully distinguish between A. baumannii and gen.sp. 13TU.  
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Recently there is increasing evidence that A. baumannii has a naturally occurring 
carbapenemase gene, which appears to be intrinsic to this species but absent from other 
Acinetobacter spp.  The blaOXA-51 gene was first described by Dr Susan Brown and 
colleagues (Brown et al, 2005) and since then several highly-related variants have been 
described in global isolates, and are referred to as blaOXA-51-like genes (Turton et al, 2006; 
Evans et al, 2008). It is a matter of some debate whether or not they are present in all 
isolates of the species, but a study screening a variety of well-characterised isolates 
including Acinetobacter spp, Acinetobacter type strains and other Gram-negative 
organisms concluded that only isolates of the A. baumannii species gave a positive result 
for the presence of blaOXA-51-like genes (Turton et al, 2006). This included the ATCC 
19606 A. baumannii type strain. At present it seems reasonable to consider identification 
of the blaOXA-51-like genes a tool for detecting A. baumannii, and to enable distinction 
between A. baumannii and gen.sp. 13TU.  
 
Analysis of the 16S-23S rRNA intergenic spacer sequence, which takes advantage of the 
low intraspecies variation but high interspecies diversification of these regions, has also 
been shown to be a valuable tool for distinguishing species of the Acb complex (Chang 
et al, 2005).  
 
1.3.3 Clinical Impact  
Acinetobacter are often mistakenly considered to be ubiquitous in nature, however this 
does not apply to all species of the genus. The natural reservoir of A. baumannii and 
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other species isolated in the clinical environment is unclear, but it is thought that the 
main transmission routes are via fluid and instrument contamination, from colonised 
patients and health-workers in hospital, and via direct contact (Dijkshoorn et al, 2007). 
Whilst Acinetobacter spp may be found in other wards, ICU wards and patients are most 
frequently affected by A. baumannii (Cisneros & Rodríguez-Baño, 2002), with risk 
factors for infection including immuno-suppression, invasive procedures and previous 
antimicrobial therapy (García-Garmendia et al, 2001). 
  
It has been reported that Acinetobacter spp can spread via airborne transmission within 
hospitals (Bernards et al, 1998) and transmission can also be via cross-infection between 
patients (Dijkshoorn et al, 1987). Additionally Acinetobacter spp are able to survive for 
long periods on dry surfaces (Jawad et al, 1998) and have been found to colonise 
surfaces and fabrics in the hospital environment, including equipment, bed linen and 
curtains (Das et al, 2002), highlighting the importance of the environment as a reservoir. 
There is even a suggestion that vegetables in particular may provide a route of 
introduction into the hospital environment (Berlau et al, 1999), although it is unclear 
whether Acinetobacter were present as colonisers or as a result of environmental 
contamination.  
 
Whilst A. baumannii, and to a lesser extent gen.sp. 13TU, are the most frequently 
associated with hospital infections, further Acinetobacter species are also isolated from 
the clinical environment. These are often considered contaminants when associated with 
clinical samples, but there is some evidence of their involvement in infections, for 
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example A. johnsonnii has been associated with catheter-related bloodstream infection 
(Seifert et al, 1993). It is likely that generally these other species are colonisers; in 
studies examining carriage of Acinetobacter spp, A. lwoffii, A. johnsonii, A. 
radioresistens and gen.sp. 3 were frequently isolated from healthy human skin, whilst A. 
baumannii and gen.sp. 13TU were only rarely isolated (Seifert et al, 1997; Berlau et al, 
1999). Although A. baumannii appears to be the species of greatest clinical importance, 
further investigation has been advocated if there is repeated isolation of other species 
(especially gen.sp. 13TU) associated with clinical symptoms (Bergogne-Bérézin & 
Towner, 1996) and it may be that these strains have as yet undiscovered importance in 
the clinical environment.  
 
The clinical impact of Acinetobacter infection is a matter of debate (Dijkshoorn et al, 
2007); as infections frequently occur in patients with an underlying disease, it has been 
argued that associated mortality is not a direct result of Acinetobacter. However, a recent 
analysis has concluded that A. baumannii infections are associated with increased 
mortality (Falagas & Rafailidis, 2007). In the hospital environment Acinetobacter 
infections are most frequently associated with pneuomonia, especially ventilator-
associated pneumonia, and bloodstream infections (Joly-Guillou, 2005). Increased 
Acinetobacter-associated pneumonia has been reported in a study analysing Gram-
negative bacteria associated with the most common nosocomial infections in the US 
(Gaynes et al, 2005). Additionally there are increasing reports of Acinetobacter 
infections occurring in situations out with the hospital setting. These include 
community-acquired infections, for example community acquired pneumonia associated 
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with A. baumannii (Anstey et al, 2002), and infections in trauma patients, for example a 
prevalence of Acinetobacter wound infections reported during military operations (Davis 
et al, 2005).  
 
1.3.4 Epidemiology  
There are global reports of multi-drug resistant A. baumannii in hospitals, often causing 
outbreaks (Perez et al, 2007). There is also evidence of the spread of multi-drug resistant 
A. baumannii strains between geographically related hospitals; in the UK circulation of 
several widespread outbreak strains of A. baumannii has been reported, the most 
prevalent in the UK being the OXA-23 clone 1 (Turton et al, 2004; Coehlo et al, 2004), 
and inter-hospital spread has been reported in other countries including the Netherlands 
(van den Broek et al, 2006) and the USA (Quale et al, 2003). Additionally, clonal spread 
is evident both within hospitals (Wisplinghoff et al, 2000) and between hospitals; for 
example clones I, II and III (Dijkshoorn et al, 1996; van Dessel et al, 2004) are 
widespread in Europe (Van Looveren & Goossens, 2004). Their widespread occurrence 
may be due to their presence in the community, and expansion in hospitals under 
antibiotic selective pressure (Dijkshoorn et al, 2007). A recent study of isolates from 25 
hospitals in 17 European countries has suggested that broader lineages of carbapenem-
resistant A. baumannii are also circulating through European hospitals (Towner et al, 
2008).  
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The spread of carbapenem-resistant Acinetobacter is of particular concern, as these 
agents are often one of the only treatment options available (Evans et al, 2008). Recent 
Health Protection Agency (HPA) figures, examining data voluntarily reported to the 
HPA for Acinetobacter spp bacteraemia in England, Wales and Northern Ireland from 
2003 to 2007, shows a significant increase in resistance to carbapenems (Imipenem and 
Meropenem) over this period, from 7% to 24% and 3% to 22% respectively (HPA 
website, 2008b). Most worrying is increasing reports of pandrug-resistant isolates (Kuo 
et al, 2004), although the term pandrug must be used cautiously as in fact the isolates 
may still be susceptible to rarely-used agents, such as polymyxin. 
 
1.3.5 Antibiotic Resistance Mechanisms of Acinetobacter spp.  
Acinetobacter was traditionally considered an organism with low pathogenicity, and so 
there were few studies into virulence factors. However, the recognition of the potential 
of A. baumannii in particular to cause specific mortality associated with infections has 
led to increased research into virulence factors, though this is still at a relatively early 
stage. Factors that are important for survival may include the ability to survive on dry 
surfaces (Jawad et al, 1998), metabolic versatility (Bouvet & Grimont, 1986), resistance 
to disinfection (Wisplinghoff et al, 2007), biofilm formation (Tomaras et al, 2003) and 
of course antibiotic resistance. The latter is undoubtedly the most important aspect of 
nosocomial Acinetobacter, particularly of A. baumannii; the ability to rapidly acquire 
multi-drug resistance, when combined with prolonged survival in the nosocomial 
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environment, is the main factor that renders A. baumannii a problematic opportunistic 
pathogen.  
 
Specific resistance mechanisms of A. baumannii for the different antibiotic classes are in 
common with other bacteria and are generally well known. Some of the mechanisms 
which are found in A. baumannii are summarised in Table 1.3, and include target site 
alteration to prevent drug action, enzymatic modification of the drug and efflux systems 
that reduce the accumulation of drug in the bacterial cell.  
 
Table 1.3 – Mechanisms of resistance in Acinetobacter baumannii 








Quinolones Target alteration GyrA  
  ParC 





Chromosomally encoded Class D β-
lactamases 
Thought to be intrinsic to A. baumannii 
  OXA-23-like Plasmid-encoded Class D β-lactamases 
  IMP-1 and others 
  VIM-2, SIM-1 
Class B metallo-β-lactamases 




e.g. AAC(3)-Ia Acetyltransferases 
  e.g. APH(3’)-Ia Phosphotransferases 
  e.g. ANT(2’’)-Ia Nucleotidyltransferases 
 Target alteration ArmA 16 ribosomal RNA methylase 










Extended-spectrum class A β-
lactamases. 
Tetracycline Active efflux Tet(A), Tet(B) Prevalent in European Clones I and II 
Broad resistance  
(inc. quinolones and 
aminoglycoside) 
Active efflux AdeABC Present in most A. baumannii strains 
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However it is the remarkable ability of A. baumannii to rapidly develop multi-drug 
resistance that appears to set it apart from not only other Acinetobacter species, but 
arguably also from other Gram-negative bacteria. So whilst the individual mechanisms 
of resistance to antibiotics are generally well known, the factors contributing to the 
success of A. baumannii in particular at rapidly developing multi-drug resistance and 
prevalence in the hospital environment are not clear.  
 
Because of the frequent isolation of not only A. baumannii but other Acinetobacter spp 
from the clinical environment, it is important to investigate the ability of all of these 
strains to develop multi-drug resistance, to gain a true picture of the clinical situation.  
 
1.4 Fluoroquinolone Resistance 
The modes of action of the major antibiotic classes are shown in Table 1.1. Amongst 
these classes, fluoroquinolones have had the greatest clinical impact of the synthetic 
antibacterials, and are one of the largest classes of antimicrobial agents in worldwide use 
(Ruiz, 2003). However, due to rising bacterial resistance, perhaps the most dramatic 
example of which is resistance to fluoroquinolones (Livermore, 2007), there is an 
increasing call for a more cautious and educated use of these antimicrobials, alongside 
surveillance, in order to maintain their efficacy and that of those developed in the future 
(Applebaum & Hunter, 2000; Emmerson & Jones, 2003; Ruiz, 2003; Van Bembeke et 
al, 2005;).  
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1.4.1 Development of Fluoroquinolones 
Quinolones, from which fluoroquinolones have evolved, originated as a modified 
compound isolated from the antimalarial agent chloroquine (Lesher et al, 1962). 
Patented in 1962, nalidixic acid was the first quinolone, still in use against urinary tract 
infections (UTIs). Further iterations were developed with the addition of fluorination 
leading to use of the first fluoroquinolone, norfloxacin, in 1978. Subsequent iterations 
included ciprofloxacin in 1981 (Appelbaum & Hunter, 2000). Ciprofloxacin has a broad 
spectrum and can be used systemically, is one of the most potent fluoroquinolones 
against Gram-negative bacteria, and is still used for the treatment of a wide range of 
infections (Emmerson & Jones, 2003).The fluoroquinolone class of antibiotics has 
therefore evolved from the limited use of the original quinolone to a large class of broad 
spectrum, systemic antibiotics, with a huge worldwide market. However, it became 
apparent even in the first decade of use that there was a rapid emergence of bacterial 
resistance to ciprofloxacin (Thomson, 1999) and to quinolones in general (Applebaum & 
Hunter, 2000).  
  
1.4.2. Mode of Action of Fluoroquinolones 
Fluoroquinolones interact with two bacterial enzymes, DNA gyrase and DNA 
topoisomerase IV, inhibiting their action. DNA gyrase is a tetramer composed of two 
GyrA and two GyrB subunits, encoded by the gyrA and gyrB genes respectively. 
Topoisomerase IV is likewise comprised of two subunits each of ParC and ParE, 
encoded by the parC and parE genes (Drlica & Zhao, 1997). 
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Both enzymes are essential for bacterial DNA replication, and their inhibition therefore 
leads to the bactericidal effect of fluoroquinolones (Drlica & Zhao, 1997). DNA gyrase 
binds to DNA as a tetramer and introduces negative superhelical twists into DNA 
(supercoiling), necessary for initiating DNA replication (Roca et al, 1995). It also 
removes positive superhelical twists ahead of the replication fork, thereby facilitating the 
movement of replication and transcription complexes through DNA, allowing DNA 
replication. Topoisomerase IV acts in the later stages of DNA replication and separates 
the interlinked daughter chromosomes by decatenation, enabling segregation into 
daughter cells (Zechiedrich et al, 1995).  
 
Fluoroquinolones inhibit these targets by binding to and stabilizing the cleaved 
complexes formed between the enzymes and their substrate DNA. The trapped DNA-
enzyme complex blocks the activities of the enzymes, hence preventing DNA 
replication. This inhibition by fluoroquinolones is not thought to be lethal in itself; the 
bactericidal effect itself is thought to arise from the gyrase-mediated release of DNA 
ends, creating the equivalent of lethal double-stranded DNA breaks (Zhao et al, 1997). 
Different fluoroquinolones have varying affinities for the two target enzymes, and this is 
also dependant on the bacterial target in question. The older fluoroquinolones tend to 
have a higher potency against DNA gyrase than topoisomerase IV in Gram-negative 
bacteria, and vice versa in Gram-positive bacteria. The newer fluoroquinolones tend to 
have a more even activity against both targets (Hooper, 2000). 
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1.4.3 Bacterial Resistance to Fluoroquinolones 
Bacterial resistance to fluoroquinolones is mediated by two main mechanisms: reduced 
drug concentration in the bacterial cell, associated with decreased permeability and over-
expression of efflux mechanisms, and mutations leading to alteration in fluoroquinolone 
targets, preventing the action of these antibiotics. Whereas a decreased drug 
concentration allows for immediate survival and may be inducible the target site 
mutations are stable, and are therefore the primary mechanism of fluoroquinolone 
resistance (Van Bembeke, 2005).  
 
Target site mutations most commonly occur in the gyrA and parC genes, and as the 
affinity of fluoroquinolones for the two targets varies between different bacteria, so the 
specific mutations associated with resistance vary. The commonly reported mutations, 
however, fall within the quinolone resistance determining regions (QRDRs) of these 
genes, comprising amino acids 67 to 106 (numbering for Escherichia coli) as first 
reported in E. coli (Yoshida, 1990).  
 
1.4.4 Clinical Importance of Bacterial Resistance to 
Fluoroquinolones 
Not only does fluoroquinolone resistance development impact upon the ability to treat 
patients and upon the future clinical usefulness of this class, it may also be linked with 
development of multi-drug resistance through associated over-expression of efflux, as 
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discussed for Acinetobacter (Section 1.4.6; Poole, 2001; Higgins et al, 2004; Van 
Bembeke et al, 2005; Vila et al, 2007). Target site mutations in gyrA and parC have also 
been found to be more frequent in outbreak-related than sporadic Acinetobacter strains 
(Wisplinghoff, 2003). There is also evidence that outbreak associated A. baumannii 
strains are significantly more resistant to fluoroquinolones than those associated with 
sporadic infections (Heinemann et al, 2000) agreeing with the suggestion that resistance 
to fluoroquinolones is a risk factor for epidemic behaviour in A. baumannii (Koeleman, 
2001). Additionally, outbreak strains of A. baumannii with high fluoroquinolone MICs 
developed target site mutations in parallel with up-regulation of the AdeB efflux pump, 
which is also associated with resistance to other antibiotics (Higgins et al, 2004; Magnet 
et al, 2001). 
 
1.4.5 Fluoroquinolone Resistance in Acinetobacter spp 
In Acinetobacter, fluoroquinolone resistance is likewise associated with mutations 
within the QRDR of the gyrA and parC genes. Since Vila’s work in the 1990s, which 
looked at the target site mutations of Acinetobacter that developed in response to 
challenge by ciprofloxacin, gyrA has been considered the primary target in 
Acinetobacter, with the Ser83 to Leu mutation being the most common. parC was 
considered the secondary target, with the Ser80 to Leu mutation being the most common 
(Vila, et al 1995; Vila et al, 1997). As such, resistance to fluoroquinolones was 
considered to develop in a stepwise fashion with a mutation in gyrA associated with low 
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level fluoroquinolone resistance and high level resistance being achieved when a parC 
mutation was also present.  
 
In gyrA the loss of the HinfI restriction site GANTC at codons 82 and 83 when the most 
common position for target site mutation is affected (serine-83) allows for analysis with 
HinfI restriction enzyme; the possible existence of a target site mutation is indicated by 
unrestricted gyrA PCR products as seen on an agarose gel. However, since there are 
many substitutions at this site which could give an unrestricted product yet not all are 
associated with fluoroquinolone resistance (Waters & Davies, 1997), sequencing is 
advocated to confirm the indications of restriction analysis. This method, however, 
provides a useful tool for the quick assessment of clinically significant ciprofloxacin 
resistance in a selection of isolates.  
 
Despite the importance of gyrA target site mutations as a stable bacterial resistance 
mechanism to fluoroquinolones, it has become apparent that the situation for parC and 
the development of high-level resistance is not so clear-cut: clinical A. baumannii 
isolates with high moxifloxacin MICs have been reported with a gyrA target site 
mutation but no parC target site mutation (Spence & Towner, 2003); novel mutations in 
both gyrA and parC have been reported in ciprofloxacin resistant A. baumannii isolates 
(Hamouda & Amyes, 2004); and high ciprofloxacin resistant laboratory-generated 
mutants have been reported with no parC mutations (Hamouda & Amyes, 2006).  
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Additionally, quinolone MICs can vary for strains with the same target site mutations 
(Wisplinghoff et al, 2003). These and other results have brought into question the 
importance of parC as a secondary target for fluoroquinolones. It is also considered that 
other mutations and mechanisms such as porin expression, outer membrane 
impermeability and efflux pumps contribute to fluoroquinolone resistance. Of these, 
efflux is increasingly recognised as playing an important role in the development of 
fluoroquinolone resistance in Gram-negative bacteria. Indeed, efflux may be a 
previously overlooked factor in earlier reports of high level fluoroquinolone resistance 
(Poole, 2004).  
 
1.4.6 Efflux-mediated Resistance 
In Gram-negative bacteria efflux systems often have broad substrate specificity, thought 
to work synergistically with the low permeability of the outer membrane to reduce 
antibiotic accumulation and leading to the development of multi-drug resistance (Poole, 
2002). In Acinetobacter the AdeB multidrug efflux pump has been described (Magnet et 
al, 2001), with substrates including aminoglycosides, cefotaxime, tetracyclines, 
erythromycin, chloramphenicol, trimethoprim, fluoroquinolones, and ethidium bromide 
(Vila, 2007). The parallel appearance of target site mutations and up-regulation of the 
adeB gene was observed in outbreaks of A. baumannii, highlighting this organism’s 
ability to rapidly develop multi-drug resistance (Higgins et al, 2004).  
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Whilst the AdeB pump confers resistance to most of these compounds, it was found that 
a further mechanism (presumed to be target site mutations) was necessary for 
fluoroquinolone resistance (Magnet et al, 2001). This supports the concept of 
fluoroquinolone target site mutations as the primary resistance mechanism; AdeB is 
associated with reduced susceptibility, rather than resistance, to fluoroquinolones.  
 
It is unclear whether efflux pump over-expression is directly induced by antibiotics 
(Poole, 2001), but it seems likely that efflux may contribute to the emergence of 
resistant mutants by enabling survival even in sub-optimal concentrations of antibiotics 
(Van Bembeke et al, 2003), as has been found in Pseudomonas aeruginosa 
(Lomovskaya et al, 1999), potentially allowing the development of the stable target site 
mutations. The role of efflux in fluoroquinolone resistance many help to explain 
previously mentioned results (Spence & Towner, 2003; Wisplinghoff et al, 2003; 
Hamouda & Amyes, 2004; Hamouda & Amyes, 2006) where there is variation in MICs 
of isolates with the same target site mutation. 
 
Whilst the development of multi-drug resistance mediated by efflux is of grave concern, 
and despite efflux being increasingly considered an important contributing factor in 
terms of fluoroquinolone resistance in Acinetobacter, it is the target site mutations that 
are the primary mechanism for resistance development, being a stable mutation rather 
than a reversible over-expression.  
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1.5 The Role of Hypermutation in the Development of Antibiotic 
Resistance 
As discussed in Section 1.1, the rise of antibiotic resistance in clinical bacterial 
populations represents a problem of increasing importance with worldwide implications. 
The development of antibiotic resistance observed with the increased use of antibiotics 
is a paradigm of the Darwinian principles of survival of the fittest and the importance of 
variation; with their short generation time bacteria are able to rapidly adapt to new 
environments and stressful conditions, such as challenge with antibiotics. In particular, 
the remarkable ability of Acinetobacter to rapidly develop multi-drug resistance is 
crucial to its predominance as an opportunistic nosocomial pathogen. Evolution through 
genetic variation and selection is fundamental to this ability. It introduces new genes and 
alleles into the population and allows continual resistance development.  
 
1.5.1 Mechanisms of Resistance Development 
As mentioned in Section 1.1.2, bacterial resistance arises through the development of 
variation via horizontal transfer or mutation. Horizontal transfer and mutation may also 
act synergistically; mutation may produce new variations of alleles that have been 
acquired by horizontal transfer. Some examples of mutation in bacterial resistance 
development are detailed in Section 1.5.2. 
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1.5.2 The Importance of Mutation in Resistance Development 
There are several antibiotic resistance mechanisms which involve mutation, 
demonstrated with the following examples. As discussed in Section 1.4.3, resistance to 
fluoroquinolones is mediated primarily via mutations in the gyrA and parC genes, which 
prevent the action of these agents. Mutation can also lead to overproduction of bacterial 
antibiotic-inactivating enzymes such as the cephalosporinase AmpC. Chromosomally 
encoded and usually produced at low-levels, antibiotic treatment can lead to the 
selection of de-repressed mutant cells producing high levels of AmpC, as observed in 
Enterobacter spp. isolates following use of broad-spectrum cephalosporins (Kaye et al, 
2001).   
 
A further effect of mutation upon the expression of ‘intrinsic’ resistance mechanisms is 
exemplified in efflux systems; over-expression of efflux can enhance resistance to 
fluoroquinolones and other agents and may be caused by mutations in regulatory genes, 
as in the efflux systems of Pseudomonas aeruginosa and Klebsiella pneumoniae (Poole, 
2001; Schneiders et al, 2003). As mentioned (Section 1.4.6), increased expression of 
efflux systems can be associated with multi-drug resistance and as such the mutations 
that lead to the over-expression of efflux systems are similarly implicated. This is 
typified in Pseudomona aeruginosa, where raised MICs of antibiotics including 
fluoroquinolones, β-lactams and tetracyclines were associated with up-regulation of the 
mexA-mexB-oprM operon by mutation of mexR. As such multidrug resistance can be 
promoted as a result of mutational over-expression of the efflux genes (Poole, 2001). 
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It is thought that horizontal transfer and mutation work together in many cases of 
antibiotic resistance development (Blázquez, 2003), for example mutation is important 
for the evolution of acquired resistance genes; whilst their dissemination is mediated by 
acquisition via horizontal transfer, mutation of these genes is essential for diversification 
and hence their continued ability to provide bacterial resistance to antimicrobial agents. 
This is exemplified by the ever-expanding group of class-D OXA carbapenemases of 
Acinetobacter; these enzymes are associated with the emergence of carbapenem 
resistance in A. baumannii and their diversification via mutation is fundamental to their 
prevalence worldwide (Brown & Amyes, 2006; Evans et al, 2008).  
 
Finally, mutation can be the predominant resistance development mechanism for a 
species, for example in Mycobacterium tuberculosis where resistance to all therapeutic 
agents is mediated by mutation rather than horizontal transfer (Gillespie, 2002).  
 
Whilst the emergence of antibiotic resistance is a complex process often involving both 
horizontal transfer and mutational events, and varies depending on different 
antimicrobial agents and bacteria, it is apparent that mutation is an important aspect of 
the development and evolution of resistance. 
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1.5.3 The Importance of Mutator Cells in Resistance 
Development 
The importance of mutation in resistance development has led to the theory that an 
increase in the bacterial mutation rate would increase bacterial resistance development 
by increasing the chance of favorable mutations developing. Early work with 
Escherichia coli led to increased interest in the potential importance of mutator cells in 
bacterial populations: Mutator genes were found to confer a selective advantage on a 
population containing them (Gibson et al, 1970); the appearance of new mutants in a 
population was suggested to be an essential part of the evolution of bacteria, with 
spontaneous mutations arising from errors in DNA replication, recombination or repair 
(Cox et al, 1972); and it was demonstrated that an advantageous mutation may become 
fixed in a bacterial population, linking the associated mutator with it, now termed ‘hitch-
hiking’ (Cox, 1976). 
 
Mutator cells and hypermutation have been identified in natural populations of several 
different species of bacteria. Reports include a high incidence of mutators in Escherichia 
coli and Salmonella enterica outbreak isolates (LeClerc et al, 1996), a high frequency of 
mutators in human uropathogenic E. coli isolates (Denamur et al, 2002) and mutators in 
both pathogenic and commensal strains of E. coli (Matic et al, 1997). A high frequency 
of mutators has also been reported in Serogroup A Neisseria meningitides isolates 
(Richardson et al, 2002) and Haemophilus influenzae and Pseudomonas aeruginosa 
isolated from the CF lung (Watson Jr. et al, 2004; Oliver et al, 2000).  
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Hypermutators have been most commonly associated with defects in the mismatch 
repair (MMR) system (detailed in Section 1.5.4), determined through analysis of clinical 
isolates (LeClerc et al, 1996; Matic et al, 1997; Watson Jr. et al, 2004; Oliver et al, 
2000) and also demonstrated in laboratory studies where defective MMR has been 
associated with hypermutation and/or resistance development in bacteria including E. 
coli, Salmonnellae spp, Staphylococcus aureus, P. aeruginosa and A. baumannii (Zahrt 
et al, 1994; Mao et al, 1997; Oliver et al, 2002; Miller et al, 2002; Schaaff et al, 2002; 
O’Neill & Chopra, 2002; Young & Ornston, 2001). 
 
Whilst it is apparent that mutators exist in the natural populations of several species of 
bacteria, their role in antibiotic resistance development is subject to some debate. There 
has been increasing interest and a great deal of research into the existence and relevance 
of mutators within bacterial populations in resistance development, including laboratory 
studies and animal modeling of mutator populations and dynamics. Some aspects of this 
area are summarized below. 
 
Laboratory studies of E. coli have indicated an advantage conferred by increased 
mutation rates, with mutator cells increasing in populations compared to non-mutators, 
and proliferating in a population following selections with antibiotics, highlighting the 
potential for antibiotics to indirectly select for mutator cells (Chao, 1983; Mao, 1997). 
Computer simulation has indicated that mutator genotypes can be important in adaptive 
evolution, and may become fixed in the population by ‘hitch-hiking’ with the 
advantageous mutations they generate (Taddei et al, 1997). This has also been shown 
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using a mouse model, demonstrating the selection of mutator bacteria present at low 
frequencies in wild type E. coli populations during a course of antibiotic treatment, the 
mutator allele being selected as the mechanism that generated the antibiotic resistance 
(Giraud et al, 2002). 
 
There is some debate about whether mutator cells are always present in populations or 
are the result of a transient increase in mutation rate (Chopra et al, 2003). Whilst it had 
been thought that the mutation rate of bacterial populations would evolve to be as low as 
possible due to the accumulation of deleterious mutations and fitness costs associated 
with the mutator phenotype (Funchain et al, 2000), the frequent occurrence of mutator 
cells isolated from naturally occurring bacterial populations questions this assumption. It 
is thought that the existence of mutators in a population may be due to their recent 
passage through a bottleneck, leading to cells within the population with increased 
mutation rates and associated beneficial mutations being selected (Chopra et al, 2003). 
Deficiencies in the MMR system, described in more detail in Section 1.5.4, are 
frequently associated with mutator phenotypes and this is thought to be an important 
aspect in the balance between variation and stability (Woodford & Ellington, 2007).  
 
There is evidence that the initial fitness costs associated with mutators may be limited by 
compensatory mutations arising. This has been demonstrated in the mouse model study 
described above, where it was found that compensatory mutations were rapidly 
accumulated (Giraud et al, 2002). Also, compensatory mutations were found to be 
common in gyrA and parC mediated quinolone resistant Pseudomonas aeruginosa 
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isolates, increasing their fitness (Kugelberg et al, 2005). Additionally, fitness costs may 
be attenuated by adaptation during multiple passages (Björkman et al, 2000). Hence it 
seems possible that mutator cells can exist in populations and that the elevated mutator 
rates of hypermutators in a bacterial population could increase the frequency of 
antibiotic resistance development, whilst also increasing the chance of parallel 
compensatory mutations arising to reduce fitness costs associated with the increased 
mutation rate.  
 
However, higher mutation rates also do not necessarily result in an increased ability to 
develop resistance (Matic et al, 1997; Denamur et al, 2002; O’Neill & Chopra, 2002;) 
and there is concern about the different uses of mutation rates and the variance in data 
from different studies (Martinez & Baquero, 2000; Woodford & Ellington, 2007). 
Therefore there must be caution in considering a higher mutation rate in isolation as a 
cause of resistance development.  
 
Whilst there is a potential role for hypermutation in resistance development, the 
relevance of hypermutators in the clinical environment can be contentious. However 
hypermutation is considered a key factor in the development of resistance in P. 
aeruginosa isolates in the CF lung and other chronic infections. There are reports of high 
frequencies of hypermutable P. aerunginosa strains in patients with cystic fibrosis and 
other chronic lung infections, compared with populations of acute infections. Mutators 
were most commonly MMR-deficient with the mutS gene implicated, were associated 
with substantially higher resistance rates, and were associated with multi-drug 
Chapter 1 – Introduction 
 55 
resistance. This has led to hypermutation being considered a key factor for multi-drug 
resistance development of P. aeruginosa and its long-term persistence (Oliver et al, 
2000; Oliver et al, 2002; Oliver et al, 2004; Maciá et al, 2005). In addition, a recent 
study reported a higher than expected prevalence of mutators in early infection and 
environmental isolates, which are thought to be the primary source of infection (Kenna 
et al, 2007).  
 
Whether hypermutation is a result of pre-existing mutator cells or transient 
hypermutation, or more likely a complex interplay between these and other aspects of 
bacterial population dynamics, the documented existence of hypermutators in natural 
bacterial populations, their association with antibiotic resistance in both laboratory and 
clinical isolates, and their potential relevance in the clinical environment is undoubtedly 
an important area of research.  
 
1.5.4 The Mismatch Repair System and Role in Hypermutation 
Genetic change mediated by mutation in bacteria occurs predominantly through errors 
arising during DNA replication. Of the mechanisms involved in regulating this process, 
the most important is the mismatch repair (MMR) system, crucial to avoid mutations 
and maintain the integrity of the genome. Hence, defects in MMR lead to associated 
replication errors and increase the spontaneous mutation rate, and are the mechanism 
most frequently associated with hypermutation in bacterial populations (Hsieh, 2001; Li, 
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2008), as mentioned above in Section 1.5.3. MMR is a highly conserved pathway, 
especially well characterized in E. coli, and its function in mismatch correction is now 
known to require several proteins in addition to the principal proteins MutS, MutL and 
MutH (Li, 2008). 
 
The primary function of MMR is to carry out post-replication repair, correcting 
mismatches that arise during DNA replication. It can also function as a barrier to 
interspecies recombination, by preventing the recombination process between similar 
but not identical sequences (Rayssiguier et al, 1989), hence its inactivation can lead to a 
potential increase in horizontal transmission between species (LeClerc et al, 1996). 
MutS, homologues of which have been found throughout prokaryotes and eurkaryotes, 
initiates MMR by recognising and binding specifically to base/base and 
insertion/deletion mismatches (Obmolova et al, 2000; Lamers et al, 2000; Lamers et al, 
2003). Recent work using atomic force microscopy has further elucidated the 
mechanism of MutS searching for and recognising mismatches (Tessmer et al, 2008). In 
the presence of ATP, MutL then interacts with MutS and activates MutH. MutH then 
specifically cleaves the transiently unmethylated daughter strand at hemimethylated 
GATC sequences (Hsieh, 2001). 
 
The importance of MMR, and in particular MutS, is apparent from the prevalence of 
mutator phenotypes associated with MMR-deficiency via defects in the mutS gene; 
defective mutS has been associated with mutators in clinical isolates of bacteria 
including E. coli, S. enterica and P. aeruginosa (LeClerc et al, 1996; Watson Jr. et al, 
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2004; Oliver et al, 2002). An elevated mutation frequency due to mutS-knockout has 
been shown to correlate with the development of vancomycin resistance in S. aureus 
isolates (Schaaff et al, 2002), and mutations in the mutS gene of Enterococcus faecium 
isolates have also been correlated to linezolid resistance, even in the absence of 
detectable hypermutation (Willems et al, 2003). Additionally inactivation of MMR has 
been demonstrated to overcome the barrier in transduction between Salmonella 
typhimurium and Salmonella typhi (Zahrt et al, 1994), due to its function as a barrier to 
interspecies recombination. Phylogenetic studies have also indicated that there is 
horizontal transfer of the mutS gene of naturally occurring E. coli, consistent with a 
possibility of transient hypermutation via the balance of adaptive changes by mutation 
and subsequent rescue of defective mutS alleles (Denamur et al, 2000; Brown et al, 
2001).  
 
1.5.5 The mutS gene of Acinetobacter 
In Acinetobacter there has to date been no study of MMR-deficiency in clinical isolates. 
However, Young and Ornston have characterized the mutS gene from Acinetobacter sp. 
strain ADP1 (Young & Ornston, 2001). ADP1, sometimes referred to as BD413, is a 
derivative of the soil isolate Acinetobacter sp. strain BD4, and has since been classified 
as a member of the recently established species Acinetobacter baylyi. ADP1 and other 
members of this species are characterized by a natural transformation system, resulting 
in an unusual potential for acquiring foreign DNA (Vaneechoutte et al, 2006).  
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Comparison of the mutS sequence of ADP1 with other Gram-negative bacteria identified 
a substantial sequence correlation, especially within the mismatch-binding and helix-
turn-helix domains, but identified six indels present in the mutS sequence of ADP1. 
Several other Acinetobacter strains examined also had these indels, separating 
Acinetobacter from other Gram-negative bacteria, with indel one also separating 
different Acinetobacter strains.  Inactivation of the mutS gene was shown to increase the 
frequency of rifampin resistance mutations in ADP1 to 54-fold greater than that of the 
wild-type strains. Additionally, inactivation of mutS significantly increased the 
transformation frequencies for most divergent donors, as has been found in other 
organisms (Young & Ornston, 2001).  
 
These results suggest that hypermutation, and particularly defective mutS causing 
malfunctioning MMR,  may be a factor in the ability of clinical Acinetobacter to rapidly 
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1.6 Summary, Hypotheses and Aims 
• Both Gram-positive and Gram-negative nosocomial bacteria are current causes 
for concern in the clinical environment, as exemplified by methicillin-resistant 
Staphylococcus aureus (MRSA) and Acinetobacter spp, particularly A. 
baumannii. 
• The rise of multi-drug antibiotic resistance and the associated threat to treatment 
and control options is the principal factor leading to increased concern. 
 
1.6.1 Acinetobacter Summary 
• The Acinetobacter genus is diverse and has a complex taxonomic history, 
traditionally making speciation difficult. 
• A. baumannii is the species of primary clinical importance, although other 
species are also isolated in the clinical environment and there is increasing 
recognition of the importance of other species, especially genospecies 13TU. 
• The ability to rapidly acquire multi-drug resistance is fundamental to the success 
of A. baumannii in particular as an opportunistic pathogen; whilst individual 
resistance mechanisms are known, factors contributing to this ability are unclear.  
• Hypermutation and mutator cells are increasingly considered an important factor 
in the development of antibiotic resistance in several bacterial species, 
particularly Pseudomonas aeruginosa. 
• Defects in the mutS gene have been associated with hypermutation via deficient 
mismatch repair, increased ability to develop resistance, and increased 
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transformation frequencies, but there has been no investigation of clinical 
isolates to date. 
• Inactivation of the mutS gene of the non-clinical Acinetobacter baylyi strain 
ADP1 led to increased frequency of rifampin resistance mutations and increased 
transformation frequencies.  
• Increased mutation frequencies alone do not necessarily predict increased 
antibiotic resistance development. 
• Fluoroquinolone resistance is a risk factor for epidemic behaviour in 




That genetically distinct sub-populations of Acinetobacter spp clinical isolates exist, 
with variations in the mutS gene, able to more rapidly develop antibiotic resistance 
through defective mismatch repair.  
 
1.6.3 Aims 
• Speciation of clinical Acinetobacter spp isolates. 
• Characterisation of the mutS gene of clinical Acinetobacter spp isolates with 
varying antibiotic susceptibilities. 
• Comparison of the mutS gene of clinical Acinetobacter spp isolates between each 
other and against non-clinical strains: is there mutS gene variation? 
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• Analysis of the mutS gene of clinical Acinetobacter spp isolates in terms of 
sensitivity: does any variation in the mutS gene of clinical isolates correlate with 
varying antibiotic susceptibility? 
• Mutation studies to determine the ability of sensitive and intermediate-resistant 
Acinetobacter spp clinical isolates to develop antibiotic resistance, measured by 
development of resistance to ciprofloxacin and comparison to resistant isolates: 
is any variation in the mutS gene of clinical isolates associated with varying 





1.6.4 MRSA Summary 
• Increasing antibiotic resistance in MRSA and the emerging threat of CA-MRSA 
in the hospital environment means infection control is an essential tool.  
• With resurgence of infection control has come an increase in the use of biocides 
such as chlorhexidine, both in the clinical and domiciliary environment. 
• Whilst in-use biocide concentrations are high, they may be present at low 
concentrations in the hospital environment. 
• Low concentrations of biocide have been found to select for reduced 
susceptibility isolates and associated antibiotic resistance. 
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1.6.5 Hypothesis: 
That low concentrations of chlorhexidine exert selective pressure on clinical MRSA 
isolates and are less effective against clinical isolates than standard strains, leading to the 
development of reduced susceptibility to chlorhexidine associated with increased 
antibiotic resistance.  
 
1.6.6 Aims 
• To assess the efficacy of low concentrations of chlorhexidine upon current 
clinical MRSA isolates: is there variation in the susceptibility of clinical isolates? 
• To compare the efficacy of low concentrations of chlorhexidine upon clinical 
MRSA isolates and standard strains: is chlorhexidine more effective against 
standard strains than against clinical MRSA isolates? 
• To determine whether exposure of clinical MRSA isolates to chlorhexidine 
residues is associated with the development of antibiotic resistance.  
 




Chapter 2: Materials and Methods 
2.1 Bacterial Strains 
Clinical Acinetobacter spp. isolates were collected from the blood culture collection of 
the Royal Infirmary Edinburgh (RIE) clinical labs, comprising isolates from 1995-1999. 
They were sub-cultured and stored at -70°C in Nutrient Broth (Oxoid, UK) containing 
10% glycerol. Previously collected isolates from worldwide sources from the isolate 
collections of Dr Paul Higgins and Dr Susan Brown were also used. Standard strains and 
prevalent outbreak Acinetobacter strains were also included for comparison. These are 
detailed in Table 2.1 and some were kindly gifted by Dr Kevin Towner and Dr Jane 
Turton, as stated.  
Table 2.1 – Type strains and other strains used 
Strain Number Source 
Acinetobacter calcoaceticus (sp. 1) ATCC 23055 Kevin Towner 
Acinetobacter baumannii (sp. 2) ATCC 19606 Laboratory collection 
Acinetobacter gen.sp. 3 ATCC 19004 Kevin Towner 
Acinetobacter haemolyticus (sp. 4) ATCC 17906 Kevin Towner 
Acinetobacter junii (sp. 5) ATCC 17908 Kevin Towner 
Acinetobacter gen.sp. 6 ATCC 17979 Kevin Towner 
Acinetobacter johnsonii (sp. 7) ATCC 17909 Kevin Towner 
Acinetobacter Iwoffii (sp. 8) ATCC 5866 Kevin Towner 
Acinetobacter radioresistens (sp. 12) - Kevin Towner 
Acinetobacter gen.sp. 13TU - Kevin Towner 
A. baumannii NW strain JTA Jane Turton 
A. baumannii W strain/European clone 1 JTB Jane Turton 
A. baumannii Midlands 2 JTC Jane Turton 
A. baumannii T strain JT3 Jane Turton 
A. baumannii SE Clone JT4 Jane Turton 
A. baumannii OXA-23 Clone 2 JT6 Jane Turton 
Escherichia coli NCTC 10418 Laboratory collection 
Pseudomonas aeruginosa NCTC 10662 Laboratory collection 
Staphylococcus aureus NCTC 6571 Laboratory collection 
 




The A. baumannii type strain ATCC 19606 and the environmental A. baylyi strain ADP1 
(also known as BD413) were also included as controls during the study. The mutS 
sequences of further non-clinical control strains (Young & Ornston, 2001) were also 
used during sequence analysis. Strains of Pseudomonas aeruginosa, Staphylococcus 
aureus and Escherichia coli were used as controls in MIC determination, as detailed in 
Section 2.7. 
 
Clinical MRSA samples were collected from the New Royal Infirmary Edinburgh 
(NRIE) clinical labs from February to April 2006, sub-cultured on blood agar and stored 
at -70°C on beads. Only hospital-acquired MRSA isolates (isolated after 48 hours of 
admission) were included. The prevalent Epidemic MRSA (EMRSA) strains 15 and 16 
were gifted by Dr Leila Vali for use in this study.  
 
2.2 Broths and Agars 
Unless otherwise indicated, all broths and agars were obtained from Oxoid (Basingstoke, 
UK), reconstituted with distilled water in the lab according to the manufacturer’s 
instructions and autoclaved before use to ensure sterility. The broths and agars used are 
detailed in Table 2.2 

















2.3 Reagents and Buffers 
Unless otherwise stated, reagents and components of buffers were obtained from Sigma-
Aldrich, Poole, UK. Commonly used solutions are detailed in Table 2.3 below. Primers 
used in PCR reactions are detailed in Table 2.4. 
 
Table 2.3 Solutions and their components 
Solution Components 
Saline (0.85%) 4.5 g NaCl in 500 ml SDW, autoclaved.  
TAE buffer 40 mM Trizma base, 20 mM EDTA (disodium), in SDW, pH 8 
10 x TBE buffer 
1.0 M Trizma base, 0.9 M Boric acid, 10mM EDTA (disodium), in SDW, pH 8.2-
8.4, autoclaved. 
TE buffer 10mM Tris-HCl, 5mM EDTA, in SDW, pH 7.5, autoclaved. 
ES buffer 
0.5mM EDTA, 10% Sarkosyl, in SDW, pH 8, filter sterilised, 1mg/ml Proteinase 
K added before use. 
Agarose LMP BioGene 
Agarose BioGene 
Neutraliser 0.75% (w/v) azolectin and 5% Tween 80 in SDW, autoclaved 
 
 
Table 2.4 Primers used for mutS PCR 























Designed by Dr Susan 




Vila et al, 1995 
 




2.4 Antimicrobial agents 
Antibiotics and other antimicrobial agents used are detailed in Table 2.5 
 
Table 2.5 Antimicrobial agents, their abbreviations and sources 
 
Antimicrobial Source 
Ampicillin AMP Sigma-Aldrich, Poole, UK 
Augmentin  
(co-amoxyclavulanic acid) 
AUG Sigma-Aldrich, Poole, UK 
Cefotaxime CTX Roussel Laboratories, Romainville, France 
Cefuroxime CEF Sigma-Aldrich, Poole, UK 
Ceftazidime CAZ GlaxoSmithKline, Stevenage, UK 
Chlorhexidine 
 diacetate hydrate 
CHX Sigma-Aldrich, Poole, UK 
Chlorhexidine digluconate CHG Sigma-Aldrich, Poole, UK 
Ciprofloxacin CIP Bayer AG, Leverkusen, Germany 
Gentamicin GEN Sigma-Aldrich, Poole, UK 
Imipenem IMP MerckSharpeDohme, NJ, USA 
Meropenem MER Zeneca Pharm., Macclesfield, UK 
Oxacillin OXA Sigma-Aldrich, Poole, UK 
Tetracycline TET Sigma-Aldrich, Poole, UK 
Vancomycin VAN Sigma-Aldrich, Poole, UK 
 
2.5.1 Preparation of DNA for PCR – Acinetobacter spp 
After growth of a sample of the stored isolate on an MC agar plate overnight, a single 
colony was resuspended in 50 µl sterile MilliQ water and boiled for 10 minutes. 
Following snap-cooling on ice and a brief centrifugal step, the supernatant was then used 
in subsequent PCR reactions.  
 
 




2.5.2 Preparation of DNA for PCR - MRSA 
DNA was prepared using the rapid lysis procedure (Ünal, 1992) whereby a 1µl loop of 
overnight growth was resuspended in 50µl 100µg/ml lysostaphin, incubated for 10 
minutes at 37°C, 50µl of 100µg/ml Proteinase K and 150µl 0.1M Tris buffer were added 
and the mixture incubated for 10 minutes at 37°C followed by boiling for 5 minutes. 
 
2.6.1 Speciation of Acinetobacter isolates 
2.6.1.1 tDNA fingerprinting method 
Speciation to genomic group level was performed by PCR amplification and restriction 
of tRNA spacer regions using a modified method (Ehrenstein et al, 1996). ATCC type 
strains (detailed in Table 2.1 above) were included to enable comparison. One pmole/µl 
aliquots of each primer T3A and T5B (Table 2.4) were added to a PCR mixture 
comprising 2µl DNA (from lysate) and PCR components from Promega: 1 x buffer, 1.5 
mM MgCl2, 0.2 mM each dNTP and 2 units of Taq DNA polymerase, with SDW to give 
a final volume of 50µl.  
 
PCR mixtures were cycled in a Hybaid Px2 Thermal Cycler under the following 
conditions: 94°C for 2 minutes; 45 cycles of: 94°C for 40 seconds, 50°C for 40 seconds, 
72°C for 2 minutes; 72°C for 3 minutes. Products were run on a 2% agarose gel 
(biogene) in 1xTAE buffer at 120V for 90 minutes, stained with ethidium bromide, and 
visualised under UV light (Bio-Rad Gel Doc 2000, Bio-Rad). Band patterns were 




compared to reference strains using the BioNumerics™ software package (version 3.0, 
Applied Maths MVBA, Saint-Martens-Latem, Belgium).  
 
2.6.1.2. OXA-51-like PCR  
OXA-51-like genes were detected using a modified method (Turton et al, 2006). 
Template DNA was amplified using primers OXA-51-likeF and OXA-51-likeR (Table 
2.4) in a 20μl PCR reaction containing HotStarTaq Plus Master Mix (Qiagen). PCR 
mixtures were cycled in a Hybaid Px2 Thermal Cycler under the following conditions: 
95˚C for 5 minutes; 30 cycles of: 94˚C for 25 seconds, 52˚C for 40 seconds, 72˚C for 50 
seconds; 72˚C for 6 minutes. Products were run on a 1.5% agarose gel (biogene) in 
1xTAE buffer at 100V for 40 minutes, stained in ethidium bromide, and visualised under 
UV light (Bio-Rad Gel Doc 2000, Bio-Rad). The presence of OXA-51-like was 
indicated by a band of 353bp.  
 
 
2.6.2 Confirmation of Presence of mecA in MRSA Isolates 
Isolates collected from the NRIE clinical labs were confirmed as MRSA by PCR of the 
mecA gene. Ten µl lysate was used in a mecA PCR reaction of final volume 50μl 
comprising SDW, 25µl HotStar Taq (Qiagen) and 10pmole each primer MecA1 and 
MecA2 (Table 2.4). PCR mixtures were amplified in a Hybaid Px2 Thermal Cycler 
(Thermal Hybaid, Ashford, UK) according to the following cycling: 1 cycle of 15 
minutes at 95°C; 30 cycles of: 1 minute at 94°C, 1 minute at 50°C, 1 minute at 72°C; 1 
cycle of 10 minutes at 72°C. PCR products were run on a 1.5% agarose gel (Biogene) 




against a mecA positive control by electrophoresis in TAE buffer at 100 volts, stained in 
0.5 mg/ml ethidium bromide and visualized under UV light (Bio-Rad Gel Doc 2000, 
Bio-Rad).  
 
2.7 Minimum Inhibitory Concentration (MIC) determination 
MIC testing for a range of antibiotics was performed by the agar dilution method, 
according to the British Society for Antimicrobial Chemotherapy (BSAC) guidelines for 
susceptibility testing (Andrews, 2001; MacGowan & Wise, 2001). To summarise, an 
overnight culture of each bacterial sample in IST broth (107-108 cfu/ml) was diluted in 
sterile 0.85% saline to approximately 104 cfu/ml and inoculated onto IST agar plates 
containing a range of antibiotic concentrations (0.002-256 mg/L), using a Denley 
Multipoint Inoculator to give 104 cfu/spot. Following overnight incubation the results 
were interpreted according to the BSAC guidelines (Andrews, 2001; MacGowan & 
Wise, 2001). Escherichia coli NCTC 10418, Pseudomonas aeruginosa NCTC 10662, 
Staphylococcus aureus NCTC 6571 and Acinetobacter baumannii ATCC 19606 were 
used as control strains.  
 
2.8 PFGE typing of Acinetobacter isolates 
The protocol was that advocated by the Antibiotic Resistance Prevention And Control 
(ARPAC) project (Bannerman et al, 1995).  
 
 




2.8.1 Plug Production 
Isolates were subcultured onto MC agar plates and a suspension made into 2 – 3 ml TE 
buffer. Turbidity was adjusted to an optical density of 1.8 – 2.0 using a 
spectrophotometer at a wavelength of 540nm. 2% w/v low-melting point agarose in TE 
buffer was prepared and kept warm until use. Bacterial solution (500µl) was transferred 
into and Eppendorf tube, and 500µl melted agarose added and mixed. Aliquots of 150µl 
were dispensed into each plug mould and plugs allowed to set for 20 minutes at 4°C. 
Plugs were transferred into a Universal bottle containing 3 ml of ES solution with 1 
mg/ml Proteinase K, then incubated at 55°C for 3 hours. Plugs were washed four times 
with 5 ml TE buffer for 3 hours, with one wash overnight, and stored at 4°C. 
 
2.8.2 Restriction Digestion 
A slice of each plug was cut and washed with TE buffer for 15 minutes. The TE was 
removed and plugs washed twice with ApaI buffer (Promega) for 20 minutes each time. 
ApaI buffer (200μl) and 20 units ApaI restriction enzyme was then added and plugs 
incubated at 30°C overnight.  
 
2.8.3 Gel Preparation 
A PFGE gel was prepared using 1.5% w/v agarose in 0.5xTBE. 0.5xTBE was added to 
the CHEF-DR II electrophoresis cell and chilled to 14°C before the beginning of the run. 
The restriction enzyme mixture was aspirated from the plugs and rinsed with 200µl 
0.5 x TBE and the slices added to the wells in the gel, with strain RUH 2034 and a 




lambda ladder being run alongside the samples. The wells were sealed with molten 
agarose and allowed to set for 10 minutes then loaded into the PFGE chamber.  
 
2.8.4 Electrophoresis and Visualisation 
PFGE was performed on the CHEF-DR II electrophoresis cell with a ramped pulse, 
initial 5 seconds, final 13 seconds, 200V for 20 hours at 14°C. Gels were then stained 
with ethidium bromide for 45 minutes and de-stained with SDW for several hours before 
being visualised under UV light (Bio-Rad Gel Doc 2000, Bio-Rad) and analysed using 
the BioNumerics™ software package (version 3.0, Applied Maths MVBA, Saint-
Martens-Latem, Belgium).  
 
2.9 Sequencing of the mutS gene of Acinetobacter isolates 
2.9.1 PCR of the mutS gene 
Degenerate primers were designed, by Dr Susan Brown, from areas of amino acid 
conservation in the mutS sequences of Acinetobacter sp. strains ADP1, 93A2, AD321, 
AC423D and LUH540 (Young and Ornston, 2001), and synthesized by MWG-Biotech 
AG (Cork, Ireland). Inosine was inserted to reduce degeneracy at positions where any of 
the four bases were required.  Sections of the N-terminal region were PCR amplified. 
The PCR required optimisation with different combinations of primer pairs. The primers 
used are shown in Table 2.4. 
 




One µl of template DNA was amplified using components from Promega, Southampton, 
UK in a PCR mixture containing: 10 x Buffer (10 mM Tris-HCl, 50 mM KCl), 1.5 mM 
MgCl2, PCR Nucleotide Mix (containing 10 mM each dNTP), 2 pmol/µl each primer 
LH1/C and RH1/F, 2 units of Taq DNA polymerase and MilliQ water to give a final 
volume of 50 µl.  
 
PCR mixtures were amplified in a Hybaid Px2 Thermal Cycler (Thermal Hybaid, 
Ashford, UK) according to the following cycling: 35 cycles of 95°C for 1 minute, 
gradient temperature of 35-50°C for 1 minute, 72°C for 1 minute; 1 cycle of 72°C for 5 
minutes. Gradient cycling was used to allow a range of annealing temperatures to be 
used simultaneously for each reaction, hence facilitating the optimization of the 
annealing temperature variable for each isolate.  
 
2.9.2 Gel Electrophoresis 
PCR products were run on a 2% low-melting-point agarose gel (preparative grade, 
Promega) by electrophoresis in TAE buffer at 100 volts, stained in 0.5 mg/ml ethidium 
bromide and visualized under UV light (Bio-Rad Gel Doc 2000, Bio-Rad). A 100 bp 
DNA ladder was run alongside for visual sizing of the bands. The specific band (489 bp) 








2.9.3 Sequencing and Analysis 
Sequencing of the purified products was performed by DNAShef, The Royal Infirmary, 
Edinburgh. Sequences were analysed by alignment using hierarchical clustering against 
control strains (Corpet, 1988).  
 
2.10 Mutation Studies of Acinetobacter isolates 
2.10.1 Generation of Mutants 
Mutants were selected by challenge with ciprofloxacin. Parent strains were sub-cultured 
onto MC agar and a colony re-suspended in IST broth for 24 hours at 37°C. First-step 
mutants were selected in triplicate on IST agar containing 2 x parent MIC of 
ciprofloxacin. 100µl of neat broth was spread onto each of three plates and a 1:100 
dilution of broth was spread onto a further three plates.  
 
Non-selective IST plates were similarly inoculated to enable a viable count to be 
determined for each parental strain. The viable count plates were incubated for 24 hours 
at 37°C and colony counting performed. The selective plates were inoculated for up to 
48 hours at 37°C and colony counting performed, using either the neat or 1:100 plates 
depending on which gave the appropriate colony numbers per plate. The mutation 
frequency was calculated as the ratio of potential mutants to viable colonies for each 
isolate.  
 




Up to 10 mutants were picked from each plate, sub-cultured on non-selective MC agar, 
and stored in nutrient broth with 10% glycerol at -70°C. Ciprofloxacin MICs were 
determined for all picked mutants. Those with raised MIC values compared to their 
parent were used to generate second-step mutants as described above, by challenge with 
2 x first-step mutant MIC of ciprofloxacin.  
 
2.10.2 Mutant Stability  
The stability of certain mutants of interest was determined by a tenfold passage on non-
selective MC agar with mutants being considered stable if the MICs remained 
unchanged after the passaging. 
 
2.10.3 PCR Amplification of the gyrA QRDR of parents and 
mutants 
The gyrA QRDRs of first-step mutants and, where appropriate, second-step mutants 
were amplified. Parental strains were also amplified for comparison. Despite 
optimization, it was not possible to amplify all gyrA QRDRs to a sufficient degree of 
specificity using standard materials. However the use of HotStarTaq DNA Polymerase 
(Qiagen), to prevent the formation of mis-primed products and primer-dimers at low 
temperatures, increased the specificity of the PCR and enabled successful amplification 
of more of the isolates.  
 




The gyrA QRDRs of samples were amplified in reactions containing: 30 pmol/µl each 
primer gyrA1 and gyrA2 (Table 2.4), 1 mM MgCl2, 10 µl template DNA, 25µl 
HotStarTaq Master Mix (2.5 units HotStarTaq DNA Polymerase, 1 x PCR buffer, 200 
µM each dNTP) with MilliQ water to give a final volume of 50 µl. 
 
Reactions were amplified in a Hybaid Px2 Thermal Cycler (Thermal Hybaid, Ashford, 
UK) according to the following cycling: 95°C for 15 minutes; 32 cycles of 94°C for 1 
minute, 57.5°C for 1 minute, 72°C for 1 minute; 72°C for 5 minutes.  
 
Products were visualised as described previously on 1.5% agarose (BioGene Ltd, 
Kimbolton, UK) stained with Ethidium Bromide under UV light. A band of 343 bp 
indicated successful amplification of the gyrA QRDR. 
 
2.10.4 HinfI RFLP analysis of gyrA PCR Products  
Target site mutations at position 83 in GyrA are associated with loss of the HinfI 
restriction site in gyrA PCR products of Acinetobacter (Vila et al, 1995). To give an 
indication of whether target site mutations were present in the isolates, 10 µl of PCR 
product was added to 2 µl restriction enzyme buffer (10 mM Tris-HCl, 50 mM NaCl, 0.1 
mM EDTA, 1 mM DTT, 50% glycerol), 0.2 µl bovine serum albumin (0.5 mg/ml) and 5 
units HinfI (Promega), with MilliQ water to a final volume of 20 µl. Reactions were 
incubated for 2 hours at 37°C and the products run on a 1.5 % agarose gel and visualised 
under UV light as described previously.  




An intact restriction site (i.e. no target site mutation) was indicated by two bands of 291 
bp and 52 bp for gyrA. Restricted and unrestricted ATCC 19606 samples were run 
concurrently as controls.  
 
2.10.5 Sequencing of gyrA PCR Products 
To confirm any indication of target site mutations from the RFLP detailed above and 
determine whether any other changes were present in the sequences gyrA PCR products 
were purified using a PCR Purification Kit (Qiagen), sequenced as described previously, 
and aligned using hierarchical clustering (Corpet, 1988) against parent strains and the 
control ciprofloxacin-susceptible strain HCP-77 (Vila et al, 1995). 
 
2.11 Biocides and MRSA 
2.11.1 Preparation of Bacterial Cells 
Where a washed suspension of bacterial cells was required, isolates were grown 
overnight in 10 ml nutrient broth at 37°C. Broths were centrifuged at 1500g for 10 
minutes, the supernatant discarded, and the pellets washed twice in 10 ml saline. Cells 
were resuspended in saline for use in the tests, giving approximately 108 cfu/mL. 
 
2.11.2 Preparation of Solutions 
Chlorhexidine diacetate hydrate salt was dissolved in SDW using magnetic stirrers and 
heat, and filter sterilised through a 0.22µm filter before use. A stock solution was made 
and diluted appropriately for the required test concentrations.  




Chlorhexidine digluconate, purchased in liquid form, was diluted to the appropriate 
concentration in SDW and filter sterilised as above.  
 
The neutraliser solution comprised 0.75% (w/v) azolectin and 5% (v/v) Tween 80 
dissolved in SDW and autoclave sterilised before use. The use of a neutraliser in the 
following tests is essential to quench the activity of the biocide and allow accurate 
biocide contact times to be tested.  
 
2.11.3 Drop Counting Method 
Counts for controls and tests were quantified using the drop counting method. 0.1ml of 
each sample was serially diluted in SDW and three 10µl drops spotted onto the surface 
of an over-dried NA plate. After overnight incubation at 37°C, colonies were counted 
and cfu/ml calculated.  
 
2.11.4 Calculation of Microbiocidal Effect 
Specific controls were performed concurrently with each biocide experiment to enable 
the calculation of a unique microbiocidal effect (ME) for that test. The ME is the log 
reduction in cell count after contact with biocide: 
ME = log cfu/mL control – log cfu/mL test 
where the control shall be explained for each experiment, but will generally consist of 
the same experimental influences except biocide is replaced by SDW. 
 




As the ME measures the reduction in cell counts, it is specific and accurate for each test, 
and hence allows comparison of the effects of chlorhexidine between different isolates.  
 
2.11.5 General Controls 
Controls testing the efficacy and toxicity of the neutraliser were performed for each new 
stock made against the chlorhexidine concentrations to be used.  
 
Neturaliser toxicity was evaluated by the addition of 1mL of neutraliser to the prepared 
bacteria, followed by 5 minutes contact time. Cells were then re-suspended, serially 
diluted, and counted using the drop counting method. The number of survivors was 
compared with those for a control where SDW replaced the neutraliser, any difference in 
counts giving an indication of the toxicity, if any, of the neutraliser.  
 
Neutraliser efficacy was evaluated to ensure the biocide was being quenched as required. 
Neutraliser was added to the chlorhexidine and 5 minutes contact time allowed before 
the addition of bacteria and a further 5 minutes of contact time. Drop counting was 
performed and the count compared to a sample without biocide quenching, the 
neutraliser being replaced by SDW.  
 
Significant differences between controls were examined using the t-Test to establish P 
values. 
 




2.11.6 Quantitative Suspension Test  
As traditional MIC testing is not appropriate for biocides quantitative suspension tests 
were used to determine the bactericidal activity of chlorhexidine (Thomas et al, 2005). 
 
One ml of the washed bacterial inoculum (2 ×108 - 2 ×109 cfu/ml) to 9 ml of a 
concentrated biocide solution. After a 1 minute contact time, 1 ml of this mixture was 
added to 9 ml of the neutraliser to quench the effect of the biocide. Counting was then 
performed by the drop counting method.  
 
A control to enable the calculation of ME was performed concurrently with each test, 
whereby biocide was replaced with SDW. The ME was then calculated as explained 
above. 
 
2.11.7 Surface Disinfection Test  
Surface disinfection tests were carried out to establish the efficacy of chlorhexidine 
against surface dried bacteria (Thomas et al, 2005). 
 
Ten µl of washed bacterial culture was added to the bottom of a 28ml flat-bottomed 
glass bottle and left to dry at room temperature for 2 and 24 hours. After drying, 0.1ml 
of chlorhexidine (100 mg/L) was placed over the top of the dried cells and left for 5 
minutes contact time. Neutraliser solution (0.9ml) was then added to quench the 
chlorhexidine, and a sterile magnetic stirrer used to resuspend the cells for 5 minutes. 




The cells were then vortexed and counted using the drop counting method as described. 
The number of survivors following exposure to chlorhexidine was compared with those 
for the controls and the ME was calculated as described. 
 
To enable the calculation of ME, a control was performed for each sample. Initially a 
non-drying control was used, whereby bacterial cells were added and without drying, 
SDW (replacing biocide) and neutraliser were added as per the above experimental 
details, and drop counting performed. The 2 and 24 hour dried tubes were inoculated at 
the same time and then left to dry.  
 
Drying controls were also performed alongside these experiments, to attempt to take into 
account the effect of drying on the viability of the bacterial cells. Bacterial cells were 
dried concurrently with the tests for the same lengths of time, and treated as in the 
experiments, with SDW added in place of biocide. This would arguably give a more 
accurate ME as it would take into account the reduced viability of the bacterial cells 
after drying time.  
 
2.11.8 Biocide Residue Test  
This test examined the effect of chlorhexidine digluconate residues on bacterial isolates 
(Thomas et al, 2005). Stock solutions of chlorhexidine were prepared to give final 
concentrations of 25 mg/L. One ml was dispensed onto the bottom of a flat-bottomed 
glass bottle, the excess removed, and the bottles left to dry at room temperature for 2, 24 




and 48 hours. After drying, 20µl of an overnight culture (1-2 x 108 cfu/ml) was added to 
the bottles containing the chlorhexidine residue. After 5 minutes contact time at room 
temperature, 1ml of neutraliser was added and an aliquot the counted using the 
previously described drop-counting method. Controls were performed concurrently with 
the tests to enable calculation of the ME. 20µl of the bacterial culture used in the 
corresponding test was added to 1 ml of neutraliser and counting performed using the 
drop counting method.  
 
MICs of the exposed cells were also determined against a panel of antibiotics to examine 
the antibiotic susceptibility profiles after exposure to chlorhexidine. 
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Chapter 3: Characterisation of Acinetobacter isolates 
3.1 Introduction 
As discussed in Section 1.3, whilst A. baumannii is considered the most prevalent in 
clinical infections it is thought that other species, especially those of the Acb complex 
(gen.sp. 13TU and 3), are also relevant in the clinical environment (Dijkshoorn et al, 
2007). Other species not frequently associated with infections are also often isolated. 
Additionally, sensitive clinical A. baumannii are not often isolated from the clinical 
environment as most are now multi-drug resistant.  As such this study included a range 
of Acinetobacter spp clinical isolates from the hospital population with varying 
sensitivities. 
 
The Acinetobacter genus is genotypically heterogenous and has a complex taxonomic 
history (as discussed in Section 1.3) hence speciation has traditionally been a 
problematic area. Edinburgh isolates collected for this study were typed in the RIE 
clinical labs using the Vitek system but, as discussed in Section 1.3.2, this is not an 
adequate method for speciation of Acinetobacter. As such the aforementioned (Section 
1.3.2) tDNA fingerprinting method, detailed in Section 2.6.1.1, was used in the first 
instance to identify species.  
 
However tDNA fingerprinting does not discriminate well between A. baumannii and 
gen.sp. 13TU, and as such PCR to detect blaOXA-51-like genes (Turton et al, 2006), as 
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detailed in Section 2.6.1.2 and discussed in Section 1.3.2, was used to distinguish 
between A. baumannii and gen.sp. 13TU. Additionally, several of these isolates have 
been typed by colleagues (Ben Evans and Dr Ahmed Hamouda, personal 
communication) using the 16S-23S rRNA intergenic spacer restriction analysis method 
(Section 1.3.2; Chang et al, 2005), which has enabled greater distinction between 
representative species. 
 
There is evidence of inter-hospital circulation of several widespread outbreak strains of 
A. baumannii, the most prevalent in the UK being the OXA-23 clone 1 (Section 1.3.4; 
Coehlo et al, 2004). Several of these outbreak strains, received from Dr Jane Turton, are 




Acinetobacter spp isolates were collected in 2002 from the blood culture collection, 
Royal Infirmary Edinburgh, comprising infection-associated isolates from 1995-1999. 
After plating on MacConkey agar to isolate pure cultures, isolates were grown overnight 
in cryogenic vials containing nutrient broth, then stored at -70˚C in glycerol for further 
use. Isolates from previous worldwide collections, including from Argentina, Singapore 
and USA, were also included. Species strains used for comparison in tDNA speciation 
were kindly gifted by Dr Kevin Towner, and several prevalent outbreak strains were 
Chapter 3 –Characterisation of Acinetobacter isolates 
 
 84 
kindly gifted by Jane Turton (strains detailed in Section 2.1) and were used as 
comparisons for several further experiments.   
3.2.1 Minimum Inhibitory Concentrations 
MICs were performed by the agar dilution method according to BSAC guidelines, as 
detailed in Section 2.7. MIC values of the tested antibiotics against the Edinburgh and 
selected worldwide isolates are detailed in Table 3.1. Recommended BSAC breakpoints 
(Andrews, 2001; MacGowan & Wise, 2001) were used to establish the sensitivity of the 
isolates, based on the MICs of the tested antibiotics. 
 
Table 3.1 MICs of a range of antibiotics on the Acinetobacter spp. isolate 
collection 
Minimum Inhibitory Concentrations (mg/L) 
Isolates 
AMP AUG CTX CAZ GENT CIP IMP MERO 
E 3 64 32 32 16 0.5 8 0.25 2 
E 5 16 16 8 16 1 8 0.25 2 
E 6 0.25 0.25 0.5 16 0.25 0.5 0.06 0.06 
E 7 8 16 8 2 1 0.12 0.12 0.12 
E 8 16 4 4 8 2 0.25 0.12 0.25 
E 9 4 4 4 2 0.25 0.06 0.06 0.12 
E 10 4 8 8 2 1 0.12 0.12 0.25 
E 11 16 8 16 8 1 0.5 0.12 0.25 
E 12 2 4 4 2 0.25 0.12 0.12 0.12 
E 13 16 4 16 4 0.5 0.5 0.12 0.25 
E 14 16 16 16 8 1 0.5 0.12 0.25 
E 15 1 0.5 4 4 0.25 0.06 0.06 0.12 
E 16 16 16 16 8 0.5 0.5 0.12 0.25 
E 17 32 8 16 8 0.5 0.25 0.12 0.25 
E 18 32 32 32 8 1 8 0.25 1 
E 19 32 32 32 16 1 8 0.25 1 
E 20 8 4 64 64 0.12 0.12 0.06 0.25 
E 21 0.5 0.5 2 4 0.25 0.032 0.12 0.06 
E 22 64 32 32 16 1 8 0.25 1 
E 23 32 16 16 8 0.25 0.12 0.12 0.25 
E 24 64 32 32 16 1 8 0.25 2 
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Table 3.1 Minimum Inhibitory Concentrations (mg/L) 
continued AMP AUG CTX CAZ GENT CIP IMP MERO 
E 25 32 8 32 8 0.25 0.25 0.12 0.25 
E 26 4 4 2 2 0.25 0.25 0.12 0.12 
E 27 16 16 16 16 0.25 0.12 0.25 0.5 
E 28 128 32 32 16 4 0.5 0.25 1 
E 29 64 16 32 16 0.5 8 0.25 1 
E 30 32 8 4 4 1 0.06 0.12 0.25 
E 31 128 32 64 16 0.5 8 0.25 1 
E 32 64 16 32 16 0.5 8 0.25 1 
E 33 1 0.5 4 4 0.25 0.12 0.06 0.06 
E 34 128 32 32 16 1 8 0.25 1 
E 35 64 32 32 16 1 8 0.25 1 
E 36 64 32 32 8 1 8 0.25 1 
E 37 64 16 32 16 0.5 8 0.25 1 
E 38 128 16 32 16 0.5 8 0.25 1 
E 39 64 16 32 16 0.5 8 0.25 1 
E 40 64 32 32 16 0.5 32 0.25 1 
E 41 32 16 16 8 1 0.5 0.12 0.25 
E 42 32 16 16 8 1 0.5 0.12 0.25 
E 43 16 8 4 4 1 0.06 0.12 0.25 
E 44 2 0.5 4 4 0.12 0.06 0.06 0.06 
E 45 64 32 32 16 1 8 0.25 1 
E 46 128 32 32 16 1 8 0.25 1 
E 47 32 8 4 4 1 0.06 0.12 0.25 
E 48 64 16 32 16 0.5 8 0.25 1 
E 49 64 32 32 16 1 32 0.5 1 
E 50 64 32 32 16 1 32 0.25 1 
E 51 64 32 16 16 1 32 0.25 1 
U 1 >128 128 64 32 64 >128 0.25 0.5 
U 4 16 16 16 8 2 2 0.06 0.25 
U 5 32 16 32 16 1 0.25 0.12 0.5 
U 6 32 16 32 16 2 >128 0.25 0.5 
U 7 >128 >128 >128 >128 16 >128 2 8 
U 8 1 1 2 2 0.06 0.03 0.03 0.06 
U 9 >128 >128 >128 >128 32 128 0.25 1 
U 10 64 32 64 16 0.25 1 0.12 0.5 
U 11 >128 >128 >128 >128 16 128 1 8 
U 12 16 16 16 8 0.25 0.5 0.12 0.25 
U 13 >128 64 32 8 128 8 0.5 0.5 
U 14 16 8 8 4 0.5 0.5 0.008 0.25 
U 15 32 16 16 8 0.25 0.25 0.12 0.5 
U 17 32 16 16 16 8 4 0.12 1 
U 20 32 16 16 8 1 0.5 0.008 0.25 
U 21 16 8 16 16 8 >128 0.25 0.5 
U 22 >128 64 32 8 128 8 0.25 0.5 
U 23 8 4 16 8 0.5 0.5 0.12 0.5 
U 24 >128 64 16 8 128 16 0.25 0.5 
U 25 32 16 16 8 0.25 0.25 0.12 0.25 
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Minimum Inhibitory Concentrations (mg/L) Table 3.1 
continued AMP AUG CTX CAZ GENT CIP IMP MERO 
U 27 32 16 32 16 0.5 0.5 0.12 0.5 
U 28 32 32 32 16 0.25 0.5 0.12 0.5 
U 29 32 16 16 8 1 0.25 0.12 0.25 
U 30 32 16 16 8 1 0.25 0.12 0.5 
U 32 >128 64 16 8 32 1 0.06 0.5 
U 34 16 8 16 4 0.5 0.5 0.06 0.25 
U 35 32 32 32 8 1 0.5 0.12 0.5 
U 36 128 64 32 32 1 64 0.5 2 
U 38 >128 >128 128 32 2 >128 0.25 2 
U 41 16 32 32 16 2 128 0.12 0.5 
U 43 16 8 32 4 1 0.25 0.12 0.25 
U 45 >128 >128 128 >128 >128 128 0.5 1 
U 46 32 32 32 8 1 0.25 0.12 0.25 
U 47 >128 >128 >128 >128 64 128 1 8 
U 49 16 32 64 16 0.5 1 0.008 0.5 
U 51 16 8 32 4 0.5 0.25 0.06 0.25 
U 52 64 32 32 16 0.5 0.25 0.12 0.5 
U 53 32 8 32 8 0.25 0.5 0.12 0.25 
U 59 32 32 32 8 0.5 0.03 0.008 0.5 
U 60 32 32 32 8 0.5 0.5 0.12 0.25 
U 61 >128 >128 32 4 1 0.25 0.12 4 
U 62 16 32 8 4 0.5 0.25 0.12 0.25 
U 63 32 32 16 8 0.25 0.5 0.06 0.25 
U 64 >128 >128 64 32 >128 >128 0.25 0.5 
U 66 1 1 2 4 0.12 0.03 0.03 0.12 
U 67 >128 >128 >128 >128 >128 128 2 16 
U 68 32 32 32 8 0.5 0.25 0.25 0.25 
U 69 32 32 16 8 1 0.25 0.12 0.25 
U 71 8 4 16 4 0.25 0.12 0.12 0.25 
U 74 0.25 0.12 1 1 0.06 0.015 0.015 0.06 
U 75 >128 >128 128 32 >128 64 0.5 1 
U 76 >128 >128 128 32 >128 128 0.25 1 
U 77 >128 >128 128 32 >128 128 0.25 1 
U 78 16 32 16 8 0.25 0.25 0.12 0.25 
U 79 32 32 64 8 0.25 0.5 0.25 0.5 
U 80 8 8 8 2 0.25 0.25 0.06 0.25 
U 81 32 32 32 16 0.5 0.25 0.25 0.25 
U 82 8 32 16 8 0.25 0.25 0.06 0.25 
U 83 16 16 16 8 0.25 0.25 0.25 0.25 
U 84 16 16 16 16 0.25 0.5 0.06 0.25 
U 86 64 16 64 16 1 1 0.06 1 
U 87 128 64 128 64 2 >128 1 2 
U 88 16 16 16 8 0.5 0.12 0.06 0.25 
U 89 32 16 64 16 0.5 0.5 0.12 0.5 
U 90 16 16 16 8 0.5 0.5 0.12 0.25 
U 91 >128 >128 >128 >128 32 >128 0.25 2 
U 93 16 16 32 8 0.5 0.25 0.12 0.25 
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Minimum Inhibitory Concentrations (mg/L) Table 3.1 
continued AMP AUG CTX CAZ GENT CIP IMP MERO 
U 97 16 16 16 8 0.5 0.25 0.12 0.5 
U 98 >128 128 64 16 >128 >128 0.25 1 
U 99 32 32 8 4 1 0.25 0.12 0.25 
U 101 32 16 16 8 1 0.25 0.06 0.25 
W 779 >128 128 64 4 0.5 >16 8 4 
W 783 >128 >128 32 4 1 >16 16 8 
W 789 >128 32 >128 >128 >64 >16 0.25 0.5 
W 790 >128 >128 64 128 >64 >16 16 4 
W 868 >128 >128 >128 >128 >128 >16 16 128 
 
E – Edinburgh, U – USA, W – worldwide. 
 
AMP - ampicillin, AUG – co-amoxyclavulanic acid, CTX – cefotaxime, CAZ – ceftazidime,  
GENT – gentamicin, CIP – ciprofloxacin, IMP – imipenem, MERO – meropenem. 
 
Of the 128 isolates, the majority were susceptible to both imipenem (breakpoint > 
4mg/L) and meropenem (breakpoint > 4mg/L), as would be expected, with 94% and 
91% susceptible respectively. There was a high percentage resistance within the whole 
sample to both cefotaxime (breakpoint > 1mg/L) and ceftazidime (breakpoint > 2mg/L), 
at 98% and 94% resistance respectively. The majority of isolates were resistant or 
intermediate-resistant to ampicillin (breakpoint > 8mg/L; 66% resistant and 20% 
intermediate-resistant) and co-amoxiclavulanic acid (breakpoint > 8mg/L; 50% resistant 
and 27% intermediately resistant). There was 77% susceptibility to gentamicin 
(breakpoint > 4mg/L) and 54% susceptibility to ciprofloxacin (breakpoint > 1mg/L), 
with 3% of the isolates intermediate-resistant to ciprofloxacin. 
 
Of the Edinburgh isolates (N=48) there was 100% susceptibility to both imipenem and 
meropenem, and 98% susceptibility to gentamicin. Similar to that described for the 
worldwide sample as a whole, there were high percentages of resistance to cefotaxime 
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and ceftazidime, of 98% and 90% resistance respectively. There was slightly more 
susceptibility to co-amoxiclavulanic acid, with 38% susceptibility in the Edinburgh 
isolates compared to 23% in the worldwide sample as a whole. There was also a slightly 
higher percentage susceptibility observed to ampicillin than in the worldwide sample, 
with 23% susceptibility in the Edinburgh isolates compared to 14% in the worldwide 
isolates. These figures are summarised in Table 3.2.  
 
Table 3.2 Percentage sensitivities of the Acinetobacter spp. sample 
Worldwide sample (N = 128)*  
 AMP AUG CTX CAZ GENT CIP IMP MERO 
% susceptible 14 23 2 6 77 54 94 91 
% intermediate 20 27 0 0 1 3 0 0 
% resistant 66 50 98 94 22 43 6 9 
         
Edinburgh population (N = 48)         
 AMP AUG CTX CAZ GENT CIP IMP MERO 
% susceptible 23 38 2 10 98 54 100 100 
% intermediate 17 29 0 0 2 0 0 0 
% resistant 60 33 98 90 0 46 0 0 
 
Breakpoints in brackets. 
AMP – ampicillin (8mg/L), AUG – co-amoxyclavulanic acid (8mg/L), CTX – cefotaxime (1mg/L), CAZ 
– ceftazidime (2mg/L), GENT – gentamicin (4mg/L), CIP – ciprofloxacin (1mg/L), IMP – imipenem 
(4mg/L), MERO – meropenem (4mg/L). 
* worldwide sample includes the Edinburgh isolates. 
 
Based on their sensitivity profiles to all tested antibiotics, 22 representative resistant 
(N=8), intermediate (N=7) and sensitive (N=7) isolates were selected for further 
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Table 3.3 Representative Acinetobacter spp. isolates used for further 
investigation 
Isolate Information MICs (mg/L) 
 AMP AUG CTX CAZ GENT CIP  IMP MERO 
E9 Edinburgh S 4 4 4 2 0.25 0.06 0.06 0.12 
E10 Edinburgh S 4 8 8 2 1 0.12 0.12 0.25 
E13 Edinburgh I 16 4 16 4 0.5 0.5 0.12 0.25 
E14 Edinburgh I 16 16 16 8 1 0.5 0.12 0.25 
E15 Edinburgh S 1 0.5 4 4 0.25 0.06 0.06 0.12 
E21 Edinburgh S 0.5 0.5 2 4 0.25 0.032 0.12 0.06 
E26 Edinburgh S 4 4 2 2 0.25 0.25 0.12 0.12 
E33 Edinburgh S 1 0.5 4 4 0.25 0.12 0.06 0.06 
E41 Edinburgh I 32 16 16 8 1 0.5 0.12 0.25 
E51 Edinburgh R 64 32 16 16 1 32 0.25 1 
U7 USA R >128 >128 >128 >128 16 >128 2 8 
U43 USA I 16 8 32 4 1 0.25 0.12 0.25 
U45 USA R >128 >128 >128 128 >128 128 0.5 1 
U51 USA I 16 8 32 4 0.5 0.5 0.06 0.25 
U66 USA S  1 1 2 4 0.12 0.03 0.03 0.25 
U71 USA I 8 4 16 4 0.25 0.12 0.12 0.25 
U80 USA I 8 8 8 2 0.25 0.25 0.06 0.25 
W779 Argentina MR >128 >128 64 4 0.5 >128 8 4 
W783 Argentina MR >128 >128 32 4 1 >128 16 8 
W789 Argentina MR >128 32 >128 >128 >64 >128 0.25 0.5 
W790 Argentina MR >128 >128 64 128 >64 >128 16 4 
W868 Singapore MR >128 >128 >128 >128 >128 >128 16 128 
S – Sensitive, I – Intermediate, R – Resistant, MR – Multi-resistant. 
 
MICs were also performed on the prevalent A. baumannii outbreak strains, gifted by Dr 
Jane Turton, which were included in several later experiments. These strains and their 
sensitivity profiles are detailed in Table 3.4. 
Table 3.4 Details of outbreak strains used in further experiments 
  MICs (mg/L) 
Isolate Description AMP CTX CAZ  GENT  CIP MERO 
JTA NW strain >128 >128 >128 4 0.032 4 
JTB W strain /  
European clone 1 
8 32 0.016 0.016 0.016 0.12 
JTC Midlands 2 >128 >128 128 >128 128 2 
JT3 T strain >128 >128 128 32 128 1 
JT4 SE Clone >128 >128 128 16 0.016 8 
JT6 OXA-23  
Clone 2 
>128 >128 >128 64 64 32 
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3.2.2 Speciation of Representative Isolates 
tDNA fingerprinting (Section 2.6.1.1) was performed on the representative isolates 
detailed in Table 3.2, as described in Section 2.6.1.1. The BioNumerics™ programme 
(Applied Maths, Ghent, Belgium) was used to store and analyse resultant band patterns 
by comparison with standard strains. This software devises algorithms to enable analysis 
of isolate profiles. Here the Dice coefficient and cluster analysis using hierarchical un-
weighted pair arithmetic average algorithm (optimisation 1.5%, tolerance 1%) were 
used. Comparisons are displayed in Figures 3.1 – 3.3.  
 
A comparison of the tDNA band patterns of the representative isolates (Figure 3.1) 
shows varied patterns within the population, although many had a close match with the 
ATCC 19606 (A. baumannii) or gen. sp. 13TU species patterns. These are shown in 
Figure 3.2, whilst non-baummannii /gen.sp. 13TU patterns are shown in Figure 3.3. 
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Figure 3.2 tDNA band patterns of suspected A. baumannii or gen.sp. 13TU 




Figure 3.3 tDNA band patterns of other representative isolates not resembling 
A.baumannii or gen.sp. 13TU 
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Of those that did not have close similarity to the A. baumannii/gen.sp. 13TU band 
pattern, there were several that had a similarity to the pattern of other species strains; 
Isolate E15 had a 70% similarity to species strain 12 (A. radioresistens), isolate E26 had 
a >55% similarity to species strain 5 (A. junii) and isolate E33 had a >55% similarity to 
species strain 8 (A. johnsonnii). Several isolates (E9, E10 and E21) did not match to any 
significance any band pattern of the species strains tested. Isolate E9 had a <50% 
similarity to species strain 4 (A. haemolyticus), E10 clustered with 3 other Edinburgh 
clinical isolates (>40% similarity) and E21 had some similarity (<40%) to species strain 
7 (A. johnsonnii). 
 
PCR for the presence of blaOXA-51-like genes was also performed, as detailed in Section 
2.6.1.2, the results shown in Table 3.5. Of the representative isolates which did have the 
A. baumannii/gen.sp. 13TU tDNA band pattern, several were subsequently found not to 
have the OXA-51 gene and were therefore most likely species 13TU.  
 
Additionally, the isolates have since been included in further studies by Dr Ahmed 
Hamouda and Ben Evans in the Molecular Chemotherapy lab (personal communication), 
and have been typed to a certain extent by 16S-23S intergenic rRNA restriction (Chang 
et al, 2005). The results from these methods are compiled in Table 3.5, with conclusions 
as to the species of the isolates.  
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Table 3.5 Speciation results for the representative Acinetobacter spp isolates 





E9 S (A. haemolyticus?) - 3,13TU gen.sp.3 
E10 S ? - 3,13TU gen.sp.3 
E13 I A. baumannii /13TU + 2 A. baumannii 
E14 I A. baumannii /13TU - 13TU 13TU 
E15 S A. radioresistens - 13TU? A. radioresistens 
E21 S (A. johnsonii)? - - A. johnsonii 
E26 S A. junii - ? A. junii 
E33 S A. johnsonii - ? A. johnsonii 
E41 I A. baumannii /13TU - 13TU? 13TU 
E51 R A. baumannii /13TU - 13TU? 13TU 
U7  R A. baumannii /13TU + 2 A. baumannii 
U43 I ? - 13TU 13TU 
U45  R A. baumannii /13TU + 2 A. baumannii 
U51  I A. baumannii /13TU + 2 A. baumannii 
U66  S ? + 2  A. baumannii 
U71  I ? + 2 A. baumannii 
U80  I ? - 3 3 
* Ben Evans, personal communication. 
S - sensitive, I – intermediate, R – Resistant. 
 
The multi-resistant isolates, from Argentina and Singapore, had been speciated as 
A.baumannii in a previous study by DNA-DNA hybridisation (Dr Susan Brown, 
personal communication), and were all confirmed as such by possession of the 
A.baumannii/gen.sp. 13TU tDNA band pattern, and the presence of blaOXA-51-like (Figure 
3.1).  
 
The U isolates, a collection from the USA, had previously been typed and those included 
had been determined to be A. baumannii (Higgins, 2002). It was apparent (Table 3.5) 
that in fact several of these were not A. baumannii isolates; U43 and U80 did not possess 
blaOXA-51-like and were identified by 16S-23S intergenic rRNA restriction to be of gen.sp. 
13TU and gen.sp. 3 respectively.  
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Taken together, within the limits of these methods, the representative isolates comprised: 
8 resistant isolates of which 7 were A. baumannii and 1 was gen.sp. 13TU; 7 
intermediate isolates of which 3 were A. baumannii, 3 were gen.sp. 13TU and 1 was 
gen. sp. 3; and 7 sensitive isolates of which 1 was A. baumannii, 2 were probable gen.sp. 
3, 2 were A. johnsonii , 1 was A. radioresistens and 1 was A. junii. 
 
3.2.3 Typing of Representative Isolates 
PFGE of ApaI digested DNA from the representative isolates was performed (Section 
2.8) to establish their relatedness (Section 1.3.2). Figure 3.4 shows the ApaI digested 
PFGE patterns for all Edinburgh isolates. 
 
Analysis of the PFGE results of ApaI digested DNA of all Edinburgh isolates (N=48) 
reveals several potential clones of Acinetobacter spp that appear to be present in the 
RIE, resistant to most of the tested antibiotics (Figure 3.4). 
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Figure 3.4 Dendrogram of ApaI digested PFGE patterns of Edinburgh isolates 
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From analysis of the PFGE results of ApaI-digested DNA it was apparent that the 
representative isolates were genotypically diverse (Figure 3.5). The most closely related 
were isolates 783 and 790 (88% similarity), both multi-resistant isolates from Argentina. 
Also closely related (82% similarity) were isolates E41 and E51, both from Edinburgh. 
E14 and E33, respectively intermediate and sensitive Edinburgh isolates, were 71% 
similar. Interestingly, clinical Edinburgh isolate E26 formed a separate branch to the rest 
of the representative isolates, whilst the non-clinical isolate ADP1 (shown on the 
diagram as BD413) was amongst the rest of the clinical isolates and was 66% similar to 
isolate E21.  
 











































































Both the Edinburgh and worldwide sample had varied sensitivities to a range of 
antibiotics. The worldwide sample included several selected multi-resistant isolates 
(from Argentina and Singapore) which would have increased its overall resistance 
profile. However, generally the worldwide sample had similar percentage susceptibilities 
to the selected Edinburgh sample. There was notably more susceptibility to gentamicin, 
and marginally more susceptibility to imipenem and meropenem, in the Edinburgh 
sample.  
 
Representative isolates were selected on the basis of their sensitivities to a range of 
antibiotics and were comprised of various Acinetobacter spp. The intermediate and 
resistant isolates were all of the clinically prevalent species A. baumannii, gen.sp. 13TU 
and gen.sp. 3. The sensitive isolates, however, were much more varied, including only 
one A. baumannii and two gen.sp. 3. This agrees with what is known of the general 
clinical population of Acinetobacter spp, as discussed in Section 1.3; that true A. 
baumannii with sensitive susceptibility profiles are now rarely isolated from the clinical 
environment, and that the most common and clinically important isolates are A. 
baumannii followed by gen.sp. 13TU and gen.sp. 3 (Section 1.3; Dijkshoorn et al, 2007; 
Dr Kevin Towner, personal communication). 
 
This study aims to examine the development of antibiotic resistance in the clinical 
Acinetobacter population, compared to that present in already established resistant 
Chapter 3 –Characterisation of Acinetobacter isolates 
 
 99 
isolates. It is therefore important to examine a sample of the clinical population, 
comprising Acinetobacter spp with varying sensitivities, to gain a valid insight into the 
hospital environment. Whilst A. baumannii is undoubtedly the most prevalent and 
important clinical species, it is clear from the data here that other species are also present 
and may have a role to play in the rise of resistance in the hospital population as a 
whole; A. johnsonnii, A. lwoffii and A. radioresistens have been reported as frequent 
colonisers of healthy human skin and there are rare cases of involvement in infections 
(Section 1.3.3; Seifert et al, 1993; Seifert et al, 1997; Berlau et al, 1999). Additionally, 
given the discussed difficulties in speciation of the Acinetobacter genus, it may be that 
some isolates reported as A. baumannii are actually different species, and their 
importance thus far has been overlooked. To better determine what may contribute to the 
success of A. baumannii, this study also examines other Acinetobacter spp isolated in the 
clinical environment. Indeed, the Edinburgh isolates examined here were all associated 
with infection, though this does not preclude their prior presence as colonisers. 
  
The representative isolates generally were genotypically diverse, as determined by 
PFGE of ApaI restricted DNA. The most closely related isolates 783 and 790 were both 
multi-drug resistant isolates from Argentina. Edinburgh gen.sp. 13TU isolates E41 and 
E51 were also closely related. E41 was isolated in 1998 and was of an intermediate 
susceptibility, whilst E51 was isolated in 1999 and was resistant. It may be that these 
isolates represent an example of the progression of an intermediate isolate to a resistant 
isolate within the clinical environment.  
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It is apparent from the speciation data that the Vitek™ automated system, as used at the 
time in the Edinburgh Royal Infirmary clinical laboratory, is an inadequate method for 
speciating Acinetobacter spp. It has previously been reported that all species of the Acb 
complex are often identified by such systems as A. baumannii, and that many other 
species are not identified at all (Section 1.3.2; Bernards et al, 1996; Apisarnthanarak et 
al, 2007; Zbinden et al, 2007), and the above results seem to support this. They also 
show that it is essential when analysing other studies to examine the speciation methods 
used by the authors, especially when the exact species is of greater relevance; it may be 
that isolates previously identified as A. baumannii are not true A. baumannii species as 
identified by current methods.  
 
Speciation of Acinetobacter spp is a continual problem. Whilst recent molecular 
techniques are more effective at delineating species, the ‘gold standard’ method of 
DNA-DNA hybridisation is not readily available to the average clinical or microbiology 
laboratory. There is still a lack of a universally comparable, rapid method that can be 
used routinely in these laboratories; this has traditionally limited our ability to examine 
and understand the epidemiology of clinical Acinetobacter spp and may have led to 
important interactions between clinical species being overlooked. Here the best methods 
available in the standard microbiological laboratory have been used to speciate the 
representative isolates.  
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Chapter 4: The mutS gene of Clinical Acinetobacter spp 
Isolates 
4.1 Introduction 
The general assumption is that antibacterial resistance results from use and misuse of 
antibiotics, which leads to the selection of resistant strains from a sensitive population. 
Increasing evidence has led to the hypothesis of subpopulations of genetically distinct 
mutator cells, able to rapidly acquire resistance through defects in MMR. 
  
As discussed in Section 1.5, mutation is a fundamental aspect of the development and 
evolution of bacterial antibiotic resistance. Hypermutation is increasingly being 
recognised as a potential factor in antibiotic resistance development; mutators, most 
commonly deficient in MMR through defective mutS, have been reported in natural 
populations of several bacteria and have been associated with increased antibiotic 
resistance. In addition hypermutation is considered a key factor in the development of 
resistance in P.aeruginosa (Section 1.5.3; LeClerc et al, 1996; Matic et al, 1997; Oliver 
et al, 2000; Miller et al, 2002; O’Neill & Chopra, 2002; Watson Jr. et al, 2004).  
 
Whilst the importance of mutator strains has been studied extensively in several bacteria 
there has been little investigation to date of the mutS gene of clinical Acinetobacter spp.  
Young and Ornston, as mentioned in Section 1.5.5, characterised and investigated the 
role of mutS from Acinetobacter strain ADP1, which has since been found to belong to 
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the newly described species Acinetobacter baylyi (Young & Ornston, 2001; 
Vaneechoutte et al, 2006).  It was found that strains lacking MutS function had 
increased spontaneous mutation frequencies to rifampin and significantly increased 
transformation frequencies for divergent donors (Young & Ornston, 2001). This 
suggests that there is potential that mutations in the mutS gene of clinically relevant 
Acinetobacter spp may be associated with hypermutation and the development of 
antibiotic resistance, similar to the situation found in other bacteria. 
 
The aims here were: to study for the first time the mutS gene of clinical  
Acinetobacter spp. isolates with varying susceptibilities (the representative isolates 
detailed in Chapter 3); to determine whether the mutS gene of clinical isolates varied 
compared to non-clinical strains; to examine whether clinical isolates had varying mutS 
sequences and, if so, whether different mutS types were associated with different 
sensitivities and species; and, described in the subsequent chapter, to determine whether 




4.2.1 Design and Use of Degenerate Primers  
Young and Ornston (2001) amplified a 1.9kb section of the mutS gene using degenerate 
primers MutSf2 and MutSf3.  However our repeated attempts at amplifying this large 
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section of the clinical isolates did not succeed, so degenerate primers (Section 2.3) were 
designed by Dr Susan Brown from areas of amino acid conservation in the mutS 
sequences of Acinetobacter sp. strains ADP1, 93A2, AD321, AC423D and LUH540 
(sequences from Young and Ornston, 2001). 
 
The first 180bp of the N-terminal region of MutS was examined, as this contains the 
mismatch recognition domain (aa 2-115 w.r.t. E. coli) (Lamers, 2000). The initial primer 
pair used to amplify the N-terminal region required lengthy optimisation of the PCR 
technique, and not all isolates were successfully amplified. This primer pair was 
eventually abandoned and primers LH1/C and RH1/F (sequences and methods detailed 
in Sections 2.3 and 2.9) were used, again after lengthy optimisation, to successfully 
amplify the N-terminal region of the mutS gene of all selected clinical isolates, with 
ADP1 and ATCC 19606 included as controls. The resultant PCR products were 
visualised on agarose gels (Figure 4.1) and the specific bands at 489 bp were excised, 
purified and sent for sequencing, as per the methods detailed in Section 2.9.  
 
Consensus sequences for each isolate were derived from alignment of the received LH 
and RH primer nucleotide sequences, and the resultant consensus mutS sequences were 
used for comparisons. Sequences were compared from all the clinical isolates, within 
each sensitivity subset (i.e. sensitive, intermediate and resistant) and also to the non-
clinical sequences (from Young & Ornston, 2001), by alignment using hierarchical 
clustering (Corpet, 1988). 
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Figure 4.1 Example of an agarose gel of mutS PCR products with bands of 489bp 
Lanes 1-6: U51. Lanes 7-12: E14. Lane 13: ADP1. 
 
4.2.2 Sequence Analysis – all Representative Isolates 
Figure 4.2 shows the alignment of the amino acid sequences of the N-terminal region of 
mutS of all the examined clinical isolates, alongside the non-clinical strains. The controls 
(C) are at the top and the clinical isolates are organised into sensitivities: multi-resistant 
(MR), resistant (R), intermediate (I) and sensitive (S).  
 
It was apparent that all examined clinical isolates had in common a section of five 
deleted amino acids, from aa 102-106 inclusive, compared to ADP1. This was also the 
case for one of the non-clinical strains (AC423D). Within the examined 180aa section of 
the MutS protein sequence there were 11 amino acid positions at which all of the clinical 
isolates varied compared to ADP1. At 7 of these positions the change compared to the 
sequence of ADP1 was conserved, whereas at the other four positions there were 
variations within the clinical isolates.  
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There were 39 positions within the same region of mutS at which there was amino acid 
variation in one or more of the clinical isolates, compared to the sequence of ADP1. At 
12 positions the majority of the clinical isolates had a conserved change compared not 
only to ADP1, but also to the other non-clinical strains. These instances are highlighted 
in red in Figure 4.2. Of these 12 positions, there were three at which all clinical isolates 
had the same amino acid. At the other positions there was either no variation or an 
alternative variation in one or more of the clinical isolates; with the exception of aa 67, 
this occurred solely in the sensitive clinical isolates.  
Figure 4.2 Alignment of the mutS gene of clinical isolates and non-clinical strains 
Numbering w.r.t ADP1. Variations compared to ADP1 highlighted. 
* indicates a position of variation of one or more of the clinical isolates compared to ADP1. 
Red – highlights variation compared to ADP1 and the other non-clinical isolates. 
Blue – highlights variation compared to ADP1, but same aa as one or more of the other non-clinical isolates. 
Yellow – highlights an alternative variation where the majority of clinical isolates have a conserved variation. 
Green – highlights non-conserved variations compared to ADP1, other non-clinical isolates and clinical isolates. 
MR = multi-resistant, R = resistant isolates, I = intermediate isolates, S = sensitive isolates, C = controls. 
 
             1                                                  **    *     60 
ADP1   (C)   MNSTETMADL SSYTPMMQQY FKVKLEHQHA LLFYRMGDFY ELFFDDARKA AKFLGITLTH 
93A2   (C)                          KVKLEHQHA LLFYRMGDFY ELFFDDARKA AKLLGITLTH 
AD321  (C)                                               ELFFEDAHKA AKLLGITLTH 
AC423D (C)                                               ELFFEDAHKA AKLLGITLTH 
ATCC19606                                                           AKLLGITLT- 
779   (MR)                                                  FEDAHLA AKLLGITLTH 
783   (MR)                                                 FFEDAHLA AKLLGITLTH 
789   (MR)                                                 FFEDAHLA AKLLGITLTH 
790   (MR)                                                                 LTH 
868   (MR)                                                     AHLA AKLLGITLTH 
U7     (R)                                                                   H 
U45    (R)                                                     AHLA AKLLGITLTH 
E51    (R)                                                  FEDAHLA AKLLGITLTH 
E13    (I)                                                LFFEDAHLA AKLLGITLTH 
E14    (I)                                                LFFEDAHLA AKLLGITLTH 
E41    (I)                                                LFFEDAHLA AKLLGITLTH 
U43    (I)                                                LFFEDAHLA AKLLGITLTH 
U51    (I)                                                LFFEDAHLA AKLLGITLTH 
U71    (I)                                                LFFEDAHLA AKLLGITLTH 
U80    (I)                                                LFFEDAHLA AKLLGITLTH 
E9     (S)                                               ELFFEDAHLA AKLLGITLTH 
E10    (S)                                               ELFFEDAHLA AKLLGITLTH 
E15    (S)                                                     AHKA AKLLGITLTH 
E21    (S)                                                  FEDAHKA AK-LGITLTH 
E26    (S)                                                LFFEDAHLA AKLLGITLTH 
E33    (S)                                                  FEDAHKA A--IGITLTH 
U66    (S)                                                LFFEDAHKA AKILGITLTH         
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Figure 4.2 continued 
                               61                                                            120 
                ** *         * *          **  *  *    *             * ** *   * 
ADP1   (C)   RGKANGEPIP MAGVPYHAAE GYLARLVRAG QTVAICEQVG EGENAGSRCK APMERKVVRI 
93A2   (C)   RGKANGEPIP MAGVPYHAAE GYLARLVRAG QTVAICEQVG EGENAGSRGK APMERKVVRI 
AD321  (C)   RGKANGEPIP MAGVPYHAAE GYLARLVKAG QTVAICEQVG EGESAGSRGK APMERKVVRI 
AC423D (C)   RGKANGEPIP MAGVPYHAAE GYLARLVKKG ETVVICEQIG E-----VTGK APVERGVVRI 
ATCC19606    RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVV-I 
779   (MR)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
783   (MR)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
789   (MR)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
790   (MR)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
868   (MR)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U7     (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U45    (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E51    (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E13    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E14    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E41    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U43    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U51    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U71    (I)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U80    (I)   RGKASGRPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E9     (S)   RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E10    (S)   RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E15    (S)   RGKANGTPIP MAGVPYHSAE GYLARLVKAG ETVAICEQVG E-----VTGK GPVDRQVVRI 
E21    (S)   RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI 
E26    (S)   RGKTNGEPIP MAGVPYHSAE GYLARLVKSG RTVAICEQVG E-----VTGK GPVERKVVRV 
E33    (S)   RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI 
U66    (S)   RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI                                                      
             
             121                                                           180 
             *    *       *** *     *  ** ***  *     *         **** **  *    
ADP1   (C)   ITPGTITDDA LLGSYQSSNL VALCIQQNKI GIALLDLSAS IFKVQQHEFK TEQLYIELAR 
93A2   (C)   ITPGTITDDA LLGSYQSSNL VALCIQQNKI GIALLDLSAS IFKVQQHEFK TEQLYIELAR 
AD321  (C)   ITPGTITDDA LLGSYQSSNL VALCIQQNKI GLALLDLSAS IFKVQEHDFK TEQLAIELSR 
AC423D (C)   ITPGTLTDDA LLTAHQSSNL VALCVQQNEI GIALLDLSAG LFKVQQQEFQ LEQLGIELSR 
ATCC19606    LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLS-G IFKVQQQDYK PEQLPIELAR 
779   (MR)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
783   (MR)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
789   (MR)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
790   (MR)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
868   (MR)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U7     (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U45    (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E51    (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E13    (I)   LTPGTLTEDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E14    (I)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E41    (I)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U43    (I)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U51    (I)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U71    (I)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U80    (I)   LTPGTLTDDA LLSSYQSSNL VSLCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E9     (S)   LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR 
E10    (S)   LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR 
E15    (S)   LTPGTLTD-A LLSSHQSSNL VALCFQQNQV GIALLDLGAG IFKVQQQDYK PEQLTIELAR 
E21    (S)   ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
E26    (S)   LTPGTLTDDA LLSSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQTYK PEQLPIELAR 
E33    (S)   ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
U66    (S)   ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
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At 16 positions one or more of the clinical isolates had a change compared to the mutS 
sequence of ADP1 but the amino acid matched one or more of the other non-clinical 
isolates at this position. These instances are highlighted in blue in Figure 4.2, where the 
equivalent amino acid in the non-clinical strains is also highlighted. At four of these 16 
positions the change was observed in all clinical isolates and was conserved throughout. 
At nine of the 16 positions a conserved change was seen only in one or more of the 
sensitive isolates. At the further three positions there was either a variation in the change 
seen or no change compared to ADP1, in one or more of the clinical isolates. 
 
There were 15 instances at five positions within this section of the mutS sequence where 
there was a conserved change compared to ADP1 in the majority of clinical isolates but 
variation in one or more of them. These instances are highlighted in yellow in Figure 
4.2. Most of these instances occurred in the sensitive isolates, but there were two which 
occurred in intermediate isolate U80 (at aa 67 and 133).  
 
Within the examined 180aa section there were a further 30 instances, at 16 positions, 
where there was non-conserved amino acid variation compared to the sequences of all 
the non-clinical isolates and to the other clinical isolates. These instances are highlighted 
in green in Figure 4.2. Again these instances occurred mostly within the sensitive 
isolates, but also at two positions in U80 (aa 65 and 142). At seven of the 16 positions, 
the amino acid was conserved in two or more of the sensitive isolates.  
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To summarise, in comparison to ADP1 there was substantial variation in the clinical 
isolates. Some of these aa variations were conserved in most clinical isolates and 
differed also to the other non-clinical controls (highlighted in red in Figure 4.2). At other 
positions of variation compared to ADP1, there were similarities in the clinical isolates 
with one or more of the non-clinical controls (highlighted in blue in Figure 4.2). 
Additionally, variation between the clinical isolates was apparent, either at positions 
where most clinical isolates varied compared to ADP1, or in positions where few 
clinical isolates varied compared to ADP1 (highlighted in yellow and green respectively 
in Figure 4.2). 
 
Figure 4.3 shows the mutS amino acid sequence alignment of all the clinical isolates, to 
enable observation of differences within the clinical population. For clarity, only the 
main section of the amplified N-terminal region is shown (aa 61-180 wrt ADP1), as this 
was the area in which the variations within the clinical isolates were observed. As the 
numbering is wrt ADP1 amino acids 102-106 inclusive are blank as this was an area of 
deletion common to all the examined clinical isolates.  
 
Highlighted in red in Figure 4.3 are 87 instances at 23 positions where there was 
conserved amino acid variation within two or more of the clinical isolates, compared to 
the majority of the clinical isolates (compared to the clinical isolates’ consensus 
sequence). There were two positions (aa 65 and 133) where this occurred in intermediate 
isolate U80, but the majority of instances were within the sensitive Acinetobacter spp 
isolates.  
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Figure 4.3 Alignment of the amino acid sequence of the mutS of clinical isolates 
Numbering w.r.t. ADP1. Variations highlighted. 
* indicates a position at which there is amino acid variation in one or more isolates compared to the clinical isolates’ 
consensus.  
Red = conserved variation within the clinical isolates. 
Blue = non-conserved variation within the clinical isolates. 
 
         61                                                            120 
            ** *         * *           *  *  *    *                * *   * 
779 (MR) RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
783 (MR) RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
789 (MR) RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
790 (MR) RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI    
868 (MR) RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U7  (R)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U45 (R)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E51 (R)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E13 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E14 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E41 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U43 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U51 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
U71 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
U80 (I)  RGKASGRPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E9  (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E10 (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E15 (S)  RGKANGTPIP MAGVPYHSAE GYLARLVKAG ETVAICEQVG E-----VTGK GPVDRQVVRI  
E21 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
E26 (S)  RGKTNGEPIP MAGVPYHSAE GYLARLVKSG RTVAICEQVG E-----VTGK GPVERKVVRV 
E33 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
U66 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
 
         121                                                    180                                    
         *            *** *     *  ** * *  *     *   *     ** * **  * 
779 (MR) LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
783 (MR) LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
789 (MR) LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
790 (MR) LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
868 (MR) LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U7  (R)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U45 (R)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E51 (R)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
E13 (I)  LTPGTLTEDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
E14 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E41 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U43 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U51 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
U71 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
U80 (I)  LTPGTLTDDA LLSSYQSSNL VSLCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E9  (S)  LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR  
E10 (S)  LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR 
E15 (S)  LTPGTLTD-A LLSSHQSSNL VALCFQQNQV GIALLDLGAG IFKVQQQDYK PEQLTIELAR  
E21 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
E26 (S)  LTPGTLTDDA LLSSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQTYK PEQLPIELAR 
E33 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
U66 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
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There were a further 14 instances, at 12 positions, where there was non-conserved amino 
acid variation in a clinical isolate compared to the clinical isolates’ consensus sequence. 
Again the majority of these instances occurred only within the sensitive isolates, with 
two exceptions occurring in intermediate isolate U80 (Acinetobacter gen.sp. 3) at amino 
acids 67 and 142.  
 
From the sequences shown in Figure 4.2 it appears that the resistant, multi-resistant, and 
most of the intermediate clinical isolates have a highly conserved MutS sequence within 
this 180aa region. Instances of amino acid variation in this region of the MutS protein 
appeared to be confined to the sensitive Acinetobacter spp isolates, with a few 
exceptions as noted.  
 
4.2.3 Sequence Analysis – Resistant isolates 
From Figure 4.3 above, it was established that the amino acid sequence of the multi-
resistant and resistant isolates was highly conserved. A comparison between the resistant 
isolates and the non-clinical control ADP1, along with the A. baumannii type strain 
ATCC 19606 is shown in Figure 4.4. This allows for observation of any amino acid 
changes in the highly conserved resistant isolates’ sequences compared to the non-
clinical ADP1 strain.  
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Figure 4.4 Alignment of the amino acid sequence of the mutS of resistant and 
multi-resistant clinical isolates with ADP1 and ATCC 19606 
Numbering wrt ADP1. 
* indicates position at which there is amino acid variation compared to ADP1. 
Red = conserved amino acid change compared to ADP1. 
 
          61                                                            120 
                *           *          *   *                ***    *  
ADP1      RGKANGEPIP MAGVPYHAAE GYLARLVRAG QTVAICEQVG EGENAGSRCK APMERKVVRI 
ATCC19606 RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVV-I 
779 (MR)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
783 (MR)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
789 (MR)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E51 (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U45 (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
868 (MR)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U7  (R)   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
790 (MR)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
 
          121                                                           180 
          *    *       *             *  *   *       *       ***  *   *   
ADP1      ITPGTITDDA LLGSYQSSNL VALCIQQNKI GIALLDLSAS IFKVQQHEFK TEQLYIELAR 
ATCC19606 LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLS-G IFKVQQQDYK PEQLPIELAR 
779 (MR)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
783 (MR)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
789 (MR)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E51 (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U45 (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
868 (MR)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U7  (R)   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
790 (MR)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
 
 
The amino acid sequence of ATCC 19606 was identical to that of the resistant and 
multi-resistant clinical isolates. There were 20 positions within this region (marked in 
Figure 4.4) at which there were identical amino acid variations in the resistant clinical 
isolates compared to ADP1. These changes are also detailed in Table 4.1. This number 
does not include the aforementioned 5 deleted amino acids. There were no occurrences 
of non-conserved amino acid variation within the resistant and multi-resistant isolates; 
within the isolates examined this region of the mutS gene was highly conserved. 
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To the best of the author’s knowledge this highly conserved sequence comprising novel 
amino acid changes compared to ADP1 is unreported to date, and has been submitted in 
the course of this study into Genbank (Genbank accession number for partial mutS 
sequence: DQ 989864). Subsequently this mutS sequence is referred to as the R-type 
sequence, for ease of comparison with the other clinical isolates.  
 
There was no amino acid variation within the resistant isolates (comprised of 
A.baumannii and gen.sp. 13TU) and from analysis of the nucleotides at the positions 
where there was amino acid variation in the resistant isolates compared to ADP1 it was 
found that there were only 5 instances of nucleotide variation at these positions (detailed 
in Table 4.1). 
 
Further analysis of the nucleotide sequences of the resistant clinical isolates showed that 
they were a highly conserved group at nucleotide level as well as at the amino acid level 
(Figure 4.5). There were 34 positions within the nucleotide sequences of this region of 
mutS at which there was variation between the resistant isolates. Of these, there were 24 
positions at which there was nucleotide variation only in gen.sp. 13TU isolate E51. 
There were a further three positions at which there was nucleotide variation only in 
A.baumannii isolate 790 (nuc 492, 513, 515), and a further position at which there was 
nucleotide variation only in A. baumannii isolate U7 (nuc 195).  
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Table 4.1 Details of the amino acid and nucleotide variation in the mutS gene of 
resistant clinical isolates compared to ADP1 
ADP1 Resistant isolates Exceptions Position 
wrt ADP1 AA Codon AA Codon Isolate Codon 
67 Glu GAG Asn AAC - - 
78 Ala GCT Ser TCA - - 
91 Gln CAA Arg CGA E51 CGC 
102 Gly GGC - - - - 
103 Glu GAG - - - - 
104 Asn AAC - - - - 
105 Ala GCA - - - - 
106 Gly GGC - - - - 
107 Ser TCT Val GTT E51 GTC 
108 Arg CGC Thr ACT E51 ACA 
109 Cys TGT Gly GGC - - 
111 Ala GCC Gly GGC E51 GGT 
113 Met ATG Val GTT - - 
121 Ile ATT Leu CTT - - 
126 Ile ATT Leu TTA - - 
133 Gly GGC Thr ACA - - 
146 Gln CAG His CAT - - 
149 Lys AAA Gln CAG - - 
152 Ile GGG Phe GGT - - 
160 Ser AGT Gly GGT - - 
167 His CAT Gln CAA - - 
168 Glu GAG Asp GAC - - 
169 Phe TTT Tyr TAC - - 
171 Thr ACT Phe CCG 790 CCC 
175 Tyr TAC Phe CCA - - 
 
 
None of these observed nucleotide variations resulted in amino acid variation within the 
clinical isolates, although some (marked in bold in Figure 4.5) did occur in the codons 
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Figure 4.5 Nucleotide sequence alignment of the mutS of the resistant and multi-
resistant clinical isolates 
Numbering wrt ADP1. Nucleotide variations highlighted. 
* indicates positions at which there is nucleotide variation between the resistant isolates.  
Red and blue = conserved nuc variation. Green = non-conserved nuc variation.  
BOLD = nucleotide changes occurring at positions where the R-type aa sequence varied compared to ADP1.  
     181                                                           240  
       *            *         *            *  *  
779  CGAGGTAAAG CAAATGGCAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
783  CGGGGTAAAG CAAATGGCAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
789  CGGGGTAAAG CAAATGGCAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
790  CGGNNTAAAG CAAATGGCAA CC-GATTCCA ANGGCAGGTG TTCCCTACCA TTCAGCCGAA  
868  CGGGGTAAAG CAAATGGCAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
U7   CGGGGTAAAG CAAACGGNAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
U45  CGAGGTAAAG CAAATGGCAA CCCGATTCCA ATGGCAGGTG TTCCCTACCA TTCAGCCGAA  
E51  CGTGGTAAAG CAAATGGCAA CCCAATTCCA ATGGCGGGCG TTCCCTACCA TTCAGCCGAA  
     241                                                           300      
           *     *     *         *  *   *                   *     *  *       
779  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGC  
783  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGT  
789  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGC  
790  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGT  
868  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGC  
U7   GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGT  
U45  GGTTATTTGG CGCGTTTAGT AAAAGCCGGC CGAACTGTAG CTATTTGTGA GCAAGTCGGC  
E51  GGTTATCTGG CACGTTTGGT AAAAGCAGGT CGCACTGTAG CTATTTGTGA ACAAGTGGGT  
     301                                                           360 
                           *  *         *  *      *  *    
779  GAA------- --------GT TACTGGCAAA GGCCCGGTTG AGCGCAAAGT TGTTCGTATT  
783  GAA------- --------GT TACTGGCAAA GGCCCGGTTG AACGCAAAGT TGTTCGTATT  
789  GAA------- --------GT TACTGGCAAA GGCCCGGTTG AACGCAAAGT TGTTCGTATT  
790  NAA------- --------GT TACTGGCAAA GGCCCGGTTG AACGCAAAGT TGTTCGTATT  
868  GAA------- --------GT TACTGGCAAA GGCCCGGTTG AACGCAAAGT TGTTCGTATT  
U7   GAA------- --------GT TACTGGCAAA GGCCCGGTTG AACGCAAAGT TGTTCGTATT  
U45  GAA------- --------GT TACTGGCAAA GGCCCGGTTG AGCGCAAAGT TGTTCGTATT  
E51  GAA------- --------GT CACAGGCAAA GGTCCTGTTG AGCGTAAAGT TGTTCGTATT  
     361                                                           420     
          *  *      *      *     *  *                   *   * 
779  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAATC GTCTAACCTT         
783  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAATC GTCTAACCTT         
789  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAGTC GTCTAACCTT         
790  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAATC GTCTAACCTT         
868  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAGTC GTCTAACCTT       
U7   CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAGTC CTCTAACCTT       
U45  CTTACACCGG GTACTTTAAC CGACGACGCA CTACTTACAA GTTATCAATC GTCTAACCTT       
E51  CTTACCCCTG GTACATTAAC TGACGATGCC CTACTCACAA GTTATCAGTC TTCTAACCTT       
     421                                                           480    
       * 
779  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT  
783  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
789  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
790  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
868  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
U7   GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
U45  GTTGCGCTAT GTATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT 
E51  GTGGCGCTAT GCATCCATCA AAACCAGATC GGTTTTGCTT TACTCGACTT AAGTGCGGGT  
     481                                                           540 
                *                      * *             *         * 
779  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATCGA ACTGGCTCGC 
783  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATCGA ACTGGCTCGC 
789  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATTGA ACTGGCTCGC 
790  ATTTTTAAAG TACAACAACA AGACTACAAA CCCGGACAAC TTCCAATCGA ACTCACCCGC                     
868  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATTGA ACTGGCTCGC 
U7   ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATTGA ACTCACCCGC                     
U45  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATCGA ACTGGCTCGC 
E51  ATTTTTAAAG TTCAACAACA AGACTACAAA CCGGAACAAC TTCCAATTGA ACTGGCACGC 
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4.2.4 Sequence Analysis – Intermediate isolates 
Compared to the R-type mutS sequence, the amino acid sequences of the intermediate 
clinical isolates (comprising A. baumannii, gen.sp. 13TU and gen.sp. 3) also appeared 
highly conserved (Figure 4.6). There were 4 positions at which there was an amino acid 
variation compared to the R-type sequence, and all of these variations were in gen.sp. 3 
isolate U80.  
Figure 4.6 Alignment of the amino acid sequences of the mutS of intermediate 
clinical isolates compared to the sequence of the resistant clinical isolates 
Numbering w.r.t. ADP1.  
Variations compared to R-type highlighted.  
* indicates position at which there is an amino acid variation compared to the R-type sequence. 
        61                                                            120 
             * *      
R-type   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E13 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E14 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E41 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U43 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U51 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
U71 (I)  RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
U80 (I)  RGKASGRPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
 
         121          180 
                      *         * 
R-type   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E13 (I)  LTPGTLTEDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E14 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E41 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U43 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U51 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U71 (I)  LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
U80 (I)  LTPGTLTDDA LLSSYQSSNL VSLCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
 
 
Whilst there was a high level of conservation within the amino acid mutS sequences of 
the intermediate isolates, there was increased variation at the nucleotide level within 
these isolates, compared to that observed within the resistant isolates, as shown in Figure 
4.7. 
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Figure 4.7 Alignment of the nucleotide sequences of the mutS of intermediate 
clinical isolates  
Numbering wrt ADP1. Nucleotide changes highlighted. 
* indicates positions at which there is nucleotide variation between the intermediate isolates.  
Red, blue and Pink = conserved nuc variation. Green = non-conserved nuc variation.  
     181                                                           240 
       *  *     *  *    ***   *            *  *         *  *   *  * 
E13  CGGGGTAAAGCA AATGGCAACC CGATTCCAAT GGCAGGTGTT CCCTACCATT CAGCCGAA  
E14  CGTGGTAAAGCA AATGGCAACC CGATTCCAAT GGCAGGCGTT CCCTACCATT CAGCCGAA  
E41  CGTGGTAAAGCA AATGGCAACC CAATTCCAAT GGCGGGCGTT CCCTACCATT CAGCCGAA  
U43  CGTGGTAAAGCA AATGGCAACC CGATTCCAAT GGCAGGCGTT CCCTACCATT CAGCCGAA  
U51  CGAGGTAAAGCA AATGGCAACC CGATTCCAAT GGCAGGTGTT CCCTACCATT CAGCCGAA  
U71  CGGGGTAAAGCA AATGGCAACC CGATTCCAAT GGCAGGTGTT CCCTACCATT CAGCCGAA  
U80  CGTGGCAAAGCC AGTGGCCGAC CTATTCCAAT GGCGGGTGTT CCCTATCACT CGGCAGAA  
     241                                                           300 
           * *  *   *  *  *      *  *   *     *  *      *  *      *  * 
E13  GGTTATTTGGCG CGTTTAGTAA AAGCCGGCCG AACTGTAGCT ATTTGTGAGC AAGTCGGC  
E14  GGTTATTTGGCG CGTTTAGTAA AAGCAGGCCG CACTGTAGCC ATTTGTGAAC AAGTGGGT  
E41  GGTTATCTGGCA CGTTTGGTAA AAGCAGGTCG CACTGTAGCT ATTTGTGAAC AAGTGGGT  
U43  GGTTATTTGGCG CGTTTAGTAA AAGCAGGCCG CACTGTAGCC ATTTGTGAAC AAGTGGGT  
U51  GGTTATTTGGCG CGTTTAGTAA AAGCCGGCCG AACTGTAGCT ATTTGTGAGC AAGTCGGC  
U71  GGTTATTTGGCG CGTTTAGTAA AAGCCGGCCG AACTGTAGCT ATTTGTGAGC AAGTCGGT  
U80  GGTTATCTTGCT CGCCTTGTTA AAGCTGGCCG TACTGTCGCC ATTTGCGAAC AAGTTGGA  
     301                                                           360 
                          *   *  *      *  *     *   *    
E13  GAA--------- ------GTTA CTGGCAAAGG CCCGGTTGAA CGCAAAGTTG TTCGTATT  
E14  GAA--------- ------GTCA CCGGCAAAGG TCCTGTTGAG CGTAAAGTTG TTCGTATT  
E41  GAA--------- ------GTCA CAGGCAAAGG TCCTGTTGAG CGTAAAGTTG TTCGTATT  
U43  GAA--------- ------GTCA CCGGCAAAGG TCCTGTTGAG CGTAAAGTTG TTCGTATT  
U51  GAA--------- ------GTTA CTGGCAAAGG CCCGGTTGAA CGCAAAGTTG TTCGTATT  
U71  GAA--------- ------GTTA CTGGCAAAGG CCCGGTTGAA CGCAAAGTTG TTCGTATT  
U80  GAA--------- ------GTGA CAGGTAAAGG CCCTGTTGAA CGTAAAGTTG TTCGTATT  
     361                                                           420 
       *  *  *      *     *   *  *  **     * **         *  *      *  * 
E13  CTTACACCGGGT ACTTTAACCG AAGATGCACT ACTTACAAGT TATCAATCGT CTAACCTT  
E14  CTTACCCCTGGT ACATTAACCG ACGATGCATT ACTCACAAGT TATCAGTCCT CTAATCTT  
E41  CTTACCCCTGGT ACATTAACTG ACGATGCCCT ACTCACAAGT TATCAGTCTT CTAACCTT  
U43  CTTACCCCTGGT ACATTAACCG ACGATGCATT ACTCACAAGT TATCAGTCCT CTAATCTT  
U51  CTTACACCGGGT ACTTTAACCG ACGACGCACT ACTTACAAGT TATCAGTCGT CTAACCTT  
U71  CTTACACCGGGT ACTTTAACTG ACGACGCACT ACTTACAAGT TATCAGTCCT CTAACCTT  
U80  CTGACCCCTGGT ACATTAACTG ATGACGCATT ACTCAGCAGT TATCAATCAT CTAATCTC  
     421                                                           480   
       ** ** *  *   *               *                       *     *  * 
E13  GTTGCGCTATGT ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCGGGT  
E14  GTTGCGTTATGT ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCAGGT  
E41  GTGGCGCTATGC ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCGGGT  
U43  GTTGCGTTATGT ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCAGGT  
U51  GTTGCGCTATGT ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCGGGT 
U71  GTTGCGCTATGT ATCCATCAAA ACCAGATCGG TTTTGCTTTA CTCGACTT AAGTGCGGGT  
U80  GTTTCATTGTGC ATTCATCAAA ACCAGATTGG TTTTGCTTTA CTCGACTT GAGTGCAGGC 
     481                                                           540  
                              *     *   *  *   * *   *  *      *  *  * 
E13  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATCGAAC TGGCTCGC  
E14  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATTGAAC TGGCACGC  
E41  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATTGAAC TGGCACGC  
U43  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATTGAAC TGGCACGC  
U51  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATTGAAC TGGCTCGC 
U71  ATTTTTAAAGTT CAACAACAAG ACTACAAACC GGAACAACTT CCAATTGAAC TGGCTCGC  
U80  ATTTTTAAAGTT CAACAACAAG ATTACAAGCC AGAGCAATTG CCTATTGAAC TTGCGCGT  
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Within the examined region, there were 74 positions at which one or more of the 
intermediate clinical isolates had a nucleotide variation within their mutS sequence 
compared to the consensus nucleotide sequence. Of these there were 38 positions at 
which there was a nucleotide variation only in gen.sp. 3 isolate U80, the same isolate 
which contained the only amino acid variations observed within the intermediate 
isolates.  
 
4.2.5 Sequence Analysis – Sensitive isolates 
In comparison to the resistant and intermediate isolates the sensitive isolates (comprising 
A. baumannii, gen.sp. 3, A. johnsonii and A. junii) were much more varied compared to 
each other at both the nucleotide and amino acid level. Compared to the R-type amino 
acid sequence observed in the mutS of the resistant and most of the intermediate isolates, 
there were 27 positions at which one or more of the sensitive isolates had a different 
amino acid. This is shown in Figure 4.8. 
 
Of these 27 positions there were none at which all sensitive isolates had the same amino 
acid variation compared to the R-type sequence. There were also nine instances where 
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Figure 4.8 Alignment of the amino acid sequences of the mutS of sensitive 
clinical isolates compared to the sequence of the resistant clinical isolates 
 
Numbering w.r.t. ADP1. Variations highlighted. 
* indicates position at which there is amino acid variation compared to the R-type sequence. 
Red = conserved variations in the sensitive isolates compared to the R-type sequence. 
Blue = conserved variations in the sensitive isolates compared to the R-type sequence. 
Green = non-conserved variations in the sensitive isolates compared to the R-type sequence. 
 
         61                                                            120 
            ** *           *           *  *  *    *                  *   
R-type   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E9  (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E10 (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E15 (S)  RGKANGTPIP MAGVPYHSAE GYLARLVKAG ETVAICEQVG E-----VTGK GPVDRQVVRI  
E21 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
E26 (S)  RGKTNGEPIP MAGVPYHSAE GYLARLVKSG RTVAICEQVG E-----VTGK GPVERKVVRV  
E33 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
U66 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
 
         121                                                           180 
         *            *** *        ** * *  *     *   *     ** * **  *   
R-type   LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR  
E9  (S)  LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR  
E10 (S)  LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR  
E15 (S)  LTPGTLTD-A LLSSHQSSNL VALCFQQNQV GIALLDLGAG IFKVQQQDYK PEQLTIELAR  
E21 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
E26 (S)  LTPGTLTDDA LLSSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQTYK PEQLPIELAR  
E33 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  




However, despite the variation within the sensitive population conserved mutS 
sequences with the same amino acid variations compared to the R-type sequence were 
observed in certain groups of isolates, as depicted in Figure 4.9. There were two groups 
with conserved mutS amino acid sequences within the sensitive isolates comprising: E9 
and E10 (both identified in Chapter 3 as probable gen.sp. 3); and E21, E33 and U66 
(identified in Chapter 3 as A. johnsonnii, A. johnsonnii and A. baumannii respectively). 
E15 (identified as A. radioresistens) and E26 (identified as A. junii) had similarities to 
both sequence types, but did not fit in to either group.  
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Figure 4.9 Conserved mutS sequences within the sensitive amino acid isolates 
         61                                                            120 
E9  (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI  
E10 (S)  RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI                                                              
 
         121                                                           180   
E9  (S)  LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR  





         61                                                            120 
E21 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
E33 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
U66 (S)  RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI  
 
         121                                                           180 
E21 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
E33 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
U66 (S)  ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR  
 
Conserved changes compared to the R-type sequence are highlighted. 
 
 
Interestingly, of the 27 positions at which there was amino acid variation compared to 
the R-type sequence, there were 17 at which the amino acid was the same as one or more 
of the non-clinical isolates. This is marked in Figure 4.10 which shows the alignment of 
the amino acid mutS sequences of the sensitive isolates compared to the non-clinical 
strains. All of the variations found within the sensitive isolates and where they 
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Figure 4.10 Alignment of the amino acid mutS sequences of the sensitive clinical 
isolates compared with the resistant isolates’ and non-clinical sequences 
 
Numbering w.r.t. ADP1. Variations highlighted. 
+ indicates positions at which there is amino acid variation in one or more of the sensitive isolates compared to the R-
type sequence, where this difference corresponds to the sequence of one or more of the non-clinical strains.  
Blue = highlighting where non-clinical isolates match sensitive clinical isolates at positions where they differ to the R-
type sequence.  
 
          61                                                            120 
                +           +           +  +  +    +                  +      
ADP1  (C) RGKANGEPIP MAGVPYHAAE GYLARLVRAG QTVAICEQVG EGENAGSRCK APMERKVVRI 
93A2  (C) RGKANGEPIP MAGVPYHAAE GYLARLVRAG QTVAICEQVG EGENAGSRGK APMERKVVRI 
AD321 (C) RGKANGEPIP MAGVPYHAAE GYLARLVKAG QTVAICEQVG EGESAGSRGK APMERKVVRI 
AC423D(C) RGKANGEPIP MAGVPYHAAE GYLARLVKKG ETVVICEQIG E-----VTGK APVERGVVRI 
R-type    RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E9    (S) RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E10   (S) RGKASGQPIP MAGVPYHAAE GYLARLVKAG RTVAICEQVG E-----VTGK GPVERKVVRI 
E15   (S) RGKANGTPIP MAGVPYHSAE GYLARLVKAG ETVAICEQVG E-----VTGK GPVDRQVVRI 
E21   (S) RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI 
E26   (S) RGKTNGEPIP MAGVPYHSAE GYLARLVKSG RTVAICEQVG E-----VTGK GPVERKVVRV 
E33   (S) RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI 
U66   (S) RGKANGQPIP MAGVPFHAAE GYLARLVKKG ETVVICEQIG E-----VTGK GPVERGVVRI 
 
          121                                                           180 
          +            +++          ++      +         +          +   +    
ADP1  (C) ITPGTITDDA LLGSYQSSNL VALCIQQNKI GIALLDLSAS IFKVQQHEFK TEQLYIELAR 
93A2  (C) ITPGTITDDA LLGSYQSSNL VALCIQQNKI GIALLDLSAS IFKVQQHEFK TEQLYIELAR 
AD321 (C) ITPGTITDDA LLGSYQSSNL VALCIQQNKI GLALLDLSAS IFKVQEHDFK TEQLAIELSR 
AC423D(C) ITPGTLTDDA LLTAHQSSNL VALCVQQNEI GIALLDLSAG LFKVQQQEFQ LEQLGIELSR 
R-type    LTPGTLTDDA LLTSYQSSNL VALCIHQNQI GFALLDLSAG IFKVQQQDYK PEQLPIELAR 
E9    (S) LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR 
E10   (S) LTPGTLTDDA LLGSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQDYK PEQLAIELAR 
E15   (S) LTPGTLTD-A LLSSHQSSNL VALCFQQNQV GIALLDLGAG IFKVQQQDYK PEQLTIELAR 
E21   (S) ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
E26   (S) LTPGTLTDDA LLSSYQSSNL VALCIQQNQI GFALLDLSAG IFKVQQQTYK PEQLPIELAR 
E33   (S) ITPGTLTDDA LLGAHQTSNL VALCVHQQQI GIALLDLSAG LFKVQQIDYD LSQLAIELAR 
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Table 4.2 Details of the variation in the mutS sequences of the sensitive isolates 
compared to the mutS sequences of the resistant isolates’ and non-clinical 
strains  
R-type 
Changes of sensitive isolates 
compared to R-type 
ADP1 




AA Codon Isolate AA Codon AA Codon Y/N Non-clin AA 
64 Ala GCA E26 Thr ACA Ala GCT N - 
65 Asn AAT E9 Ser AGT Asn AAT N - 
   E10 Ser AGT   N - 
67 Asn AAC E9 Gln CAG Glu GAG N - 
   E10 Gln CAG   N - 
   E21 Gln CAG   N - 
   U66 Gln CAG   N - 
   E33 Gln CAG   N - 
   E26 Glu GAA   Y Glu 
   E15 Thr ACG   N - 
78 Ser TCA E9 Ala GCA Ala GCT Y Ala 
   E10 Ala GCA   Y  
   E21 Ala GCT   Y  
   U66 Ala GCT   Y  
   E33 Ala GCT   Y  
   E15 Ala TCT   Y  
89 Ala GCC E26 Ser TCA Ala GCA N - 
   E21 Lys AAA   Y Lys 
   U66 Lys AAA   Y  
   E33 Lys AAA   Y  
91 Arg CGA E21 Glu CGA Gln CAA Y Glu 
   U66 Glu GAA   Y  
   E33 Glu GAA   Y  
   E15 Glu GAG   Y  
94 Ala GCT E21 Val GTG Ala GCT Y Val 
   U66 Val GTG   Y  
   E33 Val GTG   Y  
99 Val GTC E21 Ile ATC Val GTA Y Ile 
   U66 Ile ATC   Y  
   E33 Ile ATC   Y  
116 Lys AAA E21 Gly GGT Lys AAA Y Gly 
   U66 Gly GGT   Y  
   E31 Gly GGT   Y  
   E15 Gln CAA   N - 
121 Leu CTT E21 Ile ATT Ile ATT Y Ile 
   U66 Ile ATT   Y  
   E33 Ile ATT   Y  
133 Thr ACA E9 Gly GGA Gly GGC Y Gly 
   E10 Gly GGA   Y  
   E21 Gly GGT   Y  
   U66 Gly GGT   Y  
   E33 Gly GGT   Y  
   E26 Ser TCA   N - 
   E15 Ser AGC   N - 
134 Ser AGT E21 Ala GCT Ser AGT Y Ala 
   U66 Ala GCT   Y  
   E33 Ala GCT   Y  




Table 4.2 continued 
R-type 
Changes of sensitive isolates 
compared to R-type 
ADP1 




AA Codon Isolate AA Codon AA Codon Y/N Non-clin AA 
135 Tyr TAT E21 His CAT Tyr TAT Y His 
   U66 His CAT   Y  
   E33 His CAT   Y  
   E15 His CAT   Y  
137 Ser TCC E21 Thr ACC Ser TCT N - 
   U66 Thr ACC   N - 
   E31 Thr ACC   N - 
145 Ile ATC E21 Val GTT Ile ATT Y Val 
   U66 Val GTT   Y  
   E33 Val GTT   Y  
   E15 Phe TTC   N - 
146 His CAT E9 Gln CAA Gln CAG Y Gln 
   E10 Gln CAA   Y  
   E26 Gln CAA   Y  
   E15 Gln CAG   Y  
148 Asn AAC E21 Gln CAA Asn AAT N - 
   E33 Gln CAA   N - 
   U66 Gln CAA   N - 
150 Ile ATC E15 Val GTC Ile ATT N - 
152 Phe TTT E21 Ile ATT Ile ATT Y Ile 
   U66 Ile ATT   Y  
   E33 Ile ATT   Y  
   E15 Ile ATT   Y  
158 Ser AGT E15 Gly GGT Ser AGT N - 
161 Ile ATT E21 Leu TTA Ile ATA Y Ile 
   U66 Leu TTA   Y  
   E33 Leu TTA   Y  
167 Gln CAA E21 Ile ATC His CAT N - 
   U66 Ile ATC   N - 
   E33 Ile ATC   N - 
168 Asp GAC E26 Thr ACA Glu GAG N - 
170 Lys AAA E21 Asp GAC Lys AAA N - 
   U66 Asp GAC   N - 
   E33 Asp GAC   N - 
171 Pro CCG E21 Leu TTA Thr ACT Y Leu 
   U66 Leu TTA   Y  
   E33 Leu TTA   Y  
172 Glu GAA E21 Ser AGT Glu GAA N - 
   U66 Ser AGT   N - 
   E33 Ser AGT   N - 
175 Pro CCA E9 Ala GCC Tyr TAC Y Ala 
   E10 Ala GCC   Y  
   E21 Ala GCC   Y  
   U66 Ala GCC   Y  
   E33 Ala GCC   Y  
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As shown in Table 4.2, within the sensitive isolates there are 60 instances where an 
isolate varied compared to the resistant isolates’ mutS sequence, but corresponded 
instead to one or more of the non-clinical isolates.  
 
The sensitive isolates were also markedly more varied than the other clinical isolates at 
the nucleotide level, as shown in Figure 4.11. There were 146 positions at which there 
was nucleotide variation between the isolates. At 40 of these positions, there were non-
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Figure 4.11 Alignment of the nucleotide sequences of the mutS of sensitive 
clinical isolates 
Numbering w.r.t. ADP1. * indicates position at which there is aa variation compared to the R-type sequence. 
Red,  Blue and  Pink = conserved variations within the sensitive isolates compared to the majority. 
Green = non-conserved variations in the sensitive isolates compared to the majority. 
     181                                                           240 
       *  *   *  * **  *** *  *     *      *  *   *  * **    * *  *  *   
E9   CGTGGCAAAG CCAGTGGTCA GCCAATTCCA ATGGCGGGTG TACCTTATCA TGCAGCAGAG 
E10  CGCGGCAAAG CCAGTGGTCA GCCAATTCCA ATGGCAGGTG TACCTTATCA TGCAGCAGAG 
E15  CGTGGTAAAG CCAACGGTAC GCCTATTCCT ATGGCGGGGG TGCCCTATCA TTCTGCCGAA 
E21  CGCGGTAAAG CCAATGGCCA GCCAATTCCG ATGGCCGGTG TACCTTTCCA TGCTGCTGAA 
E26  CGTGGCAAAA CAAATGGTGA ACCAATTCCA ATGGCAGGTG TTCCCTACCA TTCCGCTGAA 
E33  CGNGGTAAAG CCAATGGCCA GCCAATTCCG ATGGCCGGTG TACCTTTCCA TGCTGCTGAA 
U66  CGCGGTAAAG CCAATGGCCA GCCAATTCCG ATGGCCGGTG TACCTTTCCA TGCTGCTGAA 
     241                                                           300 
       *   * *   *  ** *   *  ****  * ***  *  *  **  *  *   *  ** * 
E9   GGCTATCTGG CTCGTTTAGT CAAAGCTGGC CGTACTGTCG CCATCTGCGA ACAAGTTGGT 
E10  GGCTATCTCG CTCGTTTAGT CAAAGCTGGC CGTACTGTCG CCATCTGCGA ACAAGTTGGT 
E15  GGGTATCTGG CCCGGCTGGT AAAAGCCGGT GAGACCGTGG CCATCTGTGA ACAGGTGGGT 
E21  GGCTATTTGG CTCGTCTGGT GAAAAAAGGC GAAACGGTGG TGATCTGCGA GCAGATCGGT 
E26  GGATATTTAG CACGTTTAGT AAAGTCAGGT CGTACCGTTG CAATTTGTGA ACAAGTTGGT 
E33  GGCTATCTGG CTCGTCTGGT GAAAAAAGGC GAAACGGTGG TGATCTGCGA GCAGATCGGT 
U66  GGCTATCTGG CTCGTCTGGT AAAAAAAGGC GAAACGGTGG TGATCTGCGA GCAGATCGGT 
     301                                                           360 
       *                   *  *  *      *  *      *   ***   *  *  ** *   
E9   GAG------- --------GT CACAGGCAAA GGTCCAGTTG AGCGTAAAGT AGTCCGTATC 
E10  GAG------- --------GT CACAGGCAAA GGTCCGGTTG AGCGTAAAGT AGTACGTATC 
E15  GAA------- --------GT GACCGGTAAA GGTCCGGTTG ACCGTCAAGT CGTGCGTATC 
E21  GAA------- --------GT GACTGGTAAA GGCCCAGTTG AACGTGGTGT CGTCCGAATC 
E26  GAA------- --------GT TACAGGTAAA GGACCTGTCG AGCGTAAAGT AGTCCGAGTT 
E33  GAA------- --------GT GACTGGTAAA GGCCCAGTTG AACGTGGTGT CGTCCGAATC 
U66  GAA------- --------GT GACTGGTAAA GGCCCAGTTG AACGTGGTGT CGTCCGAATC 
     361                                                           420 
     * *  *  *   *  *      *  *     * * ** ** ** *** *  *** *  *  ** *  
E9   TTAACGCCAG GCACATTAAC CGATGATGCT TTATTGGGAA GTTACCAATC GTCGAATCTG 
E10  TTAACGCCAG GCACATTAAC CGATGATGCT TTATTGGGAA GTTACCAATC GTCGAATCTG 
E15  CTCACCCCCG GTACCTTAAC CGATNATGCT CTGCTCAGCT CACATCAGAG CTCCAATCTG 
E21  ATTACCCCTG GAACCTTAAC CGATGATGCC TTATTAGGTG CTCATCAAAC CTCCAACCTG 
E26  TTGACACCTG GTACCTTAAC TGACGATGCG CTTTTATCAA GTTATCAATC CTCAAATTTA 
E33  ATTACTCCTG GAACCTTAAC CGATGATGCC TTATTAGGTG CTCATCAAAC CTCCAACCTG 
U66  ATTACCCCTG GAACCTTAAC CGATGATGCC TTATTAGGTG CTCATCAAAC CTCCAACCTG 
     421                                                           480 
          ** *   ** *  *   ** *  ** *   ** *  **  *  *   *  **    *  *   
E9   GTTGCGCTCT GTATTCAACA AAATCAAATT GGTTTCGCCT TACTCGACTT GAGTGCAGGC 
E10  GTTGCGCTCT GTATTCAACA AAATCAAATT GGTTTCGCCT TACTCGACTT GAGTGCAGGA 
E15  GTTGCGTTAT GCTTCCAGCA AAATCAGGTC GGTATTGCAC TGCTGGACTT AGGTGCAGGT 
E21  GTTGCTCTGT GTGTTCACCA GCAACAAATC GGAATTGCAC TTCTTGACCT GAGTGCTGGT 
E26  GTTGCTCTGT GTATACAACA AAATCAAATT GGTTTTGCAT TACTTGACTT GAGTGCAGGT 
E33  GTTGCTCTGT GTGTTCACCA GCAACAAATC GGAATTGCAC TTCTTGACCT GAGTGCCGGT 
U66  GTTGCTCTGT GTGTTCACCA GCAACAAATC GGAATTGCAC TTCTTGACCT GAGTGCCGGT 
     481                                                           540 
     * *  *      *  *  *** ****   * * ******  *   ** *  *   ** *  *  *      
E9   ATCTTTAAAG TTCAACAACA AGACTATAAA CCTGAACAAT TGGCCATTGA ACTGGCGCGT 
E10  ATCTTTAAAG TTCAACAACA AGACTATAAG CCTGAACAAT TGGCCATTGA ACTGGCACGT 
E15  ATTTTTAAAG TTCAGCAGCA GGACTATAAA CCGGAACAGT TAACGATTGA GCTGGCGCGA 
E21  TTATTCAAAG TCCAGCAAAT CGATTATGAC TTAAGTCAGT TAGCCATTGA GTTGGCACGC 
E26  ATTTTTAAAG TTCAACAACA GACATATAAA CCAGAGCAAT TGCCAATAGA ACTTGCTCGC 
E33  TTATTTAAAG TCCAGCAAAT CGATTATGAC TTAAGTCAGT TAGCCATTGA GTTGGCACGC 
U66  TTATTTAAAG TCCAGCAAAT CGATTATGAC TTAAGTCAGT TAGCCATTGA GTTGGCACGC 
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4.2.6 mutS Sequence of Outbreak Strains 
As mentioned (Section 2.1) several representatives of A. baumannii outbreak strains 
were gifted by Dr Jane Turton and their sensitivities determined (Section 3.2.1). Part of 
the mutS genes of these strains were also sequenced and examined, and compared to the 
R-type amino acid sequence, as shown in Figure 4.12. 
 
Figure 4.12 Alignment of the mutS gene of several A. baumannii outbreak strains 
compared to the R-type sequence of clinical isolates examined above 
         61                                                             120    
R-type   RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL  
JTA      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
JTB      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
JTC      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
JT3      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
JT4      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
JT6      RGKANGNPIP MAGVPYHSAE GYLARLVKAG RTVAICEQVG EVTGKGPVER KVVRILTPGTL 
 
         121                                                180 
R-type   TDDALLTSYQ SSNLVALCIH QNQIGFALLD LSAGIFKVQQ QDYKPEQLPI ELARLMPSEIL 
JTA      TDDALLTSYQ SSNLVALCIH QNQIGFAL                                      
JTB      TDDALLTSYQ SSNLVALCIH QNQIGFALLD L                                  
JTC      TDDALLTSYQ SSNLVALCIH QNQIGFALLD LSAGIFKVQQ QDYKPEQLPI E            
JT3      TDDALLTSYQ SSNLVALCIH QNQIGFALLD LSAGIFKVQQ QDYKPEQLP               
JT4      TDDALLTSYQ SSNLVALCIH QNQIGFALLD L                                  




As is apparent, the mutS amino acid sequence of the examined section of the outbreak 
strains is identical to that of the R-type sequence found in the resistant, multi-resistant 
and most intermediate clinical isolates. 
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4.2.7 Sequences Analysis Summary 
Specific positions of variation were evident when the amino acid sequences of the mutS 
gene of the clinical isolates were compared to ADP1. As shown in Figure 4.2 there were 
39 positions at which there was amino acid variation of one or more of the clinical 
isolates compared to ADP1. At 10 of these positions all clinical isolates had a variation, 
at 12 the majority had a conserved variation, and at 16 there was variation compared to 
ADP1 but the amino acid change corresponded to one or more of the other non-clinical 
isolates.  
 
Variation in the mutS gene was also observed within the clinical isolates themselves, 
with 87 instances at 23 positions where one or more isolates varied in comparison to the 
consensus sequence (Figure 4.3). The majority of the variations occurred in the sensitive  
isolates, with only two occurring in the intermediate isolate U80. 
 
Looking at the differences in terms of sensitivities, the resistant and multi-resistant 
isolates had highly conserved mutS sequences at both amino acid and nucleotide level 
(Figures 4.4, 4.5 and Table 4.1) with no amino acid differences and 34 positions of  
nucleotide variation, the majority of which (24 of 34) occurred only in isolate E51.  
 
The majority of the intermediate isolates were also highly conserved, with the same 
amino acid sequence as that of the resistant isolates, with the exception of U80 which 
had 4 amino acid variations (Figure 4.6). There was, however, more variation at the 
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nucleotide level within the intermediate isolates, with 74 positions at which there was 
nucleotide variation compared to the consensus sequence (Figure 4.7).  
 
The sensitive isolates were much more varied in both amino acid and nucleotide mutS 
sequences, with 27 positions of amino acid variation compared to the R-type sequence 
and 146 positions at which there was nucleotide variation between the sensitive isolates. 
Additionally, at 17 of the 27 positions mentioned above the amino acid variation 
correlated with one or more of the non-clinical strains. (Figures 4.8, 4.10 and Table 4.2). 
 
Looking at the results in terms of species, whilst all of the clinical isolates differed from 
ADP1 and the other non-clinical isolates, A. baumannii and gen.sp. 13TU appeared to 
have a highly conserved amino acid mutS sequence (which has been referred to as the R-
type sequence), whilst the other Acinetobacter species (the sensitive isolates and the 
intermediate isolate U80) had various amino acid differences compared to this R-type 
sequence. Additionally, of the nucleotide variation seen in the resistant isolates, 24 out 
of 34 variations occurred only in the gen.sp. 13TU isolate E51; likewise the only amino 
acid variation in the intermediate isolates occurred in the gen.sp. 3 isolate U80. 
Importantly, the A. baumannii outbreak strains all had a mutS amino acid sequence 
identical to the R-type sequence examined clinical isolates. 
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4.3 Discussion 
The aims set out at the beginning of the chapter were: to examine the mutS gene of 
clinical Acinetobacter isolates; to determine whether there was variation both compared 
to non-clinical strains and within the clinical population; and to examine whether this 
variation correlated with different antibiotic susceptibilities. 
 
It was relevant to examine the mutS gene of clinical Acinetobacter isolates of different 
species for this investigation, as discussed in Sections 1.3 and 4.1. Despite the 
predominance of A. baumannii in hospital infections other species, especially gen.sp. 
13TU, are also frequently isolated from infections and further species also form part of 
the clinical population of Acinetobacter. The representative isolates used were 
genetically unrelated, as determined by PFGE of ApaI digested DNA, and comprised 
resistant, intermediate and sensitive susceptibilities as determined from the MICs of 
several tested antibiotics (Chapter 3). 
 
From the results it was apparent that the mutS gene sequence of clinical isolates did vary 
compared to the non-clinical strains. All examined clinical isolates had in common a 
section of five deleted amino acids (aa 102-106 inclusive) compared to ADP1, also 
observed in one of the non-clinical strains (AC423D). Indels have previously been 
reported within ADP1 and other non-clinical isolates of Acinetobacter, and it was 
hypothesised that they set it apart from other Gram-negative bacteria (Section 1.5.5; 
Young & Ornston, 2001). However the clinical Acinetobacter isolates examined here did 
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not share the extra five amino acids (aa 102-106) suggesting that the difference is not as 
clear as supposed. 
 
Variation was also apparent within the clinical isolates themselves. Whilst the 
comparison was predominantly with ADP1 the non-clinical isolates also varied in terms 
of their mutS gene and there were instances where an amino acid variation within the 
clinical isolates corresponded to one or more of the other non-clinical isolates. This was 
particularly evident in the sensitive Acinetobacter spp isolates when compared to the R-
type sequence found in the resistant and intermediate isolates (which comprised 
A.baumannii, gen.sp. 13TU and gen.sp. 3); there were several positions at which the 
sensitive isolates varied compared to the other clinical isolates but instead the amino 
acid corresponded to one or more of the non-clinical isolates.  
 
Looking at the Acinetobacter spp clinical isolates together, the similarity of the mutS 
sequences of some of the sensitive Acinetobacter spp isolates to the non-clinical isolates 
may be an indication that these isolates are transitional between the non-clinical species 
of Acinetobacter and the resistant isolates, in terms of their mutS sequence. In addition, 
most of the A. baumannii intermediate isolates had the same R-type amino acid 
sequence as the resistant and multi-resistant isolates; however, at the nucleotide level 
there was still greater variation seen in the intermediate compared to the resistant 
isolates. This supports the idea that, in terms of the mutS gene, they may be at an 
intermediate stage between the non-clinical and sensitive isolates and the highly 
conserved mutS sequence type associated with multi-resistant clinical isolates. The 
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intermediate isolates may therefore be an example of the next stage of progression 
between the mutS gene of sensitive isolates and that found in the resistant isolates.  
 
In terms of species, the R-type mutS amino acid sequence was found only in 
A.baumannii and gen.sp. 13TU clinical isolates. These species are genetically highly 
related, both considered important in the hospital environment (though A. baumannii 
more so), and are both part of the Acb complex. Interestingly U80, an intermediate 
isolate with only 4 amino acid differences compared to the R-type sequence, is gen.sp. 3; 
also part of the Acb complex, gen.sp. 3 is increasingly considered potentially relevant in 
the clinical environment (Section 1.3; Tjernberg & Ursing, 1989; Gerner-Smidt et al, 
1991; Dijkshoorn et al, 2007). The sensitive isolates E21 and E33, both identified as A. 
johnsonnii, had identical amino acid mutS sequences, though U66 (a sensitive A. 
baumannii isolate) also shared this sequence. 
 
Hence, whilst it could be argued that the mutS differences may be species specific, an 
identical R-type sequence was not found in the sensitive U66 A. baumannii isolate 
(identified as such in Chapter 3 following a positive blaOXA-51-like PCR and 16S-23S 
intergenic rRNA sequence analysis). Additionally, whilst A. baumannii and gen.sp. 
13TU are highly related, they are still considered separate species, and all of these 
isolates had an identical R-type mutS amino acid sequence. Furthermore, in addition to 
intermediate isolate U80, sensitive isolates E9 and E10 were also identified as probable 
gen.sp. 3. (Chapter 3). U80 was the only intermediate isolate to differ (at four aa 
positions) from the R-type mutS sequence, and one of these changes (aa 65) was in 
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common with that observed in E9 and E10 (see Figure 4.9), but the mutS sequences were 
not identical within isolates from these species. Therefore, whilst it could be argued that 
this difference is species-specific, taking the results above and species information from 
Chapter 3 together, this seems unlikely.  
 
As discussed in Section 1.3, the taxonomy and speciation of Acinetobacter spp is 
historically complicated, and even with the advent of genotypic typing methods, there 
can still be uncertainty about speciation, with members of the Acb complex frequently 
grouped together. In terms of the mutS amino acid sequence found here, and 
corresponding sensitivities, the caution regarding this grouping of different species 
seems supported, as sensitive and intermediate isolates of gen.sp. 3 would thus be 
grouped with resistant and multi-resistant A. baumannii and 13TU isolates.  
 
From these observations it appears, at least in this selection of the hospital population of 
Acinetobacter spp, that there is greater conservation of the mutS gene with higher levels 
of resistance; there was variation in the mutS gene within the clinical isolates but the 
resistant and multi-resistant isolates, and most importantly the outbreak strains, all had 
an identical R-type mutS amino acid sequence. Whilst the same was observed in most 
intermediate isolates too, they were more varied in terms of their nucleotides, supporting 
the idea of homogeneity with increased resistance. Given the reported clonal spread of 
multi-resistant A. baumannii isolates (Section 1.3.4; Coehlo et al, 2004), some of which 
were examined here, homogeneity is likely to be a characteristic of the most successful 
Acinetobacter isolates, hence the conserved R-type mutS sequence seems significant. 
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The correlation of the highly conserved mutS type with the most clinically relevant 
Acinetobacter isolates (that is, the R-type mutS sequence was found in outbreak A. 
baumannii, and other resistant and multi-resistant A. baumannii and gen.sp. 13TU 
clinical isolates) may be indicative of the relevance of mutS in the ability of these 
species, and A. baumannii in particular, to predominate in the clinical environment. As 
discussed in Section 1.3.5, whilst the individual antibiotic resistance mechanisms of 
Acinetobacter spp are well characterised, it is the remarkable ability of A. baumannii in 
particular to acquire resistance which is fundamental to its prevalence, and the reasons 
behind this are unclear; it may be that, similar to reports in other species (Section 1.5), 
defects in the mutS gene are associated with this ability.  
 
Regarding the aims of this Chapter, these observations show that the mutS gene of 
clinical Acinetobacter spp does differ from that of non-clinical strains, and that there is 
also sensitivity-associated variation in the mutS gene of clinical isolates. A highly 
conserved, novel mutS amino acid sequence was found in outbreak, multi-resistant and 
resistant isolates. As such these results support the hypothesis that differences in the 
mutS gene may be a factor in the ability of sub-populations of Acinetobacter spp in the 
clinical environment to rapidly acquire resistance. Chapter 5 examines the mutation 
potential of these isolates to determine whether the observed mutS differences are 
correlated with differences in ability to develop resistance. 
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Chapter 5: Acinetobacter mutation studies 
5.1 Introduction 
In the previous chapter it was determined that there were differences in the mutS gene of 
clinical Acinetobacter spp isolates compared to the non-clinical strains and that there 
was sensitivity-associated variation of the mutS gene within the clinical isolates. This 
chapter examines whether the different mutS types are correlated with differences in the 
ability of the isolates to develop antibiotic resistance. 
 
As discussed in Section 1.5.3, although the importance of mutation in antibiotic 
resistance development is clear, and hypermutation is also increasingly considered an 
important factor, increased mutation rates ought not to be considered in isolation as a 
direct cause of resistance development (Matic et al, 1997; Denamur et al, 2002; O’Neill 
& Chopra, 2002; Martinez & Baquero, 2000; Woodford & Ellington, 2007). 
 
As such, mutation potential must also be measured in terms of ability to develop 
clinically significant resistance. Fluoroquinolones, as discussed in Section 1.4, are of 
particular interest regarding Acinetobacter spp resistance, with fluoroquinolone 
resistance highlighted as a possible risk factor for epidemic behaviour in A. baumannii 
(Wisplinghoff et al, 2003). 
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In Acinetobacter, the primary mechanism of resistance to fluoroquinolones is target site 
mutation in the gyrA gene, most commonly Serine-83 to Leucine (Vila et al, 1995). 
Mutations in parC are also implicated as a secondary target in fluoroquinolone 
resistance development but their role is less certain (see Section 1.4.5). Over-expression 
of efflux systems is also a mechanism of Acinetobacter resistance to fluoroquinolones, 
however such changes in expression are transient and hence not associated with lasting 
clinically significant resistance (Section 1.4.6). 
 
In gyrA, the loss of the HinfI restriction site GANTC at codons 82 and 83 when the 
expected target site mutation is present can be readily indicated by restriction analysis 
with HinfI restriction enzyme. The possible existence of a target site mutation is 
suggested by unrestricted gyrA PCR products as seen on an agarose gel and confirmed 
by sequence analysis (Sections 1.4.5 and 2. 10.3). 
 
Fluoroquinolone resistance development, as measured by MICs after challenge with 
ciprofloxacin and target site mutation in the gyrA gene (Section 2.10), is used as a tool 
here to examine the mutation potential of the representative Acinetobacter spp isolates 
detailed in Chapters 3 and 4.  
 




5.2.1 Generation of First Step Mutants 
All sensitive and intermediate Acinetobacter spp isolates examined in Chapter 4 were 
challenged with 2 x MIC of ciprofloxacin to generate mutants, as described in Section 
2.10. Randomly-picked mutants thus generated were stored and their ciprofloxacin 
MICs determined as described in Section 2.7. During the generation of first step mutants 
isolates were also challenged with excess ciprofloxacin; only U43 produced any mutants 
in response to this challenge. These were stored and labelled U43+, and are discussed in 
Section 5.2.9 below.  
 
5.2.2 Mutation Frequencies 
Spontaneous mutation frequencies were calculated as the ratio of potential mutants to 
viable colonies for each isolate (Section 2.10). Table 5.1 shows the mean mutation 
frequencies of each isolate, expressed as number of resistant mutants recovered as a 
fraction of total viable count.  
 
It is clear that the mutation frequency varies within the Acinetobacter isolates examined, 
from 6 x 10-8 to 7.22 x 10-4, indicating that there is potential that some isolates in 
comparable conditions could have much higher mutation frequencies. Compared to the 
non-clinical strain ADP1, all of the intermediate isolates with the R-type mutS sequence 
had higher mutation frequencies. Four of the sensitive isolates, without the R-type mutS 
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sequence, also had higher mutation frequencies than ADP1, with the highest observed 
mean mutation frequencies in sensitive isolates E10 and U66, followed by U71, E9 and 
E26. 
 
Table 5.1 Mean mutation frequencies of parent strains 








ATCC 19606 C 7.86 x 10-7 E26 S 1.01 x 10-4 
ATCC 19606 * C 3.30 x 10-5 E33 S 6.00 x 10-8 
ADP1 C 3.45 x 10-7 E41 I 1.15 x 10-6 
E9 S 1.53 x 10-4 U43 I 8.22 x 10-5 
E10 S 5.88 x 10-4 U51 I 2.84 x 10-6 
E13 I 5.45 x 10-6 U51 * I 1.40 x 10-5 
E14 I 1.48 x 10-5 U66 S 7.22 x 10-4 
E15 S 3.68 x 10-7 U71 I 3.12 x 10-4 
E21 S 6.02 x 10-7 U80 I 3.89 x 10-6 
C = control, S = sensitive, I - intermediate 
5.2.3 Minimum Inhibitory Concentrations of First Step Mutants 
Table 5.2 shows the ciprofloxacin MICs (determined as described in Section 2.7) of the 
first-step mutants, selected from those generated by challenge of the parents with 
ciprofloxacin. Where there was an increase in the MIC of ciprofloxacin compared to the 
parent, the isolates were considered to be mutants. If there was no increase in the MIC of 
ciprofloxacin, they were disregarded for further work.  
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Parent 1  Parent 0.5  Parent 0.25  Parent 0.5  
1 4 + 1 0.5 - 1 4 + 1 2 + 
2 2 + 2 1 + 2 8 + 2 2 + 
3 2 + 3 1 + 3 4 + 3 2 + 
4 2 + 4 4 + 4 4 + 4 2 + 
5 2 + 5 2 + 5 4 + 5 2 + 
6 2 + 6 2 + 6 1 + 6 2 + 
7 2 + 7 4 + 7 2 + 7 2 + 
8 2 + 8 2 + 8 2 + 8 2 + 
9 2 +        
ADP1   E14   E33   U66   
Parent 0.06  Parent 0.5  Parent 0.12  Parent 0.03  
1 0.5 + 1 8 + 1 1 + 1 0.25 + 
2 0.5 + 2 4 + 2 0.25 + 2 0.12 + 
3 0.5 + 3 2 + 3 0.5 + 3 0.25 + 
4 0.5 + 4 4 + 4 1 + 4 0.25 + 
5 0.5 + 5 4 + 5 1 + 5 0.12 + 
6 0.5 + 6 4 + 6 1 + 6 0.12 + 
7 0.5 + 7 2 + 7 1 + 7 0.25 + 
8 0.5 + 8 8 + 8 1 + 8 0.12 + 
9 0.5 +    9 0.5 +    
E9   E15   E41   U71   
Parent 0.06  Parent 0.06  Parent 2  Parent 0.12  
1 0.016 - 1 0.25 + 1 2 + 1 0.5 + 
2 0.12 + 2 0.5 + 2 2 + 2 2 + 
3 0.06 - 3 2 + 3 4 + 3 0.12 - 
4 0.06 - 4 0.25 + 4 4 + 4 2 + 
5 0.016 - 5 0.25 + 5 2 + 5 0.5 + 
6 0.5 + 6 0.5 + 6 2 + 6 0.5 + 
7 0.016 - 7 0.25 + 7 2 + 7 1 + 
8 0.016 - 8 0.25 + 8 2 + 8 1 + 
   9 0.5 +       
E10   E21   U43   U80   
Parent 0.12  Parent 0.032  Parent 0.25  Parent 0.25  
1 0.5 + 1 0.12 + 1 2 + 1 0.25 - 
2 0.25 + 2 0.25 + 2 1 + 2 2 + 
3 0.25 + 3 0.12 + 3 1 + 3 2 + 
4 0.25 + 4 0.06 + 4 2 + 4 2 + 
5 0.5 + 5 1 + 5 2 + 5 2 + 
6 0.5 + 6 0.12 + 6 1 + 6 2 + 
7 0.5 + 7 0.12 + 7 1 + 7 1 + 
8 0.5 + 8 0.12 + 8 0.5 + 8 1 + 
   9 0.12 +       
* up MIC – was the MIC increased compared to parent strain. + = yes, - = no. 
 
It is apparent that there was a variation in the ranges of ciprofloxacin MICs in the 
potential mutants generated from different parental isolates. Those from parents with the 
R-type mutS sequence generally had higher ciprofloxacin MICs, up to 8 mg/L in two 
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mutants derived from gen.sp. 13TU isolate E14. This may be expected since the 
intermediate strains themselves had higher ciprofloxacin MICs than the sensitive 
parents, without the R-type mutS sequence. However, substantial increases in MIC 
levels were more frequent in 1st step mutants from parents with the R-type mutS 
sequence compared to the sensitive isolates without the R-type sequence.  
 
Parent strains E9 and E10 (identified as gen.sp. 3 in Chapter 3) were noted above for 
their very high mutation frequencies, as shown in Table 5.1. However strain E9 
produced only two mutants with higher ciprofloxacin MICs, and the increase in 
ciprofloxacin MICs in E10-derived mutants was not very high.  
 
5.2.4 Generation of Second Step Mutants 
Second-step mutants were generated as described in section 2.10.1 from selected first-
step mutants which had various ciprofloxacin MICs. Mutation frequencies for the 
challenged first-step mutants, as a ratio of potential mutants to viable colonies, were 
determined as above and are displayed in Table 5.3. 
 
Further mutants could not be generated from the 1st step mutants derived from parental 
isolates E9 and E10; there was no growth of E10-derived 1st step mutants on the 2 x 
ciprofloxacin MIC selective plates, and no viable growth of E9-derived 1st step mutants. 
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Table 5.3 Mutation frequencies of selected first-step mutants 
Isolate Mean mutation 
frequency 
Isolate Mean mutation 
frequency 
ATCC 19606 (1)1 6.00 x 10-6 E 26 / 7 2.38 x 10-3 
ATCC 19606 (3)10 1.63 x 10-5 E26 / 8 7.30 x 10-7 
ADP1 (1)4  9.39 x 10
-7 
E33 (2) 2 7.37 x 10
-7 
ADP1 (2)6 1.13 x 10
-6 
E33 (3) 1 5.88 x 10
-7 
E13 / 2 2.60 x 10-4 E41 / 3 1.38 x 10-6 
E14 / 2 5.10 x 10-4 U43 / 1 2.77 x 10-2 
E14 / 4 6.77 x 10
-2
 U51 (1) s1 7.40 x 10
-7 
E14 / 8 1.31 x 10-4 U51 (2) L1 6.53 x 10-7 
E15 (1) L2 3.20 x 10-7 U66 / 3 3.20 x 10-6 
E15 (2) s3 5.00 x 10
-9
 U71 / 4 2.17 x 10
-6 
E21 (1) s5 2.07 x 10
-6
 U80 / 3  2.53 x 10
-5 
E21 (3) s2 3.42 x 10-6   
E26 / 3 3.70 x 10-4 U43+ / 4 2.50 x 10-6 
E 26 / 4 5.37 x 10
-4 




As observed for the parental strains, there was great variation in the mutation 
frequencies of the 1st step mutants, ranging here from 5 x 10-9 to 6.7 x 10-2. Again the 
mutation frequencies of several isolates were very high, notably E14/4 with 6.7 x 10-2 
and U43/1 with 2.7 x 10-2. These were both 1st step mutants derived from intermediate 
parents (gen.sp. 13TU), with the R-type mutS sequence. The lowest mutation 
frequencies were found amongst the 1st step mutants derived from sensitive parents E15, 
E21, E26 and E33, as well as the non-clinical isolate ADP1. It appeared that there was a 
more obvious delineation between sensitive and intermediate isolates in terms of the 
mutation frequencies of their 1st step mutants compared to that of the isolates 
themselves.  
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5.2.5 Minimum Inhibitory Concentrations of Second Step 
Mutants 
Ciprofloxacin MICs were established for the second-step mutants as described 
previously and those with elevated MICs compared to the first-step mutants were 
considered for further study. The ciprofloxacin MICs of the second-step mutants are 
shown in Table 5.4, with the data for parents also shown for comparison and to indicate 
the progression of ciprofloxacin resistance in each isolate. Generally there appeared to 
be less variation amongst MICs of 2nd step mutants than amongst 1st step mutants. 















Parent 1 E14 Parent 0.5 E26 Parent 0.25 U43 Parent 0.25 
ATCC 
19606 (1)1 
1st   
step 
4 E14 / 4 1ststep 4 E26 / 3 1ststep 4 U43 / 1 1ststep 2 
 (1) 1 4  1 16  1 32  1 4 
 (1) 2 8  2 16  2 32  2 8 
 (1) 3 8  3 16  3 32  3 4 
 4 16  4 16  4 4 ATCC  
19606 
Parent 1 
 5 16  5 32  5 8 





E14 Parent 0.5 E26 Parent 0.25 U51 Parent 0.5 
 (1)1 16 E14 /8 1ststep 8 E26 / 4 1ststep 4 U51(1)s1 1ststep 2 
 (1)2 16  1 16  1 16  (1)1 8 
 (1)3 16  2 16  2 32  (1)2 8 
 (1)5 16  3 32  3 16  (1)3 8 
 (2)1 16  4 128  4 16  (1)4 8 
 (2)2 16  5 16  5 16  (1)5 8 
 (2)3 16  6 16  6 16  (2)1 8 
 (2)4 16 E15 Parent 0.06 E26 Parent 0.25  (2)2 8 
 (2)5 16 E15(1)L2 1ststep 0.5 E26 / 7 1ststep 2  (2)3 8 
 (3)1 16  (1)1 4  1 8  (2)4 8 
 (3)2 16  (1)2 4  2 16  (2)5 8 
 (3)3 16  (1)3 4  3 16  (3)1 32 
 (3)4 16  (1)4 4  4 8  (3)2 4 
 (3)5 16  (1)5 4  5 8  (3)3 8 
ADP1 Parent 0.06  (2)1 4  6 8  (3)4 8 
ADP1 (1)4 1stStep 0.5  (2)2 2 E26 Parent 0.25  (3)5 8 
 (1)1 2  (2)3 2 E26 / 8 1ststep 2 U51  Parent 0.5 
 (1)2 2  (2)4 2  1 4 U51(2)L1 1ststep 2 
 (1)3 1  (2)5 2  2 8  (1)1 8 
 (2)1 2  (3)1 4  3 8  (1)2 8 
 (2)2 1  (3)2 4  4 16  (1)3 8 
 (2)4 2  (3)3 4  6 4  (1)4 8 
 (3)2 2  (3)4 2 E33 Parent 0.12  (1)5 8 
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 (3)3 2  (3)5 2 E33(2)2 1ststep 1  (2)1 8 
 (3)4 2 E15 Parent 0.06  (1)1 1  (2)2 8 
 (3)5 2 E15(2)s3 1ststep 0.25  (1)2 1  (2)3 8 
ADP1 Parent 0.06  (1)1 0.25  (1)3 1  (2)4 4 
ADP1 (2)6 1ststep 0.5  (2)1 4  (1)4 2  (2)5 8 
 (1)1 1  (3)1 4  (1)5 1  (3)1 8 
 (1)2 1 E21 Parent 0.032  (2)1 1  (3)2 4 
 (1)3 1 E21(1)s5 1ststep 0.12  (2)2 1  (3)3 8 
 (1)4 16  (1)1 1  (2)3 1  (3)4 8 
 (1)5 1  (1)2 1  (2)4 1  (3)5 4 
 (2)1 1  (1)3 0.5  (2)5 1 U66 Parent 0.03 
 (2)2 1  (1)4 1  (3)1 1 U66 / 3 1ststep 0.25 
 (2)3 1  (1)5 2  (3)2 1  1 1 
 (2)4 1  (2)1 1  (3)3 1  2 1 
 (2)5 2  (2)2 1  (3)4 1  3 1 
 (3)1 2  (2)3 0.5  (3)5 1  4 1 
 (3)2 2  (2)4 1 E33 Parent 0.12  5 1 
 (3)3 2  (2)5 2 E33(3)1 1ststep 1  6 1 
 (3)4 1  (3)1 1  (1)1 1 U71 Parent 0.12 
 (3)5 2  (3)3 1  (1)2 1 U71 / 4 1ststep 2 
E13 Parent 0.5  (3)4 1  (1)3 1  1 4 
E13 / 2 1ststep 1  (3)5 1  (1)4 1  2 8 
 1 1 E21 Parent 0.032  (1)5 1  3 4 
 2 2  (2)1 1  4 4 
 4 4 
E21 (3)s2 1ststep 0.12 
 (2)2 1  5 4 
 5 4  (1)1 1  (2)3 1  6 4 
 6 4  (1)2 1  (2)4 1 U80 Parent 0.25 
E14 Parent 0.5  (1)3 1  (2)5 1 U80 / 3 1ststep 2 
E14 / 2 1ststep 4  (1)5 0.5  (3)1 1  1 4 
 1 16  (2)1 1  (3)2 1  2 4 
 2 16  (2)2 1  (3)3 1  3 4 
 3 16  (2)3 1  (3)4 1  4 4 
 4 32  (2)4 1  (3)5 1  5 4 
 5 16  (2)5 1 E41 Parent 2  6 4 
 6 32  (3)1 1 E41 / 3 1ststep 4    
    (3)3 1  1 8    
    (3)4 1  2 4    
    (3)5 1  3 8    
       4 16    
       5 16    
       6 16    
* Annotation for second step mutants shows individual mutants derived from the parent and 1st step mutant as shown. 
Bracketed numbers indicated their derivation from different plates inoculated with the 1st step mutant. 
 
The high levels of ciprofloxacin MIC were observed most frequently in 2nd step mutants 
derived from intermediate parents with the R-type mutS sequence, with ciprofloxacin 
MICs of 8 and 16 mg/L common. There were also four occurrences of 32 mg/L 
ciprofloxacin MIC; one in an A. baumannii U51-derived 2nd step mutant, and three in 
gen.sp.13TU E14-derived 2nd step mutants. Additionally an E14-derived 2nd step mutant 
had a ciprofloxacin MIC of 128 mg/L. 
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The sensitive Acinetobacter spp isolates generally did not progress to 2nd step mutants 
with high ciprofloxacin MIC levels; the highest ciprofloxacin MIC in the majority of 2nd 
step mutants derived from sensitive isolates was 4mg/L, with 1mg/L being more 
common. For example, many of the 2nd step mutants derived from E33 for example did 
not have increased ciprofloxacin MICs compared to that of their 1st step mutant. The 
exception to this were the 2nd step mutants derived from E26, a sensitive A. junii isolate 
without the R-type mutS sequence, which developed ciprofloxacin MICs of 4 to 32 
mg/L. 
 
Second step mutants from the non-clinical strain ADP1, similarly to the sensitive 
isolates, did not have very high ciprofloxacin MIC levels, the majority being 1mg/L, 
although one 2nd step mutant did have a ciprofloxacin MIC of 16 mg/L. 
 
The greatest increase in ciprofloxacin MIC was observed in one of the 18 E14-derived 
2nd step mutants. E14 is a gen.sp. 13TU intermediate isolate with the R-type mutS 
sequence. Parent to 1st step to 2nd step mutant ciprofloxacin MICs were 0.5 to 8 to 128 
mg/L respectively, an increase of 256 x ciprofloxacin MIC of E14. Interestingly, the 
second greatest increase in ciprofloxacin MIC was observed in the non-clinical isolate 
ADP1, with a 250 x ciprofloxacin MIC increase with parent to 1st step to 2nd step mutant 
ciprofloxacin MICs of 0.06 to 0.5 to 16mg/L. However, this only occurred in one of the 
25 ADP1-derived 2nd step mutants examined.  
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The lowest increase in ciprofloxacin MIC levels from parent to 2nd step mutants was 
observed in the sensitive isolate E33, with parent to 1st step to 2nd step mutant 
ciprofloxacin MICs of only 7 x ciprofloxacin MIC of E33.  
 
5.2.6 HinfI RFLP of the gyrA QRDR of parents and mutants  
Target site mutations in the gyrA QRDR of a range of 1st and 2nd step mutants from each 
parental isolate were indicated by PCR amplification and HinfI restriction, as described 
in Section 2.10.4. Isolates which have a mutation leading to loss of the HinfI recognition 
site formed by codons 82 and 83 should produce a single product, visualised as one band 
of 343 bp on an agarose gel, compared to the restricted products which should be 
visualised as two bands of 291 and 54 bp. An example of a resultant gel of isolates U51, 
E14 and 1st and 2nd step mutants derived from them is shown in Figure 5.1. 
Figure 5.1 Gel of gyrA restriction analysis of parent and mutants 
 
 
Lane 1- U51 parent, CIP MIC 0.5mg/L. Lane 2 – U51-derived 1st step mutant, CIP MIC 2mg/L.  
Lanes 3 to 5 - U51-derived 2nd step mutants, CIP MICs 4mg/L, 8mg/L and 32mg/L respectively.  
Lane 6 – blank. Lane 7 – U71 parent, CIP MIC 0.12mg/L. Lane 8 – U71-derived 1st step mutant, CIP MIC 2mg/L. 
Lanes 9 & 10 – U71-derived 2nd step mutants, CIP MICs 4 and 8mg/L respectively. 
Lane 11 – Control – unrestricted ATCC 19606. Lane 12 – Control – restricted ATCC 19606. 
Lane 13 – Control – DNA negative. 
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Table 5.5 shows the MIC data for the parents, 1st and 2nd step mutants, together with a 
summary of the range of second-step mutants derived from the different parental isolates 
and whether they were restricted or unrestricted.  
 
Table 5.5 Progression to 2nd step mutants  
 Parent 1st step 2nd step R/UR   Parent 1st step 2nd step R/UR 
4 R  16 R 
4 (R) 







4 (R) 16 R  16 R 




2 UR  8 R 
1 UR  
2 (R) 
16 R 





16 UR  8 R 
1 R  
E26 0.25 (R) 
2 (R) 
16 R 




4 R  
0.12 (R) 1 (R) 
2 R 
16 R  
E33 
0.12 1 (R) 1 - 
4 (R) 
32 R  4 R 
4 (R) 16 R  8 R 
16 R  
E41 2 (R) 4 (R) 
16 R 





128 UR  
U43 0.25 (R) 2 (R) 
8 R 
2 R  4 R 
0.5 (R) 
4 R  8 R 







4 -  4 - 
0.5 -  
U51 0.5 (R) 
2 (R) 
8 - 
1 R  U66 0.03 (R) 0.25 (R) 1 - 0.12 (R) 
2 -  4 R 
0.5 R  






1 R  U80 0.25 (R) 2 (R) 4 R 
R = gyrA PCR product restricted by HinfI – no target site mutation present.  
UR = gyrA PCR product ununrestricted by HinfI – target site mutation may be present.  
- = not tested. 
 
Of immediate note from the HinfI restriction analysis was that the ADP1 parent, 1st step 
and 2nd step mutants, were all unrestricted with HinfI, regardless of ciprofloxacin MIC 
values, which ranged from parent to 1st step to 2nd step mutant from 0.06 to 0.5 to 1-16 
mg/L respectively.  
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There were several unrestricted products, and hence potential target site mutations, in 
the 2nd step mutants. These all occurred in mutants derived from intermediate parents 
with the R-type mutS sequence: E14, U51 and U71 with unrestricted products in 2nd step 
mutants with ciprofloxacin MICs of 128, 32 and 8 mg/L respectively. There were other 
2nd step mutants which also had higher ciprofloxacin MICs, notably those derived from 
the sensitive isolate E26, of which there were several with MICs of 16 and 32 mg/L. 
However there were no unrestricted products amongst these mutants.  
 
5.2.7 Sequencing and Analysis of Parental and Mutant gyrA 
QRDRs 
To further analyse the mutations that had led to the unrestricted products, the gyrA PCR 
products were sequenced as described in Section 2.10.5. The alignment of the sequenced 
gyrA QRDR of selected parents and mutants is shown in Figure 5.2 below, with the 
sequences compared to the ciprofloxacin sensitive strain HCP-77 (Vila et al, 1995). 
 
It is apparent that whilst the gyrA QRDR appears highly conserved within these isolates, 
there is variation present within the isolates. The resistant isolates were included for 
comparison and, as expected, they have the serine-83 to leucine mutation (position 14 in 
Figure 5.2) in gyrA which has been commonly associated with ciprofloxacin resistance 
in Acinetobacter. HCP-77 is a ciprofloxacin susceptible A. baumannii strain, with the 
expected Serine at codon 83.  
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Figure 5.2 Sequences of the gyrA QRDR of selected parents and mutants 
compared to ciprofloxacin sensitive strain HCP-77 and resistant isolates 
R = resistant isolate, I = intermediate parent isolate, S = sensitive parent isolate.  
* positions where there was variation compared to strain HCP-77. 
Bold indicates amino acid variations in the gyrA QRDR compared to strain HCP-77. 
                     
             1             *   *               *           *     50 
HCP-77       VGDVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA Control  
ATCC19606          KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA A.baumannii 
ADP1               KYHP HGDTAVYDTI VRMAQDFSLR YLLVDGQGNF GSVDGDSAAA Non-clin 
R U7            VIGKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA R 
R E51             GKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA R 
R 779           VIGKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA R 
R 783           VIGKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA R 
I E14              KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 0.5 
  E14/8           GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 8 
  E14/8/4         GKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 128 
S E21            IGKYHP HGDSAVYETI VRMAQDFSLR YQLVDGQGNF GSIDGDSAAA MIC = 0.032 
S E26/4           GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 4 
  E26/4/2          KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 32 
S E33                 P HGDSAVYETI VRMAQDFSLR YQLVDGQGNF GSIDGDSAAA MIC = 0.12 
I U43             GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 0.25 
  U43+/6          GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 8 
  U43+/6/4            P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 32 
I U51                 P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 0.5 
  U51(1)s1         KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 2 
  U51(1)s1(3)   VIGKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 32 
I U71             GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 0.12 
  U71/4            KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 2 
  U71/4/2         GKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 8 
I U80              KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 0.25  
  U80/3           GEIHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 2 
  U80/3/3         GKAHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA MIC = 4 
                           *   *               *           * 
      
 
             51      *   *                           * *    *   100 
HCP77        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVP      Control 
ATCC19606    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN A.baumannii 
ADP1         MRYTEVRMTK LTHELLADLE KDTVDWVDNY DGSERIPDVL PTRIPNLLI  Non-clin 
R U7         MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN R 
R E51        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  R 
R 779        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN R  
R 783        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN R 
I E14        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 0.5 
  E14/8      MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 8 
  E14/8/4    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 128 
S E21        MRYTEVRMRK LTHELLADLE KDTVDWEDNY DGSERIPQVM PTRIPNLL   MIC = 0.032 
S E26/4      MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 4 
  E26/4/2    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  MIC = 32 
S E33        MRYTEVRMRK LTHELLADLE KDTVDWEDNY DGSERIPQVM PTRIPNLL   MIC = 0.12 
I U43        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 0.25 
  U43+/6     MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  MIC = 8 
  U43+/6/4   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSKRIPEVL PTRVPNLLI  MIC = 32 
I U51        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL            MIC = 0.5 
  U51(1)s1   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL            MIC = 2 
 U51(1)s1(3)1MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPN     MIC = 32 
I U71        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIN MIC = 0.12 
  U71/4      MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  MIC = 2 
  U71/4/2    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  MIC = 8 
I U80        MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLI  MIC = 0.25 
  U80/3      MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPETL DTRSPNNLI  MIC = 2 
  U80/3/3    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVPNLLIA MIC = 4 
                     *   *                       *   * *     
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The sequences showed that the unrestricted products seen for ADP1 and derived mutants 
were not due to the frequently reported target site mutation of serine-83 to leucine. 
Instead at this position a mutation from serine to threonine was present, conserved in the 
parent and both first and second step mutants. As shown in Table 5.6 and Figure 5.3 
below, this resulted from a nucleotide change from TCA to ACC, leading to loss of the 
HinfI GANTC recognition site.  
 
Table 5.6 Table of changes in the gyrA sequences of ADP1 and ADP1-derived 
mutants compared to HCP-77 and ATCC 19606. 






AA pos AA change Codon 
Silent 
mutations 
Parental 1 R 
1st step mutants 4 R 
ATCC 
19606 
2nd step mutants 8 R 
None - - 3 
14 Ser – Thr TCA – ACC 
Parental 0.06 UR 
18 Glu – Asp GAA – GAC 
43 Ile – Val ATC – GTC 
1st step mutants 0.5 UR 
62 Ala – Thr GCA – ACC 
77 Glu – Val GAA – GTA 
88 Glu – Asp GAA – GAT 
ADP1 
2nd step mutants 2 UR 




Additionally, there were a further 6 amino acid variations compared to HCP-77, again 
conserved in the parent and mutants of ADP1. None of these changes appeared to be 
associated with high ciprofloxacin MIC levels. There were also 33 silent mutations 
observed in the nucleotide sequence of ADP1, conserved in the 1st and 2nd step mutants 
derived from it. These changes are also detailed in Table 5.6 and Figure 5.3. 
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Figure 5.3 The gyrA QRDR of ADP1 and ADP1-derived 1st and 2nd step mutants 
compared to an A. baumannii quinolone-susceptible strain  
HCP-77 = quinolone-susceptible strain used for comparison (Vila, 1995) 
ADP1 par = ADP1 parent isolate 
ADP1 1st = ADP1 1st step mutant ADP (1) 4 
ADP1 2nd = ADP1 2nd step mutant ADP (1) 4 (1) 1 
* indicates variation in ADP1 and ADP1-derived mutants compared to strain HCP-77 
BOLD highlights changes compared to HCP-77. 
 
Amino acid sequences: 
         1             *   *                           *     50 
HCP-77   VGDVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA  
ADP1 par       KYHP HGDTAVYDTI VRMAQDFSLR YLLVDGQGNF GSVDGDSAAA   CIP MIC 0.06 
ADP1 1st      GKYHP HGDTAVYDTI VRMAQDFSLR YLLVDGQGNF GSVDGDSAAA   CIP MIC 0.5 
ADP1 2nd    VIGKYHP HGDTAVYDTI VRMAQDFSLR YLLVDGQGNF GSVDGDSAAA   CIP MIC 2 
                       *   *                           * 
 
         51          *               *           *      *   100 
HCP-77   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL PTRVP 
ADP1 par MRYTEVRMTK LTHELLADLE KDTVDWVDNY DGSERIPDVL PTRIPNLLI    CIP MIC 0.06 
ADP1 1st MRYTEVRMTK LTHELLADLE KDTVDWVDNY DGSERIPDVL PTRIPNLLI    CIP MIC 0.5 
ADP1 2nd MRYTEVRMTK LTHELLADLE KDTVDWVDNY DGSERIPDVL PTRIPNLLIN   CIP MIC 2 
                     *               *           *      * 
 
                                                                                          
 
Nucleotide sequences: 
         1                                                              60 
HCP-77   GTTGGTGACG TAATCGGTAA ATATCACCCG CATGGTGACT CAGCTGTTTA TGAAACCATT 
ADP1 par                    AA ATATCACCCA CATGGTGATA CCGCTGTTTA CGACACGATC 
ADP1 1st          G TGATCGGTAA ATATCACCCA CATGGTGATA CCGCTGTTTA CGACACGATC 
ADP1 2nd         TG TGATCGGTAA ATATCACCCA CATGGTGATA CCGCTGTTTA CGACACGATC 
         61                                                            120 
HCP-77   GTTCGTATGG CTCAAGACTT TAGCTTACGT TATTTATTGG TTGATGGTCA GGGTAACTTC 
ADP1 par GTGCGTATGG CGCAGGACTT CAGTCTGCGT TATCTATTGG TAGACGGTCA GGGCAACTTT 
ADP1 1st GTGCGTATGG CGCAGGACTT CAGTCTGCGT TATCTATTGG TAGACGGTCA GGGCAACTTT 
ADP1 2nd GTGCGTATGG CGCAGGACTT CAGTCTGCGT TATCTATTGG TAGACGGTCA GGGCAACTTT 
         121                                                           180 
HCP-77   GGTTCGATCG ATGGTGATAG CGCTGCGGCA ATGCGTTATA CCGAAGTCCG TATGACTAAG 
ADP1 par GGTTCGGTCG ATGGCGATAG TGCTGCGGCA ATGCGTTATA CCGAAGTTCG TATGACTAAG 
ADP1 1st GGTTCGGTCG ATGGCGATAG TGCTGCGGCA ATGCGTTATA CCGAAGTTCG TATGACTAAG 
ADP1 2nd GGTTCGGTCG ATGGCGATAG TGCTGCGGCA ATGCGTTATA CCGAAGTTCG TATGACTAAG 
         181                                                           240 
HCP-77   CTGGCACATG AGCTTCTTGC AGATTTAGAA AAAGACACAG TTGACTGGGA AGATAACTAC 
ADP1 par CTTACCCATG AGCTATTGGC TGATCTTGAA AAAGACACCG TAGACTGGGT AGATAACTAC 
ADP1 1st CTTACCCATG AGCTATTGGC TGATCTTGAA AAAGACACCG TAGACTGGGT AGATAACTAC 
ADP1 2nd CTTACCCATG AGCTATTGGC TGATCTTGAA AAAGACACCG TAGACTGGGT AGATAACTAC 
         241                                                           300 
HCP-77   GACGGTTCGG AACGTATCCC TGAAGTACTT CCGACACGAG TTCCA                 
ADP1 par GATGGTTCAG AACGTATTCC TGATGTTCTT CCGACACGCA TTCCAAATTT GCTGAT     
ADP1 1st GATGGTTCAG AACGTATTCC TGATGTTCTT CCGACACGCA TTCCAAATTT GCTGATTAAC 
ADP1 2nd GATGGTTCAG AACGTATTC                                              
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There were also several amino acid variations observed in E21 and E33 (both identified 
as A. johnsonii in Chapter 3) compared to HCP-77; six changes were conserved within 
the two isolates and the mutants generated from them. Again these changes were not 
associated with high ciprofloxacin MICs. Examination of the nucleotide sequences 
found that the changes were identical in the parents and mutants of both isolates at the 
nucleotide level, and also indicated the presence of 34 silent mutations in E21 and 30 
silent mutations in E33. This is detailed in Table 5.7. 
 
Table 5.7 Changes in gyrA sequences of E21 and E33 compared to HCP-77  






AA pos AA change Nuc 
Silent 
mutations 
32 Leu – Gln TTA –CAA 
Parental 0.032 R 
59 Thr – Arg ACT – CGT 
62 Ala – Thr GCA – ACC 
1st step mutants 0.12 R 
88 Glu – Gln GAA – CAA 
90 Leu – Met CTT – ATG 
E21 
2nd step mutants 1 R 
94 Val – Ile GTT – ATT 
34 
32 Leu – Gln TTA –CAA 
Parental 0.12 R 
59 Thr – Arg ACT – CGT 
62 Ala – Thr GCA – ACC 
1st step mutants 1 R 
88 Glu – Gln GAA – CAA 
90 Leu – Met CTT – ATG 
E33 
2nd step mutants 2 R 




The previously mentioned 2nd step mutants from intermediate isolates that had 
unrestricted products (E14/8/4, U51(1)s1(3)1 and U71/4/2) were all confirmed to have 
the serine-83 to leucine target site mutation, as present in the resistant isolates, and this 
was associated in each case with a high ciprofloxacin MIC. The stabilities of each of 
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these mutants and their 1st step mutants were tested (as described in Section 2.10.2) and 
all were found to be stable within these conditions.  
 
The sequences as observed in Figure 5.2 above showed that the parent and 1st step 
mutant of each 2nd step mutant that developed a target site mutation had a serine residue 
at codon 83, as present in the ciprofloxacin sensitive strain HCP-77. Figure 5.4 below 
illustrates this using U51 and mutants derived from U51 as an example.  
 
Figure 5.4 Sequences of the gyrA QRDR of U51 and derived mutants with various 
ciprofloxacin MICs 
HCP-77 = quinolone-susceptible strain used for comparison (Vila, 1995) 
U51 par = U51 parent isolate 
U51 1st = U51 1st step mutant U51(1)s1 
U51 2nd = U51 2nd step mutants U51(1)s1(3)2, U51(1)s1(1)1 and U51(1)s1(3)1 with CIP MICs 4, 8 and 32 
respectively.  
* indicates aa position 83, where Ser83 – Leu target site mutation occurs 
+ indicates codons 82 and 83, comprising the HinfI recognition site (GANTC). 
 
 
        1             *                                     50  
HCP-77  VGDVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA 
U51 Par          P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 0.5 
U51 1st       KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 2 
U51 2nd       KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 4 
U51 2nd       KYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 8 
U51 2nd    VIGKYHP HGDLAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 32 
                      * 
 
                                                                                                     82  83 
        1                                      ++++ ++      50               
HCP-77  GTTGGTGACG TAATCGGTAA ATATCACCCG CATGGTGACT CAGCTGTTTA  
U51 Par                    AA ATATCACCCG CATGGTGACT CAGCTGTTTA CIP MIC = 0.5 
U51 1st                    AA ATATCACCCG CATGGTGACT CAGCTGTTTA CIP MIC = 2 
U51 2nd        ACG TAATCGG-AA ATATCACCCG CATGGTGACT CAGCTGTTTA CIP MIC = 4 
U51 2nd                                  CATGGTGACT CAGCTGTTTA CIP MIC = 8 
U51 2nd         CG TAATCGGTAA ATATCACCCG CATGGTGACT TAGCTGTTTA CIP MIC = 32 
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The sequences showed that U51 and the 1st step mutant, as well as two 2nd step mutants 
with ciprofloxacin MICs of 4 and 8 mg/L had serine at position 83. However the 2nd step 
mutant with MIC of 32 mg/L had the serine-83 to leucine target site mutation, occurring 
from a C-T nucleotide substitution. There were no other mutations present in either the 
amino acid or nucleotide sequence of the isolate, as is observed in the resistant isolates.  
 
Also of note from the sequence analysis of the gyrA QRDR of the parents and mutants is 
that a 2nd step mutant, from a 1st step mutant which was derived from the U43 isolate 
challenged with 20 x ciprofloxacin MIC, had a mutation at codon 153, from glutamic 
acid to lysine. This is examined, along with other aspects of the U43+ isolates in Section 
5.2.8 below. 
 
5.2.8 U43+ Mutants  
These mutants were derived from challenge by 20 x MIC of ciprofloxacin, and were the 
only isolates out of those so challenged from which mutants grew. The colonies 
produced by the initial challenge were large and mucoid in appearance, in contrast to 
those seen with mutants produced by challenge with 2 x MIC of ciprofloxacin.  
 
The U43+ mutants were stored similarly to the normally challenged isolates and used to 
generate 2nd step mutants (by challenge at 2 x MIC). This procedure was also repeated 
with a confirmed amount of ciprofloxacin; U43 was challenged by 10 x MIC of 
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ciprofloxacin, and 1st step mutants (labelled U43x10) by 2 x MIC to give 2nd step 
mutants. The MICs of these U43 derived mutants are shown in Table 5.8. 
 
Table 5.8 MIC (mg/L) progression of U43 mutants challenged by excess 
ciprofloxacin 
 CIP MIC  CIP MIC  CIP MIC 
1st step mutants generated by challenge with excess ciprofloxacin 
U43 parent 0.25 U43+/4 4 U43+/6 8 
1st step mutants:  2nd step mutants:  2nd step mutants:  
U43+/1 2 U43+/4/1 4 U43+/6/1 32 
U43+/2 2 U43+/4/2 8 U43+/6/2 32 
U43+/3 2 U43+/4/3 8 U43+/6/3 32 
U43+/4 4 U43+/4/4 8 U43+/6/4 32 
U43+/5 4 U43+/4/5 8 U43+/6/5 16 
U43+/6 8 U43+/4/6 8 U43+/6/6 32 
1st step mutants generated by challenge with 10x MIC of ciprofloxacin 
U43 parent 0.25     
1st step mutants:      
U43x10/1 8 U43x10/11 8 U43x10/21 8 
U43x10/2 8 U43x10/12 16 U43x10/22 8 
U43x10/3 8 U43x10/13 16 U43x10/23 8 
U43x10/4 8 U43x10/14 16 U43x10/24 8 
U43x10/5 8 U43x10/15 8 U43x10/25 16 
U43x10/6 8 U43x10/16 2 U43x10/26 16 
U43x10/7 8 U43x10/17 8 U43x10/27 8 
U43x10/8 8 U43x10/18 4 U43x10/28 8 
U43x10/9 16 U43x10/19 8 U43x10/29 16 
U43x10/10 2 U43x10/20 8 U43x10/30 16 
2nd step mutants:      
U43x10/7/1 32 U43x10/26/1 128   
U43x10/7/2 64 U43x10/26/1 64   
U43x10/7/3 32 U43x10/26/1 128   
U43x10/7/4 32 U43x10/26/1 64   
U43x10/7/5 32 U43x10/26/1 128   
U43x10/7/6 32 U43x10/26/1 128   
U43x10/7/7 32 U43x10/26/1 64   
U43x10/7/8 32 U43x10/26/1 128   
 
As is shown in the data above, the second challenge (with 10 x MIC of ciprofloxacin) 
generated greater increases in ciprofloxacin MICs of 1st and subsequent 2nd step mutants, 
up to 128 mg/L. 




As mentioned above, the gyrA sequence analysis of the initially derived U43+ mutants 
showed a glutamic acid-153 to lysine mutation in the gyrA QRDR of several 2nd step 
mutants, shown in Figure 5.5 below. This mutation did appear to be associated with a 
higher ciprofloxacin MIC level of 32 mg/L, compared to the other 2nd step mutant with a 
ciprofloxacin MIC of 8 mg/L. The stability of the U43+/6/4 mutant was tested (as 
described in Section 2.10.2) and found to be stable within these conditions.  
 
Figure 5.5 gyrA sequences of U43 and initial U43+ isolates compared to HCP-77 
HCP-77 = quinolone-susceptible strain used for comparison (Vila, 1995) 
U43 par = U43 parent isolate 
U43/1 = U43 1st step mutant 
U43/1/1 = U43 2nd step mutant 
U43+/6 = U43 1st step mutant from challenge with excess ciprofloxacin 
U43+/6/3 and U43+/6/4 = U43+ 2nd step mutants derived from the above 1st step 
* = position where there is a change compared to HCP-77. 
 
         1                                                   50                                                                                             
HCP-77   VGDVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA  
U43 par    DVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 0.25 
U43/1      RVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 2 
U43/1/1    DVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 4 
U43+/6        GKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 8 
U43+/6/3   RVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 32 
U43+/6/4          P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 32 
 
         51                                  *    90 
HCP-77   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL   
U43 par  MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL  CIP MIC = 0.25 
U43/1    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL  CIP MIC = 2 
U43/1/1  MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL  CIP MIC = 4 
U43+/6   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL  CIP MIC = 8 
U43+/6/3 MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSKRIPEVL  CIP MIC = 32 
U43+/6/4 MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSKRIPEVL  CIP MIC = 32 
                                             *  
 
However, this mutation was not found in sequence analysis of the 2nd step U43x10 
mutants, with MICs of 32 to 128 mg/L. This is shown in Figure 5.6 below. 
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Figure 5.6 gyrA sequences of further U43+ compared to previously generated 
mutant and HCP-77 
HCP-77 = quinolone-susceptible strain used for comparison (Vila, 1995) 
U43+/6/4 = U43 2nd step mutant derived from challenge of U43 with excess CIP 1st step 
 U43+/7 and U43+/26 = 1st step mutants generated by challenge with 10 x MIC CIP of U43 
U43+/7/1, U43+/7/2, U43+/26/6 and U43+/26/7 = 2nd step mutants generated by challenge of above with CIP 
* = position where there is a change compared to HCP-77. 
 
          1                                                   50   
HCP-77    VGDVIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA 
U43+/6/4           P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 32  
U43+/7       VIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 8 
U43+/26      VIGKYHP HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 16 
U43+/7/1           P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 32 
U43+/7/2           P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 64 
U43+/26/6          P HGDSAVYETI VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 128 
U43+/26/7                       VRMAQDFSLR YLLVDGQGNF GSIDGDSAAA CIP MIC = 64 
 
          51                                  *    90  
HCP-77    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL  
U43+/6/4  MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSKRIPEVL CIP MIC = 32   
U43+/7    MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 8 
U43+/26   MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 16 
U43+/7/1  MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 32 
U43+/7/2  MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 64 
U43+/26/6 MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 128 
U43+/26/7 MRYTEVRMTK LAHELLADLE KDTVDWEDNY DGSERIPEVL CIP MIC = 64 
                                              *  
 
 
Despite the inability to replicate the amino acid change observed in the initial 2nd step 
mutants from U43 challenged with excess ciprofloxacin, the stability of this mutant may 
mean that it warrants further investigation.  
 
5.2.9 Mutation Studies Summary 
Mutation frequencies of the representative isolates and 1st step mutants derived from 
them showed great variation. Amongst the highest mutation frequencies of the parent 
isolates were E9 and E10, however 1st step mutants generated from them were not able 
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to go on to develop 2nd step mutants. The highest mutation frequencies of the 1st step 
mutants were in those derived from intermediate isolates with the R-type mutS sequence 
and the lowest was in 1st step mutants derived from sensitive isolates and ADP1.  
 
Substantial increases in ciprofloxacin MICs were more frequent in 1st step mutants 
derived from isolates with the R-type mutS sequence compared to those without this 
sequence. There was a smaller range of ciprofloxacin MIC values generally in 2nd step 
mutants compared to the 1st step mutants, and isolates without the mutS R-type sequence 
generally didn’t progress to high ciprofloxacin MIC levels. The greatest increase in 
ciprofloxacin MICs was observed in a 2nd step mutant from isolate E14 (from parent to 
2nd step, 0.5 to 128mg/L), and the lowest were observed in 2nd step mutants from isolate 
E33 (from parent to 2nd step, 0.12 to 1mg/L).  
 
Target site mutations of Ser83-Leu were confirmed to be present in representative 
resistant isolates and were found in one 2nd step mutant derived from each of E14 
(gen.sp. 13TU), U51 (A. baumannii) and U71 (A. baumannii), with ciprofloxacin MICs 
of 128, 32 and 8 mg/L respectively. 
 
The non-clinical A. baylyi isolate ADP1 and all mutants derived from it all had 
mutations at serine-83, however sequencing confirmed that this was a conserved serine 
to threonine mutation, and it did not appear to be associated with high ciprofloxacin 
MICs. 
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U43+ and U43x10 mutants, challenged with 20 x MIC and 10 x MIC respectively, 
developed high ciprofloxacin MICs, and several had an associated glutamic acid 153 to 
lysine gyrA mutation. 
  
5.3 Discussion 
The question posed at the beginning of this chapter was whether the different mutS 
sequence types discussed in Chapter 4 were correlated with any differences in the 
mutation potential of isolates, in terms of their ability to develop increased resistance to 
ciprofloxacin. It is clear from the above data that there is variation in the mutation 
frequencies of the clinical Acinetobacter spp isolates, and in their ability to develop 
significant ciprofloxacin resistance upon challenge.  
 
The varied mutation frequencies of parental isolates did not clearly correlate with mutS 
type, though the lowest mutation frequencies for both parents and 1st step mutants were 
observed in those from sensitive, non-R-type mutS isolates. There did appear to be a 
correlation of high mutation frequencies of 1st step mutants in those derived from parents 
with R-type mutS. The sensitive A. junii isolate E26 was an exception to this however, 
with a high mutation frequency of parent and several 1st step mutants compared to the 
other sensitive isolates, and also to several intermediate isolates. Additionally, high 
ciprofloxacin MICs were observed in 2nd step mutants derived from this isolate, though 
none possessed a corresponding gyrA target site mutation.  
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The variation in mutation frequencies does show that there may be certain hypermutator 
isolates that are better able to adapt to ciprofloxacin challenge by increasing their chance 
of producing beneficial mutations and of acquiring resistance through horizontal transfer 
(as discussed in Section 1.5). However it must be remembered that this is a measure of 
spontaneous mutation frequency, and as such the resultant mutant may not in fact be 
stable, nor lead to clinically significant resistance (Section 1.5; O’Neill & Chopra, 2002; 
Martinez & Baquero, 2000; Woodford & Ellington, 2007). Also of note is that reported 
bacterial mutation frequencies vary greatly between studies, possibly due to the 
complexity and variation of the environments (Woodford & Ellington, 2007) so these 
figures alone may not be a reliable measure of mutation potential, and it is very difficult 
to compare mutation frequencies between studies. Therefore, there should be caution 
when examining mutation frequencies in isolation as, whilst they give an indication of 
the potential of mutations to develop, a high mutation frequency does not guarantee the 
production of beneficial mutations in viable mutants.   
 
This is likely the case in the sensitive gen.sp. 3 isolates E9 and E10. These isolates had 
the highest mutation frequencies observed in the parental strains; however the lack of 
increase in ciprofloxacin MIC in potential mutants derived from E9, and the inability to 
generate 2nd step mutants from either E9 or E10, confirms that this did not manifest as a 
greater mutation potential. The ‘mutants’ produced and measured in the mutation 
frequency calculation were clearly not viable in the longer term. This supports the 
caution about the use of mutation frequency data in isolation to establish which isolates 
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will have greater mutation potential; whilst a higher mutation frequency may increase 
the chances of a useful mutation developing, it may also increase the risk of deleterious 
mutations and render the bacterium unviable in the longer term.  
 
In terms of the gyrA gene of initial interest was whether any of the 2nd step mutants had 
the gyrA Ser83-Leu target site mutation that was confirmed to be present in the resistant 
isolates. Within the data collected gyrA target site mutations were only observed in 
several 2nd step mutants derived from intermediate parents with the R-type mutS 
sequence (A. baumannii isolates U51 and U71, and gen.sp. 13TU isolate E14). These 
were associated with high ciprofloxacin MICs and were found to be stable in the 
absence of antibiotic selective pressure (Section 2.10.2).  
 
Whilst there were other 2nd step mutants with high ciprofloxacin MICs, including those 
derived from sensitive parents without the R-type mutS sequence, these did not have 
gyrA target site mutations; for example E26, a sensitive A. junii isolate which had 
several variations compared to the R-type mutS sequence (Chapter 4), had a high 
mutation frequency and several of its 1st step mutants also had a high mutation 
frequency in response to challenge with ciprofloxacin. In comparison with the other 
sensitive isolates E9 and E10 discussed above, the 2nd step mutants of this isolate had 
high ciprofloxacin MICs and, although producing no target site mutations, this suggests 
that this isolate may have a greater mutation potential than the other sensitive isolates.  
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This may be attributable to the over-expression of efflux mechanisms, increasingly 
considered an important secondary fluoroquinolone resistance mechanism. The AdeB 
multidrug efflux pump in A. baumannii, for example, is responsible for aminoglycoside 
resistance and also associated with reduced susceptibility to fluoroquinolones, although 
other mechanisms (target site mutations) are needed for resistance to build up (Section 
1.4.6; Higgins et al, 2004). It is thought that efflux is of importance in the first response 
to challenge with antibiotic, allowing initial survival and hence increasing the chance of 
the development of stable and lasting resistance via target site mutations (Section 1.4; 
Poole, 2002; Van Bembeke, 2005). This may be the case in the 2nd step mutants derived 
from E26; that efflux is over-expressed in response to the challenge with ciprofloxacin, 
temporarily raising the ciprofloxacin MICs as the antibiotic is pumped out of the 
bacterial cells, but without production of target site mutations.  
 
However, resistance to fluoroquinolones in Acinetobacter isolates is primarily via the 
target site mutations in gyrA genes (Section 1.4.6; Vila et al, 1995; Magnet et al, 2001; 
Higgins et al, 2004), as was confirmed in the resistant and multi-resistant isolates in this 
study which had the gyrA Ser83-Leu target site mutation (Figure 5.2). It would, 
therefore, be expected that emerging-resistant isolates would develop clinically 
significant resistance via similar methods. As such, it is reasonable to conclude that 
those isolates producing 2nd step mutants with high ciprofloxacin MICs and gyrA target 
site mutations (in this study, those that were derived from intermediate parents with the 
R-type mutS sequence) have a greater mutation potential than those with high 
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ciprofloxacin MICs but without concurrent target site mutations (in this study, those 
derived from sensitive isolate E26, without the R-type mutS sequence). 
 
In terms of gyrA gene variation beyond the observed target site mutations, the 
intermediate isolate-derived 2nd step mutants with target site mutations displayed only 
this Ser-83 to Leu mutation within their gyrA gene. Additionally, there were no 
mutations within the parent and 1st step mutants of these 2nd step mutants, compared to 
the sequences of the ciprofloxacin-sensitive strain HCP-77. There were, however, other 
gyrA variations observed in several of the sequenced sensitive strains and derived 
mutants and in the non-clinical isolate ADP1 and derived mutants, none of which were 
associated with high MIC levels. These may be species-specific differences as E21 and 
E33 (in which there were several differences in gyrA amino acid sequence) were both 
identified as A. johnsonii (Chapter 3) and they are being compared to an A. baumannii 
ciprofloxacin-sensitive strain (HCP-77).  
 
Additionally, this variation in the gyrA gene of clinical isolates is of interest; whilst the 
gyrA gene of the examined resistant and intermediate isolates and derived mutants was 
highly conserved, that of the sensitive and non-clinical isolates was more varied. 
Likewise the ciprofloxacin MICs of successful 2nd step mutants were less varied than 
those seen for 1st step mutants (Figures 5.2 and 5.4). This may be a similar observation 
as in Chapter 4 in terms of the mutS gene; that with increasing resistance, there is greater 
homogeneity.  
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The gyrA QRDR of ADP1 and all mutants derived from it were unrestricted with HinfI. 
Sequence analysis showed that instead of being due to the serine-83 to leucine mutation, 
the loss of restriction site was due to a serine-83 to threonine mutation. Serine and 
threonine are both polar amino acids, so it may be that this mutation has less effect than 
on the fluoroquinolone target site, and hence less impact on ciprofloxacin resistance, 
when compared to the change from polar to hydrophobic amino acid (leucine) at the 
same site within the gyrA QRDR. This result highlights the need for sequencing 
confirmation of initial restriction analysis results, to verify the nature of the mutation 
causing the unrestricted product; this agrees with previous reports where mutation at the 
target site, leading to PCR products unrestricted by HinfI, was not associated with higher 
MICs (Waters & Davies, 1997).   
 
The U43 mutants produced from challenge with excess ciprofloxacin (10 x MIC and 20 
x MIC) developed high ciprofloxacin MICs, but no target site mutations. Increased 
MICs resulting from a greater challenge is perhaps to be expected, however the ability of 
U43 alone of the examined isolates to respond to this challenge is worth noting. The 
glutamic acid-153 to lysine mutation seen in two of the 2nd step mutants was not 
reproducible, and is therefore unlikely to be the cause of the increase in ciprofloxacin 
MIC. It may be that the increase in MIC is due to efflux over-expression, as discussed in 
Section 1.4.6 and above; however, the mutants were stable in non-selective media and 
the gyrA mutation was the only one present in the gyrA QRDR, so the association with 
high MIC levels may warrant further investigation. Given the mucoid appearance of the 
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excessively-challenged mutants, there is a possibility that biofilm formation was 
activated by this excess ciprofloxacin challenge.  
 
Several studies report a high capacity of multiresistant A. baumannii clinical isolates to 
form biofilms (Lee et al, 2008; Rodríguez-Baño et al, 2008), and different morphologies 
have been reported in low and high nutrient conditions which are hypothesised to 
represent specialised adaptations for, respectively, attachment and colonisation or 
dispersion. (James, 1995). Environmental and clinical members of the Acinetobacter 
genus have been reported to attach to solid surfaces and form biofilms which allow them 
to persist in harsh conditions, associated with the presence of pili-like surface structures 
encoded by the csuC and csuE ORFs (Tomaras et al, 2003). It may be that the extreme 
ciprofloxacin challenge provoked similar adaptation and the initiation of biofilm 
formation in the U43+ mutants generated in this study, though of course further 
investigation would be needed to confirm this theory.  
 
In terms of the species of the Acinetobacter genus capable of ciprofloxacin resistance 
development, it is interesting to note that not only A. baumannii isolates (U51 and U71), 
but also a gen.sp. 13TU isolate (E14) was capable of developing significant 
ciprofloxacin resistance in terms of a target site mutation; indeed generally the 2nd step 
mutants derived from gen.sp. 13TU parents, compared to those from A. baumannii 
parents, developed higher ciprofloxacin MICs (Figure 5.5). This included the 
aforementioned 2nd step mutant with ciprofloxacin MIC of 128mg/L, which also had a 
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gyrA target site mutation (derived from gen.sp. 13TU isolate E14). This ability of 
gen.sp. 13TU agrees with the increasingly common consensus that gen.sp. 13TU is also 
of importance clinically (Section 1.3; Dijkshoorn et al, 2007). Additionally gen.sp. 
13TU isolate U43 developed high ciprofloxacin MICs upon challenge with 10 x MIC, 
and indeed was the only isolate able to survive this high challenge. Furthermore A. junii 
(E26)-derived 2nd step mutants, as mentioned above, also developed high levels of 
ciprofloxacin MIC. Whilst these raised levels alone may not be indicative of clinically 
significant resistance, unlike the development of target site mutation, survival of this 
challenge may allow these isolates to be more successful in the clinical environment and 
with further challenges they could go on to develop clinical significant target site 
mutations. This therefore raises questions about whether further Acinetobacter species, 
and not just those of the Acb complex, may be more relevant in the clinical situation 
than thought. Of importance is that the sensitive A. baumannii isolate without the R-type 
mutS amino acid sequence (U66) did not develop mutants with high ciprofloxacin MICs, 
nor gyrA target site mutations, agreeing with the suggestion that the ability to develop 
resistance, whilst common in A. baumannii as discussed in Section 1.3, may not be due 
to species alone.  
 
Regarding fluoroquinolone resistance itself, as opposed to its use as a tool in this study, 
the ability of Acinetobacter spp to readily develop high levels of resistance upon 
challenge with ciprofloxacin agrees with the observation that the rise in fluoroquinolone 
resistance is particularly dramatic (Livermore, 2007). As mentioned (Section 1.4.4), 
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fluoroquinolone resistance is a risk factor for epidemic behaviour in Acinetobacter 
(Koeleman, 2001) and is associated with outbreak strains of Acinetobacter 
(Wisplinghoff, 2003; Heinemann et al, 2000), therefore the ability of not only 
A .baumannii but also other Acinetobacter spp to readily develop high levels of 
ciprofloxacin resistance is of concern.  
 
In conclusion, from the examined clinical Acinetobacter isolates it appears that those 
isolates with the R-type mutS sequence delineated in Chapter 4 appeared more capable 
of following the fluoroquinolone resistance development pathway seen in the resistant 
and multi-resistant isolates, with the development of gyrA target site mutations and 
resultant increases in MICs. In species terms, these comprised two A. baumannii and one 
gen.sp. 13TU isolate. Sensitive and intermediate isolates with variations to the R-type 
sequence in comparison did not seem as capable of developing such resistance to 
ciprofloxacin, with no target site mutations observed in any mutants derived from these 
isolates, and less frequent occurrence of high ciprofloxacin MICs. Taken together, these 
observations suggest that emerging-resistant isolates become more similar as resistance 
develops, and support the hypothesis that genetically distinct sub-populations of 
Acinetobacter spp may exist in the clinical environment, with differences in the mutS 
gene and an increased ability to rapidly acquire antibiotic resistance.  
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Chapter 6: The efficacy and effects of Chlorhexidine 
upon MRSA  
6.1 Introduction 
This examination of the effects of chlorhexidine upon MRSA formed part of a project 
which also investigated the frequency of biocide resistance genes within the sample 
population of clinical MRSA (Vali et al, 2008; Appendix 1). 
 
As discussed in more detail in Section 1.2, MRSA is of great concern in the clinical 
environment with growing prevalence and resistance levels leading to resurgence in 
infection control measures as a means to limit transmission and an alternative to reliance 
upon antibiotics to treat infections (Amyes, 2005; Grayson et al, 2008). With this has 
come a rise in the use of biocides, increasingly incorporated into products in both the 
clinical and domestic environments. This increase has led to concerns about use and 
misuse leading to reduced biocide susceptibility, with the possibility of cross-resistance 
to antibiotics, and concern regarding the efficacy of biocides upon clinical isolates as 
opposed to the tested standard strains (Russell et al, 1998; Levy, 2001). Whilst the in-
use concentration is high it is thought that in practice low concentrations of biocide may 
be present, from misuse leading to diluted fluids or due to the presence of residues in the 
hospital environment (Bloomfield, 2002). As such the study of low concentration of 
biocides upon clinical isolates is increasingly advocated, and there is a paucity of 
information on this aspect at present (Maillard, 2007). Additionally, there is concern that 
the tested standard strains may not adequately reflect the efficacy of biocides against 
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current clinical isolates (Kampf et al, 1998). In particular the reliance upon infection 
control to counteract the spread of MRSA makes the importance of early detection of 
reduced susceptibility to biocides in these bacteria especially important.  
 
MICs are generally considered insufficient for the testing of biocide reduced 
susceptibility and there is a lack of internationally standardised alternative methods 
(Section 1.2; Cookson, 2005). However several methods have been developed by 
Thomas and colleagues: a suspension test, surface disinfectant test and biocide residue 
test (Thomas et al, 2005), which were adapted for use here (Section 2.11). 
 
As detailed in Section 1.6.6, this study aimed to evaluate the efficacy of chlorhexidine 
on current clinical isolates compared to control strains, and to investigate whether there 
is any correlation between exposure to chlorhexidine and the development of antibiotic 
resistance in common strains of MRSA.  
 
6.2 Results 
6.2.1 Isolate Characterisation 
All isolates in this study (except the control Acinetobacter baumannii standard strain 
ATCC 19606 and the control sensitive Staphylococcus aureus strain NCTC 6571), were 
collected from the New Royal Infirmary Edinburgh (NRIE) and subsequently tested 
positive for the presence of the mecA gene, as determined by PCR (described in Section 
2.6.2), confirming that they were MRSA. Control strains used were the aforementioned 
Chapter 6 – MRSA and Chlorhexidine 
 167 
S. aureus NCTC 6571 (S) and A. baumannii ATCC 19606 (A), and also EMRSA-16 
(C).  
 
6.2.2 Susceptibility of Isolates 
The MICs determined for the 120 confirmed hospital-acquired MRSA isolates are 
shown in Table 6.1. All of the isolates were susceptible to vancomycin (breakpoint > 8 
mg/L). Only 3.3% were resistant to tetracycline (breakpoint > 1 mg/L) and 27.5% to 
gentamicin (breakpoint > 1 mg/L). There was 89.2% resistance to oxacillin (breakpoint 
> 2 mg/L), 90% to cefuroxime (breakpoint > 4 mg/L), 96.7 to ciprofloxacin (breakpoint 
> 1 mg/L) and 98.3% to cefotaxime (breakpoint > 4 mg/L). The highest level of 
resistance was observed to ampicillin (breakpoint > 2 mg/L), with 99.2% of the isolates 
resistant.  
 
Table 6.1 MICs of eight antibiotics to MRSA isolates 
Minimum Inhibitory Concentration (mg/L) 
Isolate 
AMP GEN OXA CTX CEF CIP TET VAN 
LF 1 32 0.5 64 128 >128 64 0.25 1 
LF 2 32 0.25 64 128 >128 64 0.25 0.5 
LF 3 32 32 64 128 >128 64 0.25 0.5 
LF 4 32 32 >128 >128 >128 64 0.25 0.5 
LF 5 16 32 >128 >128 >128 128 32 0.5 
LF 6 32 0.25 64 128 >128 64 0.25 0.5 
LF 7 32 0.25 >128 >128 >128 128 0.25 1 
LF 8 32 0.25 64 128 >128 32 0.25 1 
LF 9 64 0.5 128 >128 >128 64 0.25 0.5 
LF 10 32 0.25 64 >128 >128 128 0.25 0.5 
LF 11 32 0.25 >128 >128 >128 64 0.25 0.5 
LF 12 64 8 >128 >128 >128 128 0.25 0.5 
LF 13 64 0.5 128 >128 >128 64 0.25 1 
LF 14 32 32 32 64 >128 64 0.25 0.5 
LF 15 16 0.25 8 16 64 128 0.25 0.5 
LF 16 16 64 >128 >128 >128 64 0.25 0.5 
LF 17 64 32 >128 >128 >128 64 0.25 1 
LF 18 64 64 >128 >128 >128 64 0.25 0.5 
LF 19 64 0.5 16 32 128 >128 0.25 1 
LF 20 32 0.25 16 64 128 128 0.25 0.5 
LF 21 32 32 64 64 128 64 0.25 0.5 
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MIC (mg/L) Table 6.1 
continued AMP GEN OXA CTX CEF CIP TET VAN 
LF 22 16 0.25 16 64 64 128 0.25 1 
LF 23 32 0.5 64 128 >128 16 0.25 1 
LF 24 32 0.5 64 128 >128 64 0.25 0.5 
LF 25 32 0.12 32 32 128 32 0.25 0.5 
LF 26 32 0.25 32 128 >128 64 0.25 1 
LF 27 32 0.12 128 128 >128 64 16 1 
LF 28 32 0.12 32 64 >128 64 0.25 0.5 
LF 29 32 0.12 16 64 128 16 0.25 0.5 
LF 30 32 0.032 0.12 16 0.5 64 0.12 0.5 
LF 31 64 16 128 >128 1 32 0.12 0.5 
LF 32 32 32 32 32 128 32 0.25 0.5 
LF 33 32 16 32 32 128 64 0.25 0.5 
LF 34 16 32 128 >128 >128 64 0.25 0.5 
LF 35 32 0.12 32 32 >128 16 0.25 0.5 
LF 36 16 0.25 8 32 16 64 0.25 0.5 
LF 37 32 0.02 0.002 32 0.004 64 0.06 0.02 
LF 38 64 32 128 >128 >128 64 0.25 0.5 
LF 39 32 0.12 16 32 32 64 0.25 0.5 
LF 40 64 32 128 >128 >128 64 0.25 0.5 
LF 41 16 32 128 >128 >128 64 0.25 0.5 
LF 42 64 >128 >128 >128 >128 64 >128 1 
LF 43 64 16 128 >128 >128 32 0.25 0.5 
LF 44 64 0.12 64 32 >128 64 0.25 0.5 
LF 45 32 0.5 64 128 >128 32 0.25 0.5 
LF 46 32 0.12 16 32 128 64 0.5 0.5 
LF 47 16 32 32 >128 >128 64 0.25 0.5 
LF 48 32 0.002 0.004 16 0.5 64 0.12 0.25 
LF 49 32 0.12 2 16 16 32 0.25 0.5 
LF 50 64 32 >128 >128 >128 64 0.5 0.5 
LF 51 32 0.002 0.12 128 0.25 64 0.12 0.25 
LF 52 32 0.002 0.002 8 0.002 64 0.002 0.002 
LF 53 64 0.002 0.12 >128 0.25 0.004 0.12 0.5 
LF 54 64 0.002 0.12 >128 0.25 64 0.12 0.25 
LF 55 32 32 32 32 128 64 0.25 0.5 
LF 56 32 0.25 32 32 128 64 0.25 1 
LF 57 64 0.002 0.12 >128 0.25 64 0.25 0.5 
LF 58 32 0.002 0.12 32 0.25 64 0.25 0.5 
LF 59 0.032 0.002 0.002 2 0.002 64 0.002 0.002 
LF 60 16 0.25 32 64 32 64 0.5 1 
LF 61 64 32 128 >128 >128 128 0.5 1 
LF 62 64 32 128 >128 >128 64 0.5 1 
LF 63 16 32 128 >128 >128 128 0.25 1 
LF 64 32 0.25 32 16 64 128 0.5 1 
LF 65 16 0.5 1 8 8 0.5 0.5 2 
LF 66 32 32 16 16 64 64 0.25 1 
LF 67 1 0.25 0.5 4 8 1 32 2 
LF 68 64 32 128 >128 >128 64 0.25 1 
LF 69 16 0.25 32 64 64 128 0.5 2 
LF 70 32 0.25 32 128 128 128 0.5 2 
LF 71 16 0.5 32 64 64 16 0.25 2 
LF 72 16 0.25 16 64 32 64 0.25 1 
LF 73 16 0.25 16 16 32 16 0.25 1 
LF 74 16 32 128 >128 >128 128 32 1 
LF 75 16 0.25 32 128 64 64 0.5 2 
LF 76 16 32 >128 >128 >128 128 0.5 2 
LF 77 16 0.5 8 64 32 64 0.25 1 
LF 78 32 1 64 128 >128 64 0.25 2 
LF 79 16 0.5 32 128 >128 >128 0.25 1 
LF 80 128 0.5 >128 >128 >128 128 0.5 2 
LF 81 64 32 >128 >128 >128 128 0.5 2 
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MIC (mg/L) Table 6.1 
continued AMP GEN OXA CTX CEF CIP TET VAN 
LF 82 16 0.25 8 64 32 64 0.25 2 
LF 83 64 32 >128 >128 >128 64 0.25 1 
LF 84 32 0.25 16 64 32 128 0.25 1 
LF 85 32 16 >128 >128 >128 128 0.25 1 
LF 86 16 0.25 >128 >128 >128 128 0.5 2 
LF 87 64 0.5 >128 >128 >128 128 0.25 2 
LF 88 32 0.5 32 128 128 128 0.5 2 
LF 89 64 0.25 >128 >128 >128 128 0.5 1 
LF 90 32 0.25 64 128 64 16 0.25 1 
LF 91 64 32 >128 >128 >128 128 0.25 1 
LF 92 16 0.25 32 64 32 16 0.25 2 
LF 93 16 32 >128 >128 >128 128 0.25 1 
LF 94 16 0.25 32 64 32 128 0.25 1 
LF 95 8 0.25 4 8 4 128 0.25 2 
LF 96 64 0.25 16 64 32 128 0.25 1 
LF 97 32 0.25 32 64 64 16 0.25 2 
LF 98 32 0.25 128 >128 >128 16 0.25 2 
LF 99 16 0.5 32 64 32 128 0.25 1 
LF 100 32 0.25 128 >128 128 128 0.12 0.5 
LF 101 16 0.25 32 64 32 128 0.25 1 
LF 102 32 0.25 128 >128 128 >128 0.25 1 
LF 103 32 0.25 32 128 32 32 0.25 1 
LF 104 2 0.06 16 16 32 1 0.25 2 
LF 105 4 0.5 32 64 32 32 0.12 0.5 
LF 106 32 0.25 16 64 32 128 0.25 1 
LF 107 32 0.25 32 128 64 128 0.25 1 
LF 108 32 0.5 32 128 64 128 0.25 1 
LF 109 64 0.5 >128 >128 >128 128 0.25 1 
LF 110 16 0.5 32 64 32 8 0.25 1 
LF 111 32 0.5 32 64 32 32 0.25 1 
LF 112 32 0.5 32 128 64 128 0.25 1 
LF 113 32 0.5 32 128 64 64 0.25 1 
LF 114 32 0.5 32 128 32 32 0.25 1 
LF 115 32 0.5 32 >128 64 128 0.25 1 
LF 116 32 0.5 64 128 64 64 0.25 1 
LF 117 32 0.5 16 64 32 128 0.25 1 
LF 118 32 0.5 32 128 32 128 0.25 1 
LF 119 32 0..5 16 32 16 16 0.25 1 
LF 120 32 0.5 32 128 128 128 0.25 1 
 
AMP: ampicillin, GEN: gentamicin, OXA: oxacillin, CTX: cefotaxime, CEF: cefuroxime, CIP: ciprofloxacin, TET: 
tetracycline,  VAN: vancomycin.  
 
 
These isolates were also examined (by student Lindsay Lai under the supervision of Dr 
Leila Vali; Vali et al, 2008) by PCR for the presence of the staphylococci biocide 
resistance genes norA, qacA/B, qacG, qacH and smr, and for the presence of the blaZ   
β-lactamase gene. NorA is a fluoroquinolone efflux pump which pumps out dyes and 
quaternary ammonium compounds (QACs). The smr and qac genes encode an energy-
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dependant export system. Whilst they mainly confer reduced susceptibility to QACs, 
smr, qacA/B and norA also confer reduced susceptibility to biguanides, including 
chlorhexidine. Of these 120 clinical MRSA isolates, 97.5% contained blaZ, 44.2% 
contained smr, 36.7% contained norA, 8.3% contained qacA/B and 3.3% contained 
qacH. All the isolates with qacA/B also contained blaZ. However, not all of the isolates 
with blaZ contained qacA/B. 
 
6.2.3 Selection of Isolates for Further Study 
Three isolates were selected for use in the biocide studies because they represented three 
different susceptibility profiles: LF 26 contained only blaZ and was resistant to most 
tested antibiotics except gentamicin, tetracycline and vancomycin; LF 67 contained 
qacH, blaZ and smr and was only resistant to cefotaxime, cefuroxime and tetracycline; 
and LF 93 contained norA, blaZ and smr and was resistant to all antibiotics tested except 
tetracycline and vancomycin (Vali et al, 2008). 
 
6.2.4 Controls Testing Neutraliser Toxicity and Efficacy 
Comparison of viable counts of the control strain EMRSA-16 with and without the use 
of a neutralizer (as described in Section 2.11.5) showed that the neutraliser successfully 
quenched the effect of chlorhexidine at all concentrations examined, with no significant 
difference observed in the mean counts of quenched chlorhexidine compared to a control 
with water alone (P > 0.05). Similarly, comparison of the counts with neutraliser 
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compared to water alone showed that the neutraliser had no significant toxic effect upon 
the bacteria (P > 0.05). 
 
Table 6.2 Comparison of mean counts for neutralizer controls  
 Mean cfu/ml T-test *  
C 1.43 x 107 3.67 x 106 2.10 x 107  
N 1.23 x 10
7
 1.97 x 10
6
 3.07 x 10
7
 P = 0.66 
NT 6.33 x 106 3.00 x 106 2.20 x 107 P = 0.45 
C – Control count with water alone. 
N – Neutraliser efficacy control – neutraliser applied before CHX. 
NT – Neutraliser toxicity control – neutraliser applied instead of water. 
* Paired T-test, two-tailed distribution. P>0.05 means no significant difference between means.  
 
6.2.5 Quantitative Suspension Test 
When the efficacy of biocides upon bacteria is being considered, it is the lethal effects 
rather than the inhibitory effects (as would be measured by MICs) which are more 
important. Biocides are generally required to kill bacteria and are therefore used in 
excess of MIC levels, so suspension tests rather than MIC tests are often used as a 
simple and more effective preliminary evaluation of the antibacterial activity of a 
biocide (Thomas et al, 2005). Microbiocidal Effect (ME) measures the log reduction in 
cfu/ml after biocide contact, calculated as shown in Section 2.11.4. 
 
Figure 6.1 shows the mean of three results of the ME of 5 to 100 mg/L chlorhexidine 
solutions upon a washed suspension of the control strain EMRSA-16.  Total killing was 
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observed at 50 and 100 mg/L of chlorhexidine, hence these figures equate to the log 
cfu/ml value for the control, and the maximum limit of detection for the experiment. 
 
Figure 6.1 Mean Microbiocidal effect (ME) of chlorhexidine concentrations upon 
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It is apparent that a reduction of 50% from 100 mg/L to 50 mg/L chlorhexidine did not 
result in any loss of efficacy of the biocide for this sample in these test conditions and 
within the limit of detection. The further reductions in concentration did result in a 
noticeable reduction in the microbiocidal effect of chlorhexidine, with a decrease from a 
greater than 7-log reduction in numbers to a just over 1-log reduction when a 
concentration of 5 mg/L chlorhexidine was used.   
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However, even at the lowest concentration, an inhibitory effect was still exerted by 
chlorhexidine. Such concentrations could arise in the hospital environment due to the 
misuse of biocides; for example if they are not removed after cleaning and are allowed 
to linger on surfaces.  
 
6.2.6 Controls for Surface Disinfection Tests 
Two separate controls were used in the surface disinfection tests for calculating the 
microbiocidal effect of chlorhexidine. The first control did not take into account the 
effect of drying on the viability of the bacterial cells, the second was specific not only to 
each isolate, but also to each drying time for the isolate, in an attempt to account for the 
loss of viability subsequently observed after 2 and 24 hours of bacterial drying.  
 
By calculating the non-drying control concurrently with the tests and the drying control, 
any loss of viability after drying could be observed and accounted for specifically for 
each isolate.  
 
6.2.7 Surface Disinfection Test 
This test aimed to simulate a situation that may arise in the clinical environment, that of 
low concentrations of chlorhexidine solutions being used to clean up bacterial residue on 
surfaces (see Sections 1.2 and 6.1). Initial surface disinfection tests were performed and 
microbiocidal effects calculated from one control for each isolate (taken at time 0, with 
no drying having taken place), not taking account of any drying effect. Figure 6.2 shows 
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the subsequently calculated mean microbiocidal effect of 100 mg/L chlorhexidine on 
each of the tested isolates, after 2 and 24 hour drying times. There were not enough 
results to establish whether or not there were statistically significant differences between 
observations, and as such error bars are not included in the following figures, which 
show the mean of three results. 
 
Figure 6.2 Mean MEs of the isolates after 2 and 24 hour bacterial drying times, 
calculated compared to a control without drying 
 
A – Acinetobacter baumannii ATCC 19606; C – EMRSA–16; S – Staphylococcus aureus NCTC 6571; LF 26, 67, 93 – clinical MRSA isolates.  
 
After only 2 hours of drying, the ME of chlorhexidine was less than a 2-log reduction for 
all tested isolates and control strains. However the effectiveness of chlorhexidine 
increased in all cases after 24 hours of bacterial drying, to a greater extent in the control 
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After 24 hours bacterial drying there was a pronounced difference in the microbiocidal 
effect of chlorhexidine upon the control strains compared to the clinical isolates; a much 
greater effect was observed against the control strains than against the clinical isolates.  
 
However, a reduction in the viability of the bacterial isolates was observed following 
surface drying of the bacterial solutions, as shown in Figure 6.3 which displays the mean 
(3 results) log cfu/mL for the non-drying control (0 hours) and two drying controls (2 
and 24 hours) for each isolate. In most isolates there is clearly some reduction after 2 
hours of drying, and a marked reduction in bacterial viability for most isolates after the 
cells have been surface dried for 24 hours.  
 
Figure 6.3 Mean log cfu/mL of non-drying control (0 hour) and the 2 and 24 hour 
drying controls for each sample 
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This difference appeared more pronounced in the control strains than in the clinical 
isolates, possibly suggesting that the clinical isolates sampled were more resilient to the 
drying conditions. Taken with the previous results shown in Figure 6.2, this suggests 
that the reduced microbiocidal effect of chlorhexidine compared to the control strains is 
in part to the greater resilience of the clinical isolates to the effects of drying.  
 
To attempt to account for the impact of surface drying upon the calculated microbiocidal 
effects of chlorhexidine, further surface disinfection tests were performed using drying 
controls specific for each isolate and each drying time. Figure 6.4 shows the mean 
microbiocidal effect of chlorhexidine upon the isolates, as calculated using these drying 
controls.  
 
It is apparent that the difference in the effect of chlorhexidine upon control strains and 
the clinical isolates was much less pronounced than that seen in Figure 6.2, where 
microbiocidal effect was calculated from a non-drying control and the effect of drying 
on viability was not accounted for. However there was still reduced efficacy of 
chlorhexidine upon the clinical isolates generally compared to the standard strains, 
especially after 24 hours bacterial drying for LF26 and LF93. 
 
Of importance aside from any differences between control strains and clinical isolates is 
that even after 24 hours of bacterial drying chlorhexidine did not appear to exert a 
greater than 4-log reduction on any of the isolates, once the effect of drying upon 
bacterial viability was taken into account. This is less than the “equal to or greater than 
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5-log reduction in numbers of challenged organisms” effect which is suggested as the 
desired efficacy level for biocides (Payne et al, 1999). Additionally, this reduction was 
much less than the ME at this concentration in the quantitative suspension tests 
performed upon EMRSA-16.  
 
Figure 6.4 Mean MEs of the isolates after 2 and 24 hour bacterial drying times, 
calculated compared to 2 and 24 hour drying controls respectively 
 
6.2.8 Biocide Residue Test 
In this test the effect of biocide residues on the clinical isolates was established. In the 
clinical environment, it may be that inappropriate use leaves a biocide residue on 
surfaces and that low levels of chlorhexidine are therefore being used (as mentioned in 
Sections 1.2 and 6.1). It is therefore important to investigate whether this residue exerts 
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A – Acinetobacter baumannii ATCC 19606; C – EMRSA–16; S – Staphylococcus aureus NCTC 6571; LF 26, 67, 93 –  clinical MRSA isolates.  
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mg/L chlorhexidine dried for 2, 24 and 48 hours against the control strains and clinical 
isolates.  
 
Figure 6.5 Mean MEs of the isolates after 2, 24 and 48 hours biocide drying times 
 
A – Acinetobacter baumannii ATCC 19606; C – EMRSA–16; S – Staphylococcus aureus NCTC 6571; LF 26, 67, 93 –  clinical MRSA isolates.  
 
Generally the efficacy of the chlorhexidine residues decreased with longer drying times. 
Within the control strains, the sensitive S. aureus strain seemed more susceptible to 
chlorhexidine than either EMRSA-16 or the A. baumannii strain, as seen by the greater 
mean ME. Even after 2 hours of biocide drying, there was a much lower ME of 
chlorhexidine upon the A. baumannii strain. There did not appear to be any marked 
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compared to control strains. However there was a low ME observed for all residue 
drying times in LF67. 
 
Importantly, an effect was still being exerted by chlorhexidine after drying, in all cases 
after 24 hours, and in all but one (the clinical isolate LF 26) even after 48 hours of 
drying. The effect was minimal, hence not sufficient to kill all bacteria, which may allow 
the less susceptible bacteria in the population to become selected out.  
 
6.2.9 Post Biocide Residue Exposure MICs 
The MICs of the control strains and the isolates were determined following their contact 
with each of the chlorhexidine residues. Table 6.3 shows the MICs for the originally 
tested antibiotics after exposure to chlorhexidine residues dried for 2, 24 and 48 hours, 
compared to the initial MICs where there had been no exposure. 
 
For the majority of isolates there was little or no change in the MICs of the antibiotics 
tested after exposure to chlorhexidine dried for the different times. However there were 
substantial increases (greater than one concentration step) observed in the MICs of 
several antibiotics against EMRSA-16 and clinical isolate LF 26, and of all antibiotics 
against S. aureus strain NCTC 6571, after exposure of the isolates to chlorhexidine 
residues dried for 48 hours (Table 6.3).  
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Table 6.3 Post-chlorhexidine exposure MICs (mg/L) for the tested clinical isolates 





AMP CTX VAN GEN CIP CEF  TET  OXA 
ATCC 0 128 16 128 2 1 64 2 128 
19606 2 >128 16 128 4 2 64 2 128 
(A) 24 128 16 128 2 1 64 2 128 
 48 128 16 128 2 1 64 2 128 
EMRSA 0 >128 8 1 0.5 1 8 2 4 
16 2 >128 8 1 0.5 2 8 2 8 
(C) 24 >128 8 1 0.5 2 4 2 4 
 48 >128 16 128 2 2 64 2 128 
NCTC  0 0.06 1 1 0.25 0.25 4 0.5 0.12 
6571 2 0.06 1 1 0.5 0.25 1 0.25 0.12 
(S) 24 0.002 1 0.002 0.25 0.002 0.002 0.002 0.002 
 48 128 32 >128 2 2 64 1 128 
LF 26 0 32 64 1 0.25 64 128 0.5 32 
Clinical 2 64 128 2 0.25 64 >128 0.5 64 
MRSA 24 64 128 2 0.12 64 >128 0.5 64 
 48 128 128 4 0.25 64 >128 0.5 64 
LF 67 0 4 4 4 0.016 1 4 64 0.5 
Clinical 2 4 4 4 0.016 1 4 64 0.5 
MRSA 24 4 4 4 0.016 1 4 64 0.5 
 48 4 4 2 0.016 2 4 32 0.5 
LF 93 0 32 >128 2 32 128 >128 0.5 >128 
Clinical 2 32 >128 2 32 128 >128 0.5 >128 
MRSA 24 32 >128 2 32 128 >128 0.5 >128 
 48 32 >128 2 64 128 >128 0.5 >128 
 
AMP– ampicillin, CTX– cefotaxime, VAN- vancomycin, GEN– gentamicin, CEF– cefuroxime, TET– tetracycline, OXA– 
oxacillin. 
 
Most worryingly, this included a change from an MIC of 1 mg/L of vancomycin to 128 
and >128 mg/L in EMRSA-16 and NCTC 6571 respectively, and an increase to 4 mg/L 
vancomycin for the clinical isolate LF 26, approaching the resistance level (breakpoint 
>8 mg/L). Of particular concern is that the MICs against the S. aureus strain for all 
antibiotics tested had increased, leading to a previously sensitive strain becoming more 
resistant across the spectrum of antibiotic usage.  
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6.3 Discussion 
The work described in this Chapter formed part of a study into the effects of 
chlorhexidine, the frequency of biocide resistance genes, and antibiotic resistance of 
MRSA, and has subsequently been published (Vali et al, 2008; Appendix 1). The tests 
were intended to mimic situations that may arise in the clinical environment such as 
when chlorhexidine is used incorrectly or when poor infection control practices exist, 
leading to residues of biocide or bacteria on surfaces, or to non-lethal concentrations of 
biocide being used. 
 
Whilst there may be debate about the clinical relevance of results testing sub-lethal 
concentrations of chlorhexidine, as it is intended for high in-use concentrations, research 
into low concentrations is increasingly being advocated due to their incorporation in 
many products and the likelihood of low concentrations being present in the clinical 
environment (Section 1.2.9; Levy, 2001; Bloomfield, 2002; Russell, 2003; Maillard, 
2007). 
 
As would be expected, the efficacy of chlorhexidine was reduced when applied to 
bacterial residues and the ME decreased with longer bacterial drying times. Once the 
effect of drying upon bacterial viability had been taken into account by the use of 
controls specific to each drying time, the results from the surface disinfection tests did 
not demonstrate a clear difference between the efficacy of chlorhexidine against control 
strains compared to the clinical isolates.  
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However the results of the counts at each time did suggest that the viability of the S. 
aureus and EMRSA-16 strains may have been more affected by surface drying than the 
clinical isolates. This would at least partially account for the clear difference in the ME 
of chlorhexidine upon control strains and clinical isolates shown in Figure 6.2 (where 
the controls did not take into account the effect of drying).  
 
The observation of variation in the efficacy of chlorhexidine against the clinical isolates 
tested is disconcerting in itself as it may indicate that certain isolates are able to survive 
chlorhexidine exposure and be selected out of the population under this selective 
pressure, a critical concern in the issue of the development of reduced susceptibility to 
biocides (Sections 1.2.8 & 1.2.9; Bloomfield, 2002; Russell, 2003). 
 
The prevalence of biocide resistance genes in the clinical MRSA population in general 
and in the three clinical isolates tested in more detail was varied (Vali et al, 2008), 
which is likely to account for the variation in the ability of the clinical isolates to survive 
the presence of low concentrations of chlorhexidine.  
 
When residues of chlorhexidine were tested for their efficacy against bacterial 
suspensions, it was clear that even after 48 hours of biocide drying there was an effect 
being exerted by the biocide upon most isolates, both control and clinical. This was a 
low level inhibition, and as such is a cause for concern as it supports the concept that 
chlorhexidine residues in the hospital environment, as might occur through the misuse of 
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the biocide, can act as a selective pressure allowing less-susceptible bacteria in a 
population to survive through incomplete eradication (Sections 1.2.8 and 1.2.9; 
Bloomfield, 2002; Russell, 2003). 
 
The observation of increased MICs of several antibiotics after exposure to 
chlorhexidine, is of critical importance as it supports the concern that reduced 
susceptibility in biocides may be correlated to increased resistance in antibiotics, as has 
been observed in other work (detailed in Sections 1.2.8 and 1.2.9). Increases were not 
only observed in the control EMRSA-16 strain, but also in a current clinical isolate from 
the NRIE (LF26) and, of particular concern, the sensitive S. aureus control strain 
demonstrated an increase in all of the tested antibiotics after exposure to chlorhexidine 
residues that had been drying for 48 hours.  
 
It may be partly that the minimal effect exerted by the chlorhexidine residue allowed a 
greater number of the population to survive, thereby increasing the chance of survival 
against each antibiotic, but that resistance was not actually selected by exposure to 
biocide. Equally, selection for over-expression of efflux pumps with both antibiotic and 
biocide substrates may be a factor in this observation, as has been reported elsewhere; E. 
coli mutants selected for reduced susceptibility to pine oil also showed resistance to 
several antibiotics and over-expression of the marA gene, which activates the multidrug 
AcrAB efflux pump (Moken et al, 1997; Levy, 2002b).  
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Similarly, in this study all of the clinical MRSA isolates which contained qacA/B also 
contained blaZ, as has previously been reported. However, not all of those with the blaZ 
gene contained qacA/B. This suggests that biocide reduced susceptibility mediated by 
the qacA/B gene may be a risk factor for acquisition of antibiotic resistance (mediated by 
the blaZ gene) but that antibiotic resistance may not necessarily encode biocide 
resistance (Vali et al, 2008). It may be that further antibiotic genes are similarly borne 
on plasmids alongside biocide resistance genes, and that residues of chlorhexidine 
selected for the biocide resistance genes whilst subsequently co-selecting for antibiotic 
resistance.   
 
Vancomycin resistant Staphylococcus aureus (VRSA) is not yet widespread but is a 
cause for concern, particularly as VanA-type resistance may result via acquisition from 
more widespread vancomycin resistant entericocci (VRE) (Foucault et al, 2009). 
Additionally, vancomycin-heteroresistant strains have been reported, which may 
complicate analysis and surveillance of this problem (Linden, 2008). From the results of 
the present study, the observed increase in vancomycin MIC to unusually high levels is 
particularly disturbing, as isolates with such high resistance are unreported in natural 
clinical populations, and such dramatic increase in resistance following biocide exposure 
is also unreported. Chlorhexidine and other biocides are already in widespread use in the 
hospital environment. The implication from these results that chlorhexidine residues 
may induce this unusual increase in antibiotic resistance, especially in previously 
sensitive S. aureus strains as well as MRSA isolates, threatens biocide usage and also 
treatment options, and requires urgent further investigation.  
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Initially the biocide residue test would need to be repeated several times on a range of 
strains to examine the reproducibility of these observations. It would be useful too to 
develop a modified technique whereby the biocide and neutraliser are removed from the 
solution before re-culturing for measurement of the post-exposure MIC, as it may be that 
they interfere with MIC measurements. Additionally, isolates could be tested before and 
after biocide exposure for further biocide and antibiotic resistance genes, including 
vanA, and the fitness of post-exposure ‘mutants’ could be tested to determine the 
stability of the increased MICs observed. It has recently been suggested that the 
induction of VanA-type resistance is highly costly for MRSA, but minimal when not 
induced (Foucault et al, 2009). If due to this mechanism, the observed increase in 
vancomycin MIC may therefore not be stable, but the presence of vanA and its ready 
induction by chlorhexidine exposure, if responsible for the increase, would have serious 
implications for the potential spread of VRSA clinical isolates.  
 
 
This study highlights the importance of efficacy testing on clinical isolates and not just 
on the standard strains which are currently used, as there is clearly variation within the 
clinical population. This agrees with reports of reduced susceptibility of MRSA strains 
to chlorhexidine, compared to MSSA strains (Kampf et al, 1998). Screening a biocide 
against a panel of the problem strains within specific hospitals or regions to determine 
efficacy and highlight any potential problems before it is introduced would be ideal, but 
logistically this would be difficult to implement.  
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The results also re-emphasise the need for good infection control practices, and the 
correct use of chlorhexidine in particular and biocides in general so that they may 
continue to be useful in the fight against infection; the targeted, rather than excessive, 
use of biocides has been increasingly advocated, so that they may retain their usefulness 
in preventing infection where they are most needed (Bloomfield, 2002; Maillard, 2007; 
Russell, 2003). It may not seem obvious to the general public that residues of a 
substance designed to eradicate bacteria may in fact encourage the survival of the worst 
of the bacterial population, but this is an aspect that needs to be brought to the attention 
of at least any hospital workers responsible for the use of biocides. Of course it may be 
that the increasing use of biocides such as chlorhexidine in the domiciliary environment 
also plays, or will play, a part in any development of reduced biocide susceptibility, but 
unfortunately that was out with the scope of this study.  
 
The potential problem of reduced susceptibility to biocides and the techniques used to 
investigate this area are a relatively new concern compared to that of antibiotic 
resistance, and as discussed (Section 1.2) there is lack of internationally approved and 
reproducible methods to test susceptibility. The methods used here are based on 
previously described work (Thomas et al, 2005), incorporating some aspects of methods 
used to test the efficacy of biocides (Payne et al, 1999). However these techniques 
proved quite limiting in practice for the analysis of many isolates, as would have been 
useful to determine the effect of chlorhexidine on clinical isolates within the hospital 
population. It proved logistically impossible to test more than a few isolates at one time, 
due to amount of materials needed and the timescale required, and of course repetition 
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was required to gain more meaningful results. The results also highlight the importance 
of using proper controls to account for variations such as the effect of drying upon 
bacterial cells as in the surface disinfection test, demonstrated in Figure 6.2 (without 
drying controls) and Figure 6.4 (with a drying control).  
 
For future work, and to allow the essential screening of many isolates, it would be useful 
to develop a technique, possibly utilizing ELISA plates and a plate reader, which would 
enable the testing of biocide effect upon a large number of isolates at once, giving a 
greater number of quick results and allowing better control of conditions such as 
temperature, innoculum concentration and timings, leading to more reproducible results. 
This could also be a useful technique for the screening of specific hospital isolates 
before the implementation of the use of a biocide, as mentioned above.  
 
Within the actual hospital environment there are of course other factors which may 
influence the effects of chlorhexidine such as temperature, other suspensions and fluids, 
and surface contaminants (Section 1.2; Bloomfield, 2002). Whilst it would be possible to 
take some account of such factors, it was not within the scope of this study, and may be 
another aspect to bear in mind for any future work on this subject.  
 
There is increasing reliance upon biocides as a means to control infection by and spread 
of both HA-MRSA and emerging CA-MRSA in the clinical environment in light of the 
growing resistance to antibiotics (Section 1.2); as such the development of reduced 
susceptibility to chlorhexidine and the possible correlation with antibiotic resistance is a 
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serious cause for concern. Additionally, the rise of CA-MRSA and the increased use of 
biocides in domiciliary products may in theory promote reduced susceptibility to 
biocides and associated antibiotic resistance in CA-MRSA and, given the reports of 
movement of these strains within hospitals, this could also exacerbate any problems 
arising from HA-MRSA reduced susceptibility to biocides (Sections 1.2.4 & 1.2.6).  
 
As hypothesised (Section 1.6.5), these results indicate that low concentrations of 
chlorhexidine, as may be present in the clinical environment, could exert selective 
pressure on clinical MRSA isolates by producing a minimal effect and that this may lead 
to cross-resistance to antibiotics. Additionally, there are differences in susceptibility to 
these low concentrations between clinical isolates and compared to standard strains. 
Most importantly, the increases in antibiotic MICs following exposure to chlorhexidine, 
particularly the unusual increase observed for vancomycin MICs, may have dramatic 
implications for biocide use in both the hospital and domiciliary environments and 
requires urgent attention. Biocides are a fundamental tool in the fight against hospital 
infections, but they will only remain such when used properly; as these results suggest, it 
may be that incorrect use could dramatically worsen the situation.  
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Chapter 7: Conclusions 
This study has aimed to examine whether there is cause for concern regarding reduced 
biocide susceptibility in MRSA, and to further understanding of what factors may set 
certain Acinetobacter spp apart from others in their ability to acquire resistance. Rapid 
resistance development is likely to arise via a complex interplay of factors, both 
environmental and bacterial; therefore, examining specific aspects in isolation has 
limitations. However, whilst it can be difficult to link laboratory studies with the clinical 
situation, the benefit of such investigations is indisputable, especially for predicting 
worse case scenarios and examining the potential of new threats.    
 
7.1 Acinetobacter spp 
Regarding the hypothesis (Section 1.6.2) that distinct sub-populations of Acinetobacter 
spp clinical isolates exist, with varied mutS genes and an increased ability to develop 
antibiotic resistance, the results presented here show that this could be possible. The 
aims (Section 1.6.3) were to speciate clinical Acinetobacter spp isolates of varying 
antibiotic sensitivities, characterise and compare their mutS gene to non-clinical isolates 
and within the clinical population in order to establish any correlation between 
susceptibility and mutS type, and to assess whether any differences in mutS were 
associated with varying ability to develop ciprofloxacin resistance.  
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Acinetobacter spp clinical isolates with varying susceptibilities were speciated and their 
mutS gene sequenced, allowing comparison. There was variation in the mutS gene, 
compared to non-clinical strains and between clinical isolates, which was associated 
with different antibiotic susceptibilities. A novel mutS amino acid sequence (the R-type 
mutS sequence) was discovered, highly conserved in clinical multi-resistant, resistant 
and outbreak Acinetobacter isolates. Furthermore, mutation studies found that 
possession of this mutS sequence in intermediate Acinetobacter spp clinical isolates was 
associated with increased ability to develop clinically significant ciprofloxacin resistance 
in response to challenge. 
 
An increased mutation frequency itself did not correlate well with either possession of 
the R-type mutS gene, nor the ability to develop significant ciprofloxacin resistance, 
which agrees with the caution concerning the use of an increased rate of mutation alone 
to imply an increased ability to develop resistance (Section 1.5.5; Martinez & Baquero, 
2000). It may be that fitness costs in some isolates were not successfully ameliorated by 
the parallel development of compensatory mutations (Section 1.5.3). Increased 
transformation frequencies due to deficient mismatch repair, as has been reported in 
mutS defective Salmonella spp and in A. baylyi strain ADP1 (Section 1.5.4), may 
contribute to resistance development in this situation; the ability to take on exogenous 
resistance genes from a greater reservoir of bacteria in the hospital environment may 
lead to a more rapid development of resistance. Furthermore, the growing reports of 
Acinetobacter spp associated with infections out with the hospital environment (Section 
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1.3.3; Anstey et al, 2002; Davis et al, 2005) may mean there is an even greater reservoir 
of resistance genes available.  
 
Variation via mutation is fundamental to the development of antibiotic resistance. 
However the success of clonal strains of multi-resistant bacteria suggests that an 
effective combination of resistance factors is maintained in bacterial populations; hence 
it is likely that the conserved R-type mutS sequence present in resistant and outbreak 
Acinetobacter spp (Chapter 4) is of importance in the success of these isolates. This 
ever-increasing similarity with increasing resistance is also indicated by the reduced 
range of ciprofloxacin MICs observed in developing mutants, and the lack of other 
mutations observed in the gyrA gene of mutants that developed target site mutations 
(Chapter 5). It may be that the mutS gene variation observed here in the sensitive and 
intermediate Acinetobacter spp clinical isolates is indicative of their position in the 
population as emerging-resistant isolates, progressing from the non-clinical strains to the 
resistant clinical isolates, and as such they may be progenitors of the resistant clinical 
strains. Phylogenetic studies would be needed to expand upon this theory.   
 
The correlation of mutS type with increased ability to develop resistance is not evident 
solely within the A. baumannii species; the potential importance of gen.sp. 13TU in 
particular was highlighted, confirming increasing reports that this is also an important 
clinical species of the Acinetobacter genus (Section 1.3.1; Spence et al, 2002; 
Dijkshoorn et al, 2007). Additionally, other species may also have relevance in the 
clinical environment; indeed isolates of other Acinetobacter spp were able to develop 
Chapter 7 - Conclusions 
 192 
mutants with high ciprofloxacin MICs (Chapter 5), suggesting that they may also have 
potential, under certain conditions, to develop significant resistance.  
 
The grouping of gen.sp. 3 with A. baumannii and gen.sp. 13TU as the Acb complex is 
questionable in light of these results; gen.sp. 3 isolates did not possess the R-type mutS 
sequence and moreover did not seem capable of developing significant resistance. This 
agrees with cautions from others about this grouping of distinct species (Section 1.3.2; 
Dijkshoorn et al, 2007) and highlights the importance of speciation of isolates belonging 
to the Acinetobacter genus.  
 
Despite the association between mutS gene variation and an increased ability to develop 
resistance, direct cause and effect cannot be demonstrated by these results alone, though 
they do suggest that this area merits further investigation. If differences in the mutS gene 
are a factor in causing certain Acinetobacter isolates to predominate in the clinical 
environment, this could have implications for the treatment, control and surveillance of 
these isolates. For example, analysis of the mutS gene could be used to determine which 
emerging-resistance isolates are likely to progress to multi-resistance, a ‘hit them hard’ 
approach might be advocated for treatment of infections likely to contain mutator cells, 
as advocated for treatment of P. aeruginosa (Kenna et al, 2007), and it may be that 
research into future treatment options could focus on this aspect of Acinetobacter 
resistance development. Additionally, the increasing importance of other species of 
Acinetobacter in the clinical environment is an area that must be addressed with 
thorough surveillance and multi-centre analysis; if species other than A. baumannii are 
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of growing concern both as infectious agents and as a potential reservoir of resistance 
genes for the more prevalent isolates, then surveillance must also include these species. 
 
Further investigations should focus on establishing whether there is a causal link 
between mutS variations and resistance development; rescue of defective mutS alleles by 
recombination has been demonstrated in E. coli (Brown et al, 2001) and a similar 
method could enable determination of whether it is, in fact, the mutS type that is 
responsible for the observed increase in ability to develop resistance. It would also be of 
benefit to examine a wider range of Acinetobacter spp to see whether the observations of 
this study hold true for a greater sample; likewise a wider range of resistance 
mechanisms could also be examined. Additionally the aforementioned phylogenetic 
studies would be useful to discover whether the distinct isolates now current have 
derived from common progenitors, and population dynamics could be investigated by 
competition studies of isolates with different mutS genes to see which proliferated, both 
with and without antibiotic challenge.  
 
7.2 MRSA 
Regarding the hypothesis (Section 1.6.5) that exposure to low rather than the 
recommended in-use concentrations of biocide in the clinical environment may 
encourage reduced susceptibility and cross-resistance to antibiotics in MRSA, the results 
presented here (Chapter 6) show that this may indeed be a possibility. The aims (Section 
1.6.6) were to assess the efficacy of low concentrations of chlorhexidine to determine 
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whether there was variation between clinical MRSA isolates and variation compared to 
standard strains, and to determine whether exposure to chlorhexidine was associated 
with increased antibiotic resistance in clinical MRSA isolates.  
 
The efficacy of low concentrations of chlorhexidine was tested upon clinical MRSA 
isolates and variation was found between them. Additionally, there was variation in the 
susceptibility of clinical isolates to chlorhexidine compared to standard strains. 
Furthermore, increases in antibiotic MICs were found after exposure of clinical MRSA 
isolates to chlorhexidine residues. Whilst biocides are designed for use at high, lethal 
concentrations, misuse could easily lead to residues or diluted product and hence the 
presence of low concentrations in the clinical environment. It has been thought that, at 
low concentrations, biocides act more as antibiotics, exerting non-lethal effects and 
thereby allowing isolates with reduced susceptibility to survive their presence and have 
an advantage if challenged again (Section 1.2.9; Bloomfield, 2002). The results 
presented here (Chapter 6) show that even low concentrations and residues of 
chlorhexidine exert a minimal effect upon clinical MRSA isolates, thereby providing 
selective pressure.  
 
Additionally, although further investigation would be required to confirm the clinical 
relevance, the increase in a range of antibiotic MICs after exposure to chlorhexidine 
residue, particularly the dramatic increase in vancomycin resistance, is a great cause for 
concern, and adds weight to previous reports of the possibility of cross-resistance 
between reduced susceptibility to biocides and resistance to antibiotics (Section 1.2.9; 
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Moken et al, 1997; Levy 2002b; Kõljalg et al, 2002). This could have dramatic 
consequences for the management of infections, colonised patients, and the use of 
biocides in the hospital environment. The varying efficacy of chlorhexidine upon 
clinical isolates compared to standard strains suggests that efficacy testing of biocides 
should be performed on a range of strains including current clinical isolates, to ensure 
that they are effective against the bacteria which they are aimed against. 
 
The concern regarding reduced susceptibility to biocides is not a new area, but is of 
growing interest at present with the increased use of and reliance upon biocides in the 
clinical environment. Whereas there has been much attention directed at antibiotic 
resistance the same is not true of investigation into biocides and the implication of their 
greatly increased use, not just in the clinical environment but increasingly in healthy 
households (Section 1.2.8; Levy 2001; Cookson 2005). The emergence of CA-MRSA, 
and especially its recent manifestation and movement within the hospital environment, is 
also disconcerting in light of the rise of biocide-containing products in the home, 
particularly their prevalence at low levels; in theory this could lead to reduced biocide 
susceptibility occurring in CA-MRSA, allowing cross-resistance to antibiotics to 
develop if these strains move into the hospital environment.  
 
Of course, further investigation is needed both to clarify the clinical relevance of the 
results presented here, and determine whether biocide use in the home is a cause for 
concern. However, these results highlight areas of concern associated with biocide use 
and indicate that problems could indeed arise. Given the ineffectiveness of MICs for 
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testing biocide susceptibility, the development of reliable and internationally agreed 
methods for quick biocide susceptibility determination of a large number of isolates is 
important. The growing awareness of the potential impact of reduced susceptibility to 
biocides has led to calls for surveillance and monitoring of the problem in the clinical 
environment (Maillard 2007), and such calls seem to be supported by these results. 
Equally, the use of biocides in a targeted and informed way has been advocated 
(Bloomfield 2002; Russell 2003); again in light of these results this seems appropriate to 
prevent overuse and misuse which could lead to the presence of low concentrations. 
 
7.3 General Conclusions 
The predominant Gram-positive and Gram-negative nosocomial pathogens, MRSA and 
Acinetobacter spp, are both characterised by multi-drug resistance and emerging 
problems which jeopardise the ability to control spread and treat infections of these 
bacteria; control of MRSA is threatened by the potential development of reduced 
susceptibility to biocides, and the treatment of infections caused by Acinetobacter spp is 
threatened by emerging pan-drug resistance. The work presented here shows that 
reduced biocide susceptibility could indeed be a threat to the future ability to control 
MRSA and requires further research, and that the mutS gene may play a role in the 
ability of certain Acinetobacter spp to develop clinically significant multi-drug 
resistance, and likewise warrants further investigation. Whilst this work alone is not 
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